The role of the non-canonical IKK complex in glioblastoma multiforme by Stellzig, Julia
  
 
The role of the non-canonical IKK 
complex in glioblastoma multiforme 
 
 
DISSERTATION 
zur Erlangung des Doktorgrades  
der Naturwissenschaften 
- Dr. rer. nat. - 
 
 
angefertigt am Biochemischen Institut 
des Fachbereichs Medizin und dem Fachbereich Biologie und Chemie 
der Justus-Liebig-Universität Gießen 
 
 
vorgelegt von 
Julia Stellzig 
 
 
 
 
Gießen im Oktober 2013 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dekan: Prof. Dr. Holger Zorn  
Institut für Lebensmittelchemie und Lebensmittelbiotechnologie  
Fachbereich für Biologie und Chemie  
Justus-Liebig-Universität Gießen 
 
1. Gutachter Prof. Dr. Reinhard Dammann 
Institut für Genetik 
Fachbereich Biologie und Chemie 
Justus-Liebig-Universität Gießen 
 
2. Gutachter Prof. Dr. M. Lienhard Schmitz 
Biochemisches Institut 
Fachbereich Medizin 
Justus-Liebig-Universität Gießen 
  
 
 
  
  
 
 
 
 
 
- meinen Eltern - 
 
 
 
 
 
I 
 
TABLE OF CONTENT 
LIST OF ABBREVIATIONS .............................................................................................................. IV 
1. INTRODUCTION ................................................................................................................ 1 
1.1. GLIOBLASTOMA MULTIFORME – ONE OF THE MOST LETHAL BRAIN TUMORS .............................. 1 
1.1.1. CLASSIFICATION OF GLIOBLASTOMA MULTIFORME .................................................................... 1 
1.1.2. GENETIC AND MOLECULAR ALTERATIONS IN GLIOBLASTOMA MULTIFORME ................................. 2 
1.1.3. CANCER THERAPY FOR GLIOBLASTOMA MULTIFORME ............................................................... 4 
1.2. THE NON-CANONICAL IKK COMPLEX IN ONCOGENESIS ............................................................ 5 
1.2.1. THE IKK-RELATED KINASES AND THEIR ADAPTOR TANK .......................................................... 6 
1.2.2. INVOLVEMENT OF THE NON-CANONICAL IKK COMPLEX IN NF-ΚB AND IRF TRANSCRIPTION 
FACTOR SIGNALING PATHWAYS ............................................................................................ 7 
1.2.3. IKKΕ AND TBK1 IN CANCER ................................................................................................. 10 
1.3. THE AKT SIGNALING PATHWAY IN CANCER ........................................................................... 11 
1.3.1. AKT IS A NODE IN SIGNALING AND INFLUENCES MANY CELLULAR PROCESSES .......................... 11 
1.3.1.1. Activation of Akt .............................................................................................................. 11 
1.3.1.2. Cellular functions of activated Akt .................................................................................. 13 
1.3.2. AKT SIGNALING IN CANCER ................................................................................................... 15 
1.4. TUMORIGENIC ERK1/2 SIGNALING ....................................................................................... 16 
1.4.1. THE RAS-RAF-MEK-ERK SIGNALING PATHWAY .................................................................... 17 
1.4.2. THE ROLE OF RAS-RAF-MEK-ERK PATHWAY IN CANCER ...................................................... 20 
1.5. THE CROSSTALK BETWEEN AKT AND ERK1/2 SIGNALING ..................................................... 21 
1.6. AIM OF THIS STUDY .............................................................................................................. 23 
2. MATERIALS AND METHODS ......................................................................................... 24 
2.1. MATERIALS ......................................................................................................................... 24 
2.1.1. EUKARYOTIC CELL LINES ...................................................................................................... 24 
2.1.2. E.COLI STRAINS ................................................................................................................... 24 
2.1.3. ANTIBODIES ........................................................................................................................ 25 
2.1.3.1. Primary antibodies for immunoblotting ........................................................................... 25 
2.1.3.2. Secondary antibodies for immunoblotting ...................................................................... 25 
2.1.3.3. Antibodies used for co- and chromatin-immunoprecipitation ......................................... 25 
2.1.4. EXPRESSION PLASMIDS ....................................................................................................... 26 
2.1.5. SYNTHETIC OLIGONUCLEOTIDES ........................................................................................... 26 
2.1.5.1. Oligonucleotides for shRNA cloning ............................................................................... 26 
2.1.5.2. Oligonucleotides for real-time PCR ................................................................................ 26 
2.1.5.3. Oligonucleotides for site-directed mutagenesis ............................................................. 27 
2.1.5.4. Oligonucleotides for chromatin-immunoprecipitation ..................................................... 27 
2.1.6. ANTIBIOTICS ........................................................................................................................ 27 
2.1.7. INHIBITORS ......................................................................................................................... 28 
2.1.8. ENZYMES ............................................................................................................................ 28 
2.1.9. KITS ................................................................................................................................... 29 
2.1.10. CHEMICAL REAGENTS .......................................................................................................... 29 
2.1.11. OTHER REAGENTS ............................................................................................................... 31 
2.1.12. MEDIA, BUFFERS AND SOLUTIONS ......................................................................................... 31 
2.1.12.1. Media for cultivating prokaryotic cells ............................................................................ 31 
2.1.12.2. Media for cultivating eukaryotic cells .............................................................................. 32 
II 
 
2.1.12.3. Buffers and other solutions ............................................................................................. 32 
2.2. METHODS ........................................................................................................................... 34 
2.2.1. METHODS IN CELL BIOLOGY .................................................................................................. 34 
2.2.1.1. Eukaryotic cell culture ..................................................................................................... 34 
2.2.1.2. Freezing and thawing ..................................................................................................... 34 
2.2.1.3. Transfection of eukaryotic cells ...................................................................................... 35 
2.2.1.4. Retro- and lentiviral infection of glioblastoma cell lines .................................................. 35 
2.2.1.5. MTT cell viability and proliferation assays ...................................................................... 36 
2.2.1.6. Proliferation assays ........................................................................................................ 36 
2.2.1.7. Cell migration assays ..................................................................................................... 36 
2.2.1.8. Cell cycle analysis by flow cytometry ............................................................................. 37 
2.2.2. METHODS IN BIOCHEMISTRY ................................................................................................. 37 
2.2.2.1. Preparation of protein extracts ....................................................................................... 37 
2.2.2.2. Co-immunopecipitation ................................................................................................... 38 
2.2.2.3. Polyacrylamide gel electrophoresis ................................................................................ 39 
2.2.2.4. Western blot and immune detection ............................................................................... 39 
2.2.3. METHODS IN MOLECULAR BIOLOGY ....................................................................................... 40 
2.2.3.1. Preparation of competent E.coli ..................................................................................... 40 
2.2.3.2. Competent E.coli transformation .................................................................................... 40 
2.2.3.3. Plasmid DNA Purification ............................................................................................... 41 
2.2.3.4. Introduction of DNA fragments in vector molecules – cloning ........................................ 41 
2.2.3.5. RNA extraction ............................................................................................................... 45 
2.2.3.6. Synthesis of complementary DNA .................................................................................. 46 
2.2.3.7. Semi-quantitative real-time polymerase chain reaction ................................................. 46 
2.2.3.8. Chromatin-immunoprecipitation ..................................................................................... 47 
3. RESULTS ......................................................................................................................... 49 
3.1. THE EXPRESSION OF THE NON-CANONICAL IKK COMPLEX IN GLIOBLASTOMA MULTIFORME ..... 49 
3.1.1. PROTEIN AND MRNA LEVELS OF THE NON-CANONICAL IKK COMPLEX IN  
PRIMARY PATIENT TISSUE SAMPLES .................................................................................... 49 
3.1.2. PROTEIN AND MRNA LEVELS OF THE NON-CANONICAL IKK COMPLEX IN GLIOMA CELL LINES .... 51 
3.1.3. THE INTERPLAY OF GENE TRANSCRIPTION AND MRNA STABILITY IN THE REGULATION OF  
TANK EXPRESSION........................................................................................................... 53 
3.2. THE INFLUENCE OF TANK AND TBK1 ON CELLULAR FUNCTIONS OF GLIOMA CELL LINES........ 56 
3.2.1. THE ROLE OF THE NON-CANONICAL IKK COMPLEX IN PROLIFERATION ..................................... 56 
3.2.2. THE ROLE OF THE NON-CANONICAL IKK COMPLEX IN CELL CYCLE PROGRESSION .................... 59 
3.2.3. THE ROLE OF THE NON-CANONICAL IKK COMPLEX IN MIGRATION ............................................ 62 
3.3. THE INFLUENCE OF THE NON-CANONICAL IKK COMPLEX ON CELL DEATH INDUCED BY 
CHEMOTHERAPEUTIC DRUGS ................................................................................................ 64 
3.4. THE NON-CANONICAL IKK COMPLEX IN AKT AND ERK1/2 SIGNALING PATHWAYS .................. 65 
3.4.1. THE EFFECTS OF TANK ON CONSTITUTIVE AKT AND ERK1/2 SIGNALING ............................... 67 
3.4.2. THE EFFECTS OF TBK1 ON CONSTITUTIVE AKT AND ERK1/2 SIGNALING ................................ 68 
3.4.3. THE INTERPLAY OF SIGNALING PATHWAYS IN GLIOMA CELL LINES ............................................ 71 
3.5. THE EFFECT OF TANK AND TBK1 ON THE PRO-INFLAMMATORY MICROENVIRONMENT IN  
GLIOMA CELL LINES ............................................................................................................. 75 
3.6. THE INFLUENCE OF TANK PROTEIN LEVELS ON SIGNAL OUTPUT ............................................ 76 
3.7. THE ROLE OF THE NON-CANONICAL IKK COMPLEX IN DIFFERENT CANCER TYPES .................... 77 
 
 
III 
 
4. DISCUSSION .................................................................................................................... 79 
4.1. THE EXPRESSION OF TANK IS DYSREGULATED IN GLIOBLASTOMA MULTIFORME .................... 79 
4.2. THE NON-CANONICAL IKK COMPLEX INFLUENCES CELLULAR FUNCTIONS IN GLIOMA CELL LINES
 .......................................................................................................................................... 82 
4.3. THE IMPORTANCE OF STOICHIOMETRIC TANK EXPRESSION .................................................. 84 
4.4. THE NON-CANONICAL IKK COMPLEX IS INTEGRATED IN A COMPLEX NETWORK OF  
SIGNALING PATHWAYS ......................................................................................................... 85 
4.4.1. THE INFLUENCE OF TANK AND TBK1 ON THE PROLIFERATION OF GLIOMA CELL LINES IS 
REGULATED BY INTRINSIC SIGNALING ................................................................................. 85 
4.4.2. TANK AND TBK1 INFLUENCE THE PHOSPHORYLATION OF AKT AND ERK1/2 IN GLIOMA CELL 
LINES ............................................................................................................................... 86 
4.4.3. THE ROLE OF MEK1/2 AND TAK1 IN TANK/TBK1/IKKΕ-MEDIATED ERK1/2  
PHOSPHORYLATION ........................................................................................................... 88 
4.4.4. THE ROLE OF THE NON-CANONICAL IKK COMPLEX IN OTHER CANCER CELL LINES .................... 90 
4.5. TANK AND TBK1 REGULATE INFLAMMATORY SIGNALING CASCADES IN  
GLIOBLASTOMA MULTIFORME ............................................................................................... 91 
4.6. THE ROLE OF THE NON-CANONICAL IKK COMPLEX IN THE TREATMENT WITH 
CHEMOTHERAPEUTIC DRUGS ................................................................................................ 92 
5. SUMMARY........................................................................................................................ 94 
6. ZUSAMMENFASSUNG .................................................................................................... 96 
7. SUPPLEMENTARY FIGURES ......................................................................................... 98 
8. REFERENCES ............................................................................................................... 101 
DANKSAGUNG ............................................................................................................................. 131 
EIDESSTATTLICHE ERKLÄRUNG .............................................................................................. 132 
PUBLICATIONS............................................................................................................................. 133 
  
IV 
 
LIST OF ABBREVIATIONS 
% (v/v) volume/volume percentage (ml/100 ml) 
% (w/v) weight/volume percentage (g/100 ml) 
°C degree Celsius 
µ micro 
2-HG R-2 hydroxyglutarate 
4EBP eukaryotic translation initiation factor 4E-binding protein 
aa amino acids 
Ack1 activated Cdc42-associated kinase 
AGC cAMP-dependent protein kinase/ protein kinase G/ protein kinase C 
AP-1 activator protein 1 
AraC cytarabine 
ARE AU-rich elements  
ASK1 apoptosis signal-regulating kinase 1 
ATM ataxia telangiectasia mutated 
ATR ataxia telangiectasia and Rad3 related 
BAD Bcl-2-associated death promoter 
Bcl-2 B-cell lymphoma 2 
Bcl-6 B-cell lymphoma 6 
BIM bisindolyl maleimide-based, nanomolar protein kinase C inhibitors 
BUB3 Budding uninhibited by benzimidazole 3 
cAMP cyclic adenosine monophosphate 
CBP CREB-binding protein 
CDK4/6 cyclin-dependent kinases 4/6 
cDNA complementary DNA 
ChIP chromatin-immunoprecipitation 
Chk Checkpoint kinase 
CHX cycloheximide  
CK2 casein kinase 2 
Co-IP co-immunoprecipitation 
COX2 cyclooxygenase 2 
CREB cAMP-responsive element binding protein 
CTP cytidine triphosphate 
CYLD cylindromatosis 
Da Dalton (g/mol) 
DAI DNA-dependent activator of IFN-regulatory factors 
DAPK death-associated protein kinase 
DNA deoxyribonucleic acid 
dsDNA double stranded DNA 
V 
 
dsRNA Double stranded RNA 
e.g. exempli gratia (for example) 
ECM extracellular matrix 
EGFR epidermal growth factor receptor 
EGR-1 early growth response protein 1 
eIF2B eukaryotic initiation factor 2B 
eIF4E eukaryotic initiation factor 4E 
Elk-1 ETS domain-containing protein 
erbB2 epidermal growth factor receptor 2 
ERK extracellular signal-regulated kinase 
ERα estrogen receptor α 
et al. et alii (and others) 
FACS fluorescence activated cell sorting 
Fig figure 
FITC fluorescein isothiocyanate 
FOXO Forkhead box protein O 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GBM glioblastoma multiforme 
GEF guanine nucleotide exchange factors 
GLUT glucose transporter 
GPCR G coupled receptors 
Grb2 growth-factor-receptor-bound 2 
GSK3 glycogen synthase kinase 3 
GTP guanosine triphosphate 
h(s) hour(s) 
HDAC histone deacetylase 
HER2 epidermal growth factor receptor 2 
HLH helix-loop-helix 
HNSCC head and neck cancer 
Hsp27 heat shock protein 27 
HuR human antigen R 
IB immunoblotting 
IDH Isocitrate dehydrogenase 
IFN interferon 
IGF-1 insulin-like growth factor 1 
IKK IκB kinase 
IL interleukin  
ILK integrin-linked kinase 
IP immunoprecipitation 
IRAK interleukin-1 receptor-associated kinase 
VI 
 
IRF interferon egulatory factor 
ISGF3 interferon-stimulated gamma factor 3 
ISRE Interferon-stimulated response element 
IκB Inhibitor of κB 
JAK janus kinase 
JNK c-Jun N-terminal kinase 
kDa kilo Dalton 
KSR kinase suppressor of Ras 
l liter 
LGI1 leucine-rich, glioma activated 1  
LPS lipopolysaccharide 
LZ leucine zipper 
M Molar (mol/l) 
m milli 
MAPK mitogen-activated protein kinase 
MAPKKAP-K2 mitogen-activated protein kinase-activated protein kinase 2 
MAVS mitochondrial antiviral signaling adaptor 
MCL-1 myeloid leukemia cell differentiation protein 
MCL-1 myeloid leukemia cell differentiation protein 
MDA5 melanoma differentiation-associated protein 5 
MDM2 mouse double minute 2 homolog 
MDR-1 multi-drug-resistant 1 
MDR-1 multi-drug-resistant 1 
MEF mouse embryonic fibroblast 
MEK mitogen-activated protein kinase kinase 
MGMT O
6
-alkylguanine DNA alkyltransferase 
min minutes 
MKKK MAP kinase kinase kinase 
MLCK myosin light chain kinase 
MLK3 mixed lineage kinase 3 
MLTK MLK-like mitogen-activated protein triple kinase 
MMP9 matrix metallopeptidase 9 
MP1 MEK partner 1 
mRNA messenger RNA 
MTIC 3-methyl-(triazen-1-yl)imidazole-4-carboxamide 
mTORC mammalian target of rapamycin complex 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MXI1 MAX-interacting protein 
MyD88 myeloid differentiation primary response gene (88) 
NAP1 NAK-associated protein 1 
VII 
 
NEMO NF-κB essential modulator 
NFAT3 nuclear factor of activated T cells 3 
NFKBIA/ IκBα nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
OD optical density 
PAMP pathogen-associated molecular pattern 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PDE-4 phosphodieesterase 4 
PDK1/2 phosphoinositide-dependent kinase-1 and -2 
PH domain Pleckstrin homology domain 
PI propidium iodide 
PI3K phosphatidylinositide 3-kinase 
PIP2 phosphatidylinositol-4,5-bisphosphat 
PIP3 phosphatidylinositol-3,4,5-triphosphat 
PKA Protein kinase A 
PKB Protein kinase B (also referred to as Akt) 
PKC Protein kinase C 
PMA phorbol 12-myristate 13-acetate 
Pol II S2 polymerase II phosphorylated at serine 2 
PP2A protein phosphatase 2A 
PTEN phosphatase and tensin homolog 
Ral Ras-like 
RalGEF Ras-like-guanine nucleotide exchange factor 
Ras Rat sarcoma 
RasGEF Ras guanine nucleotide exchange factor 
RASSF1A Ras Association Domain family 1 alpha 
RB1 retinoblastoma protein 1 
RIG-I retinoic acid-inducible gene 1 
RNA ribonucleic acid 
RNAi RNA interference 
rpm revolutions per minute 
RSK ribosomal S6 kinases 
RTK receptor tyrosine kinase 
S Serine 
SAPK Stress- activated protein kinase 
sec second 
Sec5 exocyst complex component 2 
SEK1 SAPK/Erk kinase 1 
Shc SHC-transforming protein 
VIII 
 
SHIP SH2-domain-containing inositol phosphatases 
shRNA short hairpin RNA 
SINTBAD similar to NAP1 TBK1 adaptor 
SOS son of sevenless 
SOX11 SRY-related HMG-box 
SREBP sterol regulatory element-binding protein 
STAT signal transducer and activator of transcription 
T Threonine 
TAB TAK1-binding protein 
TAK1 TGF-β-activated kinase 1 
TANK TRAF Family Member-Associated NF-κB Activator 
TBK1 TANK-binding kinase 1 
TERT telomerase reverse transcriptase 
TGF-β transforming growth factor β 
TIMP3 metalloproteinase inhibitor 3 
TLR Toll like receptor 
TMZ Temozolomide 
TNFα tumor necrosis factor-α 
TPL2 tumor progression locus 2 
TRADD tumor necrosis factor receptor type 1-associated death domain protein 
TRAF tumor necrosis factor receptor-associated factor 
TRAIL tumor necrosis factor-related apoptosis-inducing ligand 
TRAM TRIF-related adaptor molecule 
TRIF TIR domain-containing adapter-inducing IFN-β 
TSC2 tuberous sclerosis 2 
ULD ubiquitin-like domain 
UTR untranslated region 
V volt 
VCAM1 vascular cell adhesion molecule 1 
WB Western blot 
WHO World Health Organization 
Y Tyrosine 
YB1 Y box binding protein 1 
ZEB zinc finger E-box-binding homeobox 
α-KG α-ketoglutarate 
  INTRODUCTION 
1 
 
1. INTRODUCTION 
 
1.1. Glioblastoma multiforme – one of the most lethal brain 
tumors 
1.1.1. Classification of glioblastoma multiforme 
After a long history of neurosurgery, in the beginning of the 20th century Bailey and 
Cushing were the first neurosurgeons to classify brain tumors histologically and to 
describe GBM (glioblastoma multiforme). The name derives from both, the cell type the 
cancer arises from, so called glia cells, and the fact that the tumors are characterized by a 
variable appearance in morphology and histology [1]. 
Glia cells are non-neuronal brain cells and constitute a group with distinct morphology and 
function. Whereas neurons are responsible for the transfer of information, glia cells are 
considered to be nutrient suppliers as well as to provide structural and metabolic support 
to neurons [2]. Astrocytes represent the majority of glia cells in the brain and have been 
found to additionally play a role in synaptic transmission and information processing [3]. 
Other types of glia cells are for instance microglia [4], oligodendrocytes [5], and satellite 
cells [6]. 
The WHO (World Health Organization) classification of gliomas defines three categories: 
astrocytic, oligodendroglial and oligoastrocytic gliomas [7]. Furthermore, a grading system 
that considers malignancy and histological alterations specifies four grades (WHO grade 
I – IV) of glioma tumors where grade I (pilocytic astrocytomas) and grade II (diffuse 
astrocytomas) represent low-grade gliomas with a comparatively good prognosis, 
whereas grade III covers anaplastic astrocytomas. WHO grade IV is referred to as GBM 
[8]. In general, GBM can be divided into primary and secondary glioblastoma depending 
on the precursor cells and genetic properties [9-11]. Primary glioblastomas develop de 
novo after multiple genetic alterations and represent the majority of all GBM cases. On the 
other hand, about 5% of glioblastomas are derived from lower grade astrocytomas (WHO 
grade II - III) and therefore display a different pattern of genetic alterations. This type is 
referred to as secondary glioblastoma [11]. 
Glioblastoma multiforme is one of the most common brain cancer types and accounts for 
16% of all primary brain tumors in the United States with an incidence rate of 3.19 per 
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100,000 inhabitants [12]. GBM is also one of the most lethal brain tumors. Depending on 
grade and genetic alterations, the prognosis of glioblastoma is very poor. Ohgaki et al. 
reported a median survival of around 4.7 months after diagnosis for patients with primary 
GBMs and 7.8 months for patients with secondary GBMs [13]. However, the difference in 
survival between primary and secondary GBM is rather due to the age of patients, since 
secondary glioblastomas have been shown to be more prevalent in younger aged patients 
[11]. Younger age has been associated with longer survival in glioblastoma patients [13]. 
Treatment of glioblastoma with standard therapies merely prolongs the survival up to 12 –
 15 months [14]. The five-year survival rate of glioblastoma patients is even less than 5% 
[12]. 
1.1.2. Genetic and molecular alterations in glioblastoma multiforme 
Genetic and molecular alterations in GBM have been extensively studied within the last 
decades. Some widely spread changes will be subsequently described. 
The tumor suppressor p53 is a transcription factor that responds to DNA damage and 
leads to the expression of genes that are involved in the regulation of cellular processes 
such as apoptosis and cell cycle inhibition [15]. Because of its key role in apoptosis, p53 
mutations are involved in a wide range of cancers [16]. Here, p53 undergoes loss-of-
function mutations or even deletions, resulting in increased proliferation and survival [17]. 
p53 mutations are also frequently detected in GBM [18]. Two-third of precursor 
astrocytomas exhibit TP53 mutations and potentially develop to secondary GBM [11]. The 
occurrence in de novo developed GBM (primary GBM) is lower [11]. Also a complete loss 
of p53 function has been discovered in GBM [10]. 
Another comparatively common alteration among primary and secondary glioblastomas 
occurs at the PTEN (phosphatase and tensin homolog) gene. Mutations in this tumor 
suppressor have been reported in 15% (primary) - 40% (secondary) of glioblastomas [19]. 
Loss of PTEN functionality thereby leads to an activation of PI3K-Akt (phosphatidyl-
inositide 3-kinase - Akt) signaling [20, 21]. This activation of Akt promotes cell 
proliferation, cell growth [22] as well as survival [23]. On the other hand, also PI3K itself 
can be mutated in GBM. Kita et al. reported a low frequency of PIK3CA mutations 
(mutations in the catalytic subunit of PI3K) in about 5% (primary) and 3% (secondary) of 
glioblastoma [23]. Also somatic mutations of PI3KR1 (mutations in the regulatory subunit 
of PI3K) are known to be involved in gliomagenesis by activating PI3K and subsequently 
Akt [24]. Additionally, the amplification of the Akt1 gene in glioblastomas has been 
reported by Knobbe et al. [25]. Taken together, genomic alterations occur at several steps 
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of the PI3K-Akt pathway which lead to increased survival and proliferation of degenerated 
glia cells. 
The EGFR (epidermal growth factor receptor) regulates growth, proliferation and survival 
as well as angiogenesis and migration by the activation of several signaling pathways 
such as Akt, STAT3 and MAPK signaling [26] upon binding of ligands such as growth 
factors [11]. The amplification of EGFR can be detected in about 50% of primary 
glioblastomas [10], while these mutations are found less often in secondary glioblastomas 
[27]. Besides, the mutation variant EGFRvIII, where 801 base pairs are deleted, leading to 
continuous autophosphorylation and activation of the receptor [28], occurs in 20 – 50% of 
glioblastomas with EGFR amplification [29]. It has been shown that the amplification of the 
EGFR gene results in resistance to common chemotherapeutic treatment [30, 31]. 
Continued and uncontrolled proliferation is one hallmark of cancer [32]. Glioblastomas 
frequently show loss of the RB1 (retinoblastoma protein 1) gene and amplification of the 
CDK4 and CDK6 (cyclin-dependent kinases) genes [9, 11, 27]. Rb1 controls the 
progression of the cell cycle in G1-phase in either a HDAC (histone deacetylases) -
dependent or -independent manner [33]. The direct E2F inhibition by Rb1 is abrogated 
upon the phosphorylation of Rb1 by the CDK4/cyclin D1 complex leading to the release of 
E2F1 transcription factor which activates the expression of genes controlling G1-to-S 
transition [11, 34-37]. So, increased levels of phosphorylated Rb1 consequently result in 
ongoing cell cycle progression and thus in increased proliferation. On the other hand, 
active gene repression by binding of an HDAC-Rb-E2F complex to promoters of cell cycle 
genes plays an important role in the regulation of the cell cycle [36, 38-40]. About 25% of 
glioblastoma cases are marked by a loss of Rb1 expression due to promotor 
hypermethylation resulting in ongoing cell cycle progression and proliferation [41]. 
Other known defects in GBM are the loss-of-heterozygosity especially of chromosome 10 
[9, 11, 42, 43], resulting in loss of tumor suppressors such as LGI1 (Leucine-rich, glioma 
inactivated 1) [44], BUB3 (budding uninhibited by benzimidazole 3) [45] or MXI1 (MAX-
interacting protein 1) [46]. Furthermore, IDH (isocitrate dehydrogenase) mutations can 
lead to a hypermethylation of promotors resulting for instance in the repression of 
CDKN2C (p18) transcription [10, 47]. The hypermethylation is caused by the IDH product 
2-HG (R-2 hydroxyglutarate) which inhibits the function of α-KG (α-ketoglutarate)-
dependent enzymes such as dioxygenases that are involved in the demethylation of DNA 
and histones [48, 49]. Besides, heterozygous deletions of NFKBIA (nuclear factor of 
kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) have been described in 
glioblastomas by Bredel et al. This deletion is associated with increased disease 
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progression and seems to be associated with reduced sensitivity to the chemotherapeutic 
drug TMZ (Temozolomide) [50, 51]. The most frequent mutations and their prevalence in 
either primary or secondary glioblastoma are summarized in figure 1.1.  
 
 
Fig. 1.1: Genetic alteration leading to initiation and progression of primary and secondary 
glioblastoma. Mutations as well as amplifications or loss of certain genes and their occurrence in 
gliomagenesis are depicted. More detailed information are given in the text. (modified from [10, 11]) 
 
Besides genetic alterations also epigenetic changes play a role in the development and 
progression of GBM. Especially the hypermethylation of CpG island promoters leads to 
inactivation of tumor suppressors such as RB1 and RASSF1A (Ras Association Domain 
family 1 alpha), cell cycle regulators such as p16INK4a and p15INK4b, apoptosis regulators 
including DAPK (death-associated protein kinase) and TIMP3 (metalloproteinase inhibitor 
3), as well as DNA repair enzymes as for example MGMT (O6-alkylguanine DNA 
alkyltransferase) [52, 53]. 
The genetic and molecular heterogeneity in GBM described above does not just 
complicate the classification of the tumors, but does also affect treatment outcome in 
patients. General treatment strategies of GBM will be described in the following section. 
1.1.3. Cancer therapy for glioblastoma multiforme 
In general, cancer therapy consists of three main distinct approaches which are also 
implemented in the treatment of glioblastoma: surgery, radiotherapy and chemotherapy 
[54]. Surgery is one of the initial steps in the treatment of GBM [9], but is depending on the 
indication based on localization of the tumor, age of the patient, and diagnosis [55]. Tumor 
resection leads to reduction of tumor mass, relief of intracranial pressure and re-
establishment of neuronal functions [9, 55]. The removal of >98% of tumor cells is 
associated with increased survival and improved response to radiation and chemotherapy 
[56]. A second important step in the treatment of cancer is radiation and has also been 
precursor cells/astrocytes
primary glioblastoma
TP53 mutation
CDK4 amplification
RB1 mutation/ loss
EGRF amplification
PTEN mutation/ loss
NFKBIA loss
low grade astrocytoma 
(WHO grade II)
TP53 mutation
IDH1 mutation
anaplastic astrocytoma 
(WHO grade III)
CDK4/6 amplification
RB1 mutation/ loss
secondary glioblastoma
EGRF amplification
PTEN loss
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shown to further prolong survival of glioblastoma patients for approximately 5 months after 
surgery [57]. The most studied field in the treatment of glioblastoma is chemotherapy. The 
standard-of-care treatment is comprised of the administration of either Gliadel or TMZ 
after resection [9, 58]. The chemotherapeutic drug Gliadel, also called carmustine, is an 
alkylating agent that can be supplied as polymer wafer for a local treatment of brain 
tumors after surgery and is usually combined with radiotherapy [59]. TMZ is a prodrug that 
gets converted into the active compound within the systemic circulation and is able to 
cross the blood-brain barrier [9]. The active compound (MTIC, 3-methyl-(triazen-1-
yl)imidazole-4-carboxamide) causes base-pair mismatch in the DNA by methylating the O6 
position of guanine [60, 61]. The resulting DNA damage triggers apoptosis [62]. However, 
not just tumor cells but all rapidly dividing cells are affected by TMZ [9]. Combined therapy 
with surgery, radiation and chemotherapeutic treatment increases mean survival of 
glioblastoma patients merely about 14 months [14, 63]. Nevertheless, patients with MGMT 
methylation respond better to TMZ [64]. O6-methyl guanine methyltransferase is an 
enzyme that removes alkyl groups from the O6 of guanine thereby preventing DNA 
damage and compromising the cell response to TMZ [53].  
A major problem in the treatment of GBM is the occurrence of innumerable resistances 
against radiation and/ or chemotherapeutic drugs. As already mentioned, the expression 
of MGMT interferes with TMZ treatment [64]. Most studies, mainly performed in tumor 
stem cells, revealed the role of efflux pumps as well as multiple dysregulated signaling 
pathways to lead to the development of resistances [65, 66]. 
At present, promising clinical studies deal with implementation of small molecular 
inhibitors, novel immunotherapeutic approaches, growth factor targeting and gene therapy 
as well as with combinations of drugs against distinct targets [9]. New treatments need to 
be developed based on genetic and molecular changes in every individual case. Since 
there are multiple, redundant signaling pathways involved in initiation and progression of 
GBM, a reasonable combination of therapies needs to be employed for each patient [9]. 
 
1.2. The non-canonical IKK complex in oncogenesis 
The innate immune system senses PAMPs (pathogen-associated molecular patterns) and 
subsequently induces a variety of transcription factors that mediate the first defense 
against pathogens [67, 68]. NF-κB (nuclear factor kappa-light-chain-enhancer of activated 
B cells) is one of the most important transcription factors that can be triggered by bacterial 
and viral pathogens leading to expression of pro-inflammatory cytokines [69]. Also IRF 
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(interferon regulatory factor) transcription factors respond to viral pathogens and 
contribute to the expression of the type I IFN (interferon) gene as well as genes encoding 
pro-inflammatory cytokines [67, 70]. Both NF-κB and IRF signaling pathways depend on 
signal transduction via IKKs (inhibitor of κB kinases) and IKK-related kinases. 
1.2.1. The IKK-related kinases and their adaptor TANK 
Both IKK-related kinases have been discovered in 1999. A yeast two-hybrid screen using 
TANK (TRAF family member-associated NF-κB activator) as a bait revealed TBK1 (TANK 
binding kinase 1) as a kinase interacting with this adaptor which modulates NF-κB 
function [71]. IKKε (IκB-kinase ε) has been identified in a subtractive cDNA hybridization 
screen of LPS (lipopolysaccharide)-treated macrophages [72]. Furthermore, Peters and 
colleagues identified IKKε as a homolog to IKKα and IKKβ that phosphorylates IκBα in 
response to PMA (phorbol-12-myristate-13-acetate) [73]. While TBK1 is expressed 
ubiquitously [74], IKKε has been found to be expressed in pancreas, spleen and thymus 
as well as peripheral blood leukocytes [72]. The transcription of IKKε is enhanced upon 
the exposure to LPS or viral infection, therefore IKKε is also called IKK-i (IKK-inducible) 
[72, 75]. Both kinases exhibit a close structural similarity to the canonical IKKs, IKKα and 
IKKβ. While the kinase domain of IKKε displays a similarity of 30% with IKKα and IKKβ 
[72, 73, 76], the TBK1 kinase domain shares 27% identity with both kinases [71, 74]. 
TBK1 and IKKε share 64% sequence identity among each other [77]. The domain 
structure of IKKε as well as TBK1 and their adaptor protein TANK is depicted in figure 1.2. 
The kinases are composed of an N-terminal kinase domain, a subsequent ULD (ubiquitin-
like domain), a LZ (leucine zipper) and HLH (helix-loop-helix) region [78, 79]. The C-
terminal coiled-coil domains facilitate binding to adaptor proteins [80] such as NAP1, 
SINTBAD or TANK. 
 
 
 
Fig. 1.2: Schematical structure of the IKK-related kinases TBK1 and IKKε as well as their adaptor 
TANK. Abbreviations: KD: kinase domain; ULD: ubiquitin-like domain; LZ: leucine zipper; HLH: helix-loop-
helix; CC: coiled-coil; TBD: TBK1/IKKε binding domain; Znf: Zinc finger. (modified from [78, 79, 81]) 
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Both kinases are bound by adaptor proteins such as NAP1 (NAK associated protein 1), 
SINTBAD (similar to NAP1 TBK1 adaptor) and TANK [81]. All three adaptors compete for 
the binding to the kinases [80]. TANK has first been described by Rothe et al. in 1996 as a 
protein that interacts with TRAFs (tumor necrosis factor receptor associated factors) and 
prevents activation of NF-κB. Therefore, TANK was first named I-TRAF (inhibitor of TRAF) 
[82]. The assembly of the non-canonical IKK complex by TANK is necessary to activate 
TBK1 and IKKε leading to phosphorylation of several downstream targets such as IRF3, 
IRF7 and IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor 
alpha) [67, 80, 83, 84]. The impact of the complex on IRF as well as NF-κB signaling 
pathways will be described in detail subsequently. 
1.2.2. Involvement of the non-canonical IKK complex in NF-κB and IRF 
transcription factor signaling pathways 
The NF-κB signaling pathway is involved in the innate immune system to defend the 
organism against viral and bacterial pathogens [69, 85]. Ligand binding to TLRs (toll-like 
receptors) such as TLR1,2 and 5-9 triggers a signaling cascade via the adaptor molecule 
MyD88 which results in the activation of the IKK complex formed by IKKα, IKKβ and their 
adaptor protein NEMO (NF-κB essential modulator) [86]. The active kinases subsequently 
phosphorylate IκBα which retains the NF-κB dimer in the cytosol in unstimulated cells. 
This phosphorylation leads to the polyubiquitination and proteasomal degradation of IκBα 
[79, 85, 87]. The released NF-κB dimer then translocates into the nucleus and induces the 
expression of pro-inflammatory cytokines such as IL-6 (interleukin 6) and COX2 
(cyclooxygenase 2) [88, 89]. TBK1 as well as IKKε are also able to phosphorylate IκBα at 
S36 thereby activating NF-κB target gene expression in vitro [71, 72]. However, in MEFs 
(mouse embryonic fibroblasts) deficient for IKKε and TBK1 the expression of certain NF-
κB target genes is decreased, even though IκBα is degraded normally [90, 91]. 
Furthermore, IKKε as well as TBK1 target the NF-κB subunit p65 at residue S536 [92, 93]. 
Upon T cell costimulation, IKKε is able to additionally phosphorylate p65 at S468 [94] 
which allows IKKε to be translocated into the nucleus where it contributes to gene 
transcription of NF-κB target genes [95]. Furthermore, IKKε, that can translocates into the 
nucleus upon genotoxic stress exposure, has been found to repress apoptosis in 
response to DNA-damage by the phosphorylation of p65 at S468 [96]. The NF-kB 
signaling pathway is summarized in figure 1.3.A. 
Both IKK-related kinases are more prominently involved in the activation of IRF 
transcription factors [97, 98]. Here, TLRs [99] as well as intracellular receptors, that 
recognize double stranded RNA, such as RIG-I (retinoic acid-inducible gene 1) [100] or 
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MDA5 (melanoma differentiation-associated protein 5) [101], or receptors detecting 
double stranded DNA such as DAI (DNA-dependent activator of IFN-regulatory factors) 
[102] are triggered by infections. Figure 1.3.B illustrates the pathway that is activated upon 
the stimulation of TLRs. The stimulation of TLR4 by LPS (or TLR3 by viral dsRNA) 
induces the recruitment of the adaptor molecules TRAM (TRIF-related adaptor molecule) 
and TRIF (TIR-domain-containing adapter-inducing interferon-β) [103, 104]. TRIF 
subsequently recruits TRAF3 which mediates the activation of the non-canonical IKK 
complex composed of TANK, IKKε and TBK1 [83, 104]. Besides, LPS-induced TLR4 
signaling through MyD88 can lead to the recruitment of TRAF6 which also assembles with 
the non-canonical IKK complex. Subsequently, the IKK-related kinases TBK1 and IKKε 
phosphorylate cytoplasmatic IRF3, 5 or 7 [97, 98, 105, 106] leading to their homo- or 
heterodimerization and nuclear translocation [97, 107]. In the nucleus, IRF dimers 
associate with the IFN enhanceosome at ISREs (interferon-stimulated response 
elements) and induce the expression of type I interferon [108-110]. A second pathway 
activating the non-canonical IKK complex is triggered by viral infections. Here, intracellular 
sensors such as MDA-5 and DAI (figure 1.3.C) facilitate the activation of the non-
canonical IKK complex by MAVS (mitochondrial antiviral signaling adaptor) resulting in 
subsequent phosphorylation of IRF transcription factors by the activated kinases TBK1 
and IKKε [101, 102, 111]. This phosphorylation leads to the dimerization of IRF 
transcription factors which translocate into the nucleus and induce the expression of type I 
IFN gene [109, 112, 113]. 
Besides IRF transcription factors, both IKK-related kinases have further distinct 
downstream targets. TBK1 phosphorylates Sec5 at the Ral binding domain resulting in 
interferon induction [114]. IKKβ is phosphorylated by TBK1 in the activation loop 
promoting its kinase activity [74]. Furthermore, the insulin receptor is phosphorylated by 
TBK1 at S994 resulting in insulin resistance [115]. IKKε mediates STAT1 (signal 
transducer and activator of transcription 1) phosphorylation at S708 resulting in ISGF3 
(interferon-stimulated gamma factor 3) stabilization [116] and also phosphorylates CYLD 
(cylindromatosis) at S418, thereby decreasing its deubiquitinase activity [117]. 
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Fig. 1.3: The role of the non-canonical IKK complex in the network of NF-κB signaling. (A) The 
canonical NF-κB signaling is stimulated by ligand-binding to specific TLRs. This results in subsequent 
activation of the adaptor protein MyD88 which leads to further activation of IRAKs. Subsequently, TRAF6 
gets activated and recruits the TAK1/TAB2/TAB3 complex which in turn phosphorylates and activates the 
canonical IKK complex consisting of NEMO, IKKα and IKKβ. The two kinases then phosphorylate IκB leading 
to its ubiquitination and proteasomal degradation which results in the release of NF-κB heterodimer p65/p50. 
The NF-κB dimer translocates into the nucleus and induces the transcription of pro-inflammatory genes. (B) 
In an alternative pathway, activation of TLR (e.g. TLR3 or 4) activates TRAM/TRIF adaptors that recruit 
TRAF3 (or TRAF6 in response to TLR4 activation) which then activates the non-canonical IKK complex 
consisting of an adaptor protein such as TANK and the kinases IKKε and TBK1. The two kinases 
phosphorylate IRF transcription factors resulting in dimerization and translocation of the IRF dimers into the 
nucleus where type I interferon expression is induced. Besides, IKKε and TBK1 have an impact on the 
canonical NF-κB pathway. (C) The pathway described in (B) can also be triggered by intracellular dsRNA and 
dsDNA originated from viruses. Here sensors such as MDA5 (dsRNA) and DAI (dsDNA) activate signaling 
adaptor MAVS which leads to subsequent activation of TRAF3 and the non-canonical IKK complex. Both 
IKK-related kinases phosphorylate cytosolic IRF transcription factors that dimerize and translocate into the 
nucleus where interfon type I expression is induced. Abbreviations: TLR: toll-like receptor; MyD88: myeloid 
differentiation primary response gene (88); IRAK: interleukin-1 receptor-associated kinase; TRAF: TNF 
receptor-associated factor; TAB: TAK1-binding protein; TAK1: TGF-β-activating kinase; NEMO: NF-κB 
essential modulator; IKK: IκB kinase; IκB: inhibitor of NF-κB; TRAM: TRIF-related adaptor molecule; TRIF: 
TIR domain-containing adaptor-inducing IFNβ; TANK: TRAF family member-associated NF-κB activator; 
TBK1: TANK binding kinase 1; IRF: interferon regulatory factor; MDA5: melanoma differentiation-associated 
protein 5; DAI: DNA-dependent activator of interferon-regulatory factors; MAVS: mitochondrial antiviral-
signaling protein. (modified from [67, 70, 79, 118]) 
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1.2.3. IKKε and TBK1 in cancer 
The relation between NF-κB-mediated regulation of inflammation and cancer is 
elaborately described [119-123]. Besides, the IKK-related kinases TBK1 and IKKε recently 
have been shown to be involved in a wide range of signaling cascades which lead to 
oncogenic transformation. 
TBK1 has been reported to be over-expressed in lung, colon and breast cancer and to be 
mutated in lung cancer [69, 79]. Moreover, TBK1 is involved in Ras-induced oncogenetic 
transformation. RasGEF (Ras guanine nucleotide exchange factor) can be activated by a 
variety of extracellular stimuli leading to the transformation of Ras into its active form. 
Activated Ras then activates RalGEF (Ras-like-guanine nucleotide exchange factor) 
leading to RalB-induced (Ras-related protein Ral-B) TBK1 activation and complex 
assembly with Sec5 which is part of the exocyst complex. This in turn activates Akt and 
leads to tumorigenic transformation [69, 79, 114, 124, 125]. 
IKKε attracted much importance in breast cancer. The kinase is over-expressed in about 
two-third of analyzed human breast cancer tissues as well as in most breast cancer cell 
lines [126, 127]. A copy-number amplification of IKBKE has been reported for 16.3% of 
breast cancer cell lines [127]. On the other hand, expression of CK2 (casein kinase 2) 
seems to be involved in increased expression of IKKε in breast cancer tissues [126]. IKKε 
has been found to replace activated Akt kinase and to cooperate with constitutive active 
MAPK pathway resulting in tumorigenesis and enhanced proliferation and survival in 
breast cancer cell lines [127, 128]. Moreover, IKKε-dependent NF-κB signaling is also 
important in breast cancer. In line with the finding that IKKε is able to phosphorylate p65 at 
S536, NF-κB target genes MMP9 (matrix metallopeptidase 9) and BCL2 (B-cell lymphoma 
2) expression is enhanced in breast cancers where IKKε is over-expressed [127]. While 
MMP9 is involved in the degradation of collagen IV leading to tumor progression [129], 
Bcl-2 mediates the inhibition of apoptosis [130]. Furthermore, IKKε phosphorylates ERα 
(estrogen receptor α) resulting in increased expression of cyclin D1 in breast cancer [131] 
which is necessary for G1-to-S transition in the cell cycle and thereby influences 
proliferation ability [132]. 
A novel target of IKKε is STAT1 which is involved in tumorigenesis. Tenoever and 
colleagues showed the phosphorylation of STAT1 at S702 by IKKε and subsequent 
formation of the ISGF3 (interferon-stimulated gene factor 3) complex which consists of a 
STAT1-STAT2 heterodimer and IRF9 transcription factor [116]. The role of STAT1 in 
oncogenesis is contradictory. On the one hand, STAT1 transcription factors are 
associated with inhibited tumorigenesis. For instance, STAT1 has been shown to 
  INTRODUCTION 
11 
 
negatively regulate the cell cycle by inducing p21 in ovarian cancer [133], thus blocking 
cell cycle progression and proliferation. On the other hand, STAT1 also enhances tumor 
progression. Constitutive over-expression of STAT1 has been demonstrated to reduce 
apoptosis in several cancer types by the induction of anti-apoptotic genes [134, 135]. 
Finally, both IKK-related kinases have been found to directly phosphorylate and activate 
Akt at T308 and S473, thereby promoting tumorigenic transformation [125, 136, 137]. The 
role of oncogenic Akt signaling will be described in the following chapter. 
 
1.3. The Akt signaling pathway in cancer 
1.3.1. Akt is a node in signaling and influences many cellular processes 
The serine/threonine protein kinase Akt, also called protein kinase B (PKB), represents a 
node in signaling and is involved in the regulation of survival, proliferation, migration and 
metabolism [22, 138-142]. Dysregulated Akt kinase signaling is associated with the 
development of many diseases such as diabetes [143] and particularly cancer [144, 145]. 
Akt kinase, that belongs to the AGC (cAMP-dependent protein kinase/ protein kinase G/ 
protein kinase C) family of kinases, has been discovered independently by three groups in 
1991 [22]. While Bellacosa et al. found Akt to be an oncogene in mouse leukemia virus 
AKT8 [146], Jones et al. as well as Coffer and colleagues used an homology-based 
approach to find a new cellular homolog of protein kinase C resulting in the identification 
of protein kinase B [147, 148]. So far, three isoforms have been identified, all share the 
same structural organization that is highly conserved: the N-terminal PH (pleckstrin 
homology) domain facilitates binding to 3-phosphoinositides which is necessary for the 
activation of Akt [149, 150]; the PH domain is followed by a kinase catalytic domain that is 
conserved among the members of AGC kinases [151]. The phosphorylation of Akt within 
the activation loop at T308 is crucial for the activation of the kinase [150, 152]. 
Furthermore, phosphorylation at S473 within the C-terminal hydrophobic tail, containing a 
regulatory domain, supports the full activation of Akt [142, 152, 153]. 
1.3.1.1. Activation of Akt 
The activation of Akt is a multistep process and typically mediated by PI3K 
(phosphoinositide 3-kinase) which can be activated by RTK (receptor tyrosine kinase) and 
GPCR (G-protein-coupled receptors) [154-156]. Growth factors, cytokines as well as other 
extracellular stimuli like insulin or stressors such as oxidative stress trigger those 
receptors [22, 152, 156]. Their activation leads to the recruitment of PI3K to the plasma 
membrane and subsequent phosphorylation of PIP2 (phosphatidylinositol-4,5-bisphosphat) 
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at the 3-OH group which results in the generation of PIP3 (phosphatidylinositol-3,4,5-
triphosphat) [157, 158]. Phosphatases such as PTEN (phosphatase and tensin homolog) 
or SHIP (SH2-domain-containing inositol phosphatases) mediate dephosphorylation of 
PIP3 and thereby negatively regulate the activation of Akt [159-162]. PIP3 induces the 
recruitment of Akt to the plasma membrane dependent on its PH domain [163, 164]. PI3K-
dependent activation of Akt is typically mediated by PDK1 and 2 (phosphoinositide-
dependent kinase 1 and 2) that are also recruited to the membrane by PIP3 and facilitate 
the direct phosphorylation of Akt at T308 (by PDK1) and S473 (by PDK2), respectively 
[165-167]. Besides PDK2, Akt can be phosphorylated at S473 by ILK (integrin-linked 
kinase) [168, 169] as well as by autophosphorylation [170]. Phosphorylated and thereby 
activated Akt kinase translocates from the membrane to the cytoplasm or to the nucleus to 
phosphorylate its substrates [163, 171, 172]. Dephosphorylation of Akt by PP2A (protein 
phosphatase 2A) inactivates the kinase [171, 173]. The process of Akt activation is 
depicted in figure 1.4. 
 
 
Fig. 1.4: The mechanism leading to Akt activation. Following ligand binding, RTK recruits and activates 
PI3K leading to phosphorylation of PIP2 to PIP3. PIP3 recruits inactive Akt kinase as well as PDK1/2 to the 
membrane where Akt is phosphorylated by PDK1 at T308 and PDK2 at S473 for full activity. Active Akt can 
be inactivated by dephosphorylation by PP2A. Abbreviations: RTK: receptor tyrosine kinase; PI3K: 
phosphatidylinositol 3-kinase; PIP2: phosphatidylinositol-4,5-bisphosphat; PIP3: phosphatidylinositol-3,4,5-
trisphosphat; PDK1/2: phosphoinostide-dependent kinase 1 or 2; PP2A: protein phosphatase 2A. (modified 
from [138, 140, 153, 174]). 
 
Since phosphorylation of Akt at T308 and S473 is a critical step in its activation, this point 
was focused by many research groups, leading to the identification of many kinases that 
are involved in the activation of Akt. Downstream substrates of Akt as for instance 
mTORC (mammalian target of rapamycin complex) have been associated with the 
phosphorylation of Akt indicating a feedback-loop [175, 176]. More kinases involved in 
PI3K-independent activation of Akt are PKA (protein kinase A) in response to insulin [177, 
178] or Hsp27 (heat shock protein 27) that activates Akt in response to cellular stress 
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[179, 180]. As already mentioned, also both IKK-related kinases, TBK1 and IKKε, have 
been reported to phosphorylate Akt depending on its PH domain and PI3K signaling [136]. 
1.3.1.2. Cellular functions of activated Akt 
Once activated, Akt influences many different signaling pathways by phosphorylation of 
intermediates and thereby has a great impact on cellular functions. Most important 
downstream substrates and the consequences of their phosphorylation will be described 
subsequently.  
Akt kinase is involved in the regulation of metabolism by phosphorylation of its 
downstream substrates. GSK3 (glycogen synthase kinase-3), for instance, plays a role in 
lipid and glucose metabolism [141]. Phosphorylation of GSK3 by Akt results in its 
inactivation [181]. Active GSK3 induces proteasomal degradation of its substrates such as 
the transcription factor SREBP (sterol regulatory element-binding protein) which initiates 
the expression of genes involved in cholesterol and fatty acid biosynthesis [182, 183]. 
Thus, activation of Akt stabilizes SREBP and enhances lipid production. The Akt substrate 
GSK3 also modulates glucose metabolism by inhibiting glycogen synthase [184]. 
Furthermore, glycolysis is increased by phosphorylation of phosphofructokinase upon Akt 
activation [185, 186] and activation of hexokinase [187]. Moreover, glucose uptake is 
modulated by Akt upon insulin stimulation in insulin responsive tissue. Whereas the 
transcription and translation of glucose transporters GLUT1 and GLUT3 is increased by 
Akt downstream target mTORC1 [188-190], GLUT4 is recruited to the plasma membrane 
to support glucose uptake [191-193]. The phosphorylation of transcription factor FOXO1 
(Forkhead box protein O1) by Akt leads to its degradation resulting in decreased 
transcription of glucose-6-phosphatase [194, 195]. 
Other members of the transcription factor family Forkhead box such as FOXO3 and 
FOXO4 can be directly phosphorylated by Akt [196-198] which results in decreased 
transcription of genes involved in apoptosis such as Fas ligand, TRAIL (tumor necrosis 
factor-related apoptosis-inducing ligand), TRADD (tumor necrosis factor receptor type 1-
associated death domain protein), BIM and BCL-6 (B-cell lymphoma 6) [198-205]. 
Besides Forkhead box, other transcription factors are indirectly influenced by Akt. The NF-
κB transcription factor has been shown to be activated by phosphorylation of IKKα by Akt 
which results in transcription of anti-apoptotic and pro-survival genes [206-209]. 
Furthermore, CREB (cAMP-responsive element binding protein) is phosphorylated by Akt 
resulting in enhanced transcription of MCL-1 (myeloid leukemia cell differentiation protein) 
which promotes cell survival by inhibiting apoptosis [210-212]. Phosphorylation of the Akt 
substrate GSK3 is known to inhibit DNA binding of c-Jun and in turn of the AP-1 (activator 
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protein 1) transcription complex [213, 214]. Besides transcription, Akt also plays a role in 
translational control. Induction of mRNA translation is amongst others facilitated by Akt-
dependent phosphorylation of eukaryotic translation initiation factor 4EBP (4E-binding 
protein) and eIF4E (eukaryotic initiation factors 4E) [215] as well as by indirect 
phosphorylation of eIF2B (eukaryotic initiation factor 2B) [216]. 
The regulation of apoptosis and cell survival are the most considerable functions of Akt in 
cancer. Akt has emerged as a general inhibitor of apoptosis. Besides its impact on the 
regulation of anti-apoptotic gene transcription (Forkhead box, NF-κB) and translational 
control, Akt targets several proteins involved in the apoptotic machinery. The Bcl-2 family 
member BAD (Bcl-2-associated death promoter) is a direct target of Akt and inhibited by 
phosphorylation [217-219]. Akt substrate GSK3 phosphorylates and inhibits MCL-1, a pro-
survival Bcl-2 family protein [212, 220]. Furthermore, phosphorylation of pro-caspase-9 by 
Akt prevents its cleavage and thereby its pro-apoptotic activity [221]. Moreover, MAP 
(mitogen-activated protein) kinases JNK and p38 have been reported to be negatively 
affected by Akt. Here, the phosphorylation of upstream kinases such as ASK1 (apoptosis 
signal-regulating kinase 1), MLK3 (mixed lineage kinase 3) or SEK1 (SAPK/Erk kinase 1) 
leads to the repression of the MAPKs and eventually to the inhibition of apoptosis [222-
226].  
Besides apoptosis, Akt is also involved in the regulation of proliferation. Cell cycle 
progression and thereby cell proliferation is generally regulated by cyclins [227]. Akt 
promotes the expression of cyclin D1 and D3 by enhancing their translation [228]. The Akt 
substrate GSK3 additionally promotes the degradation of cyclin D1 by its phosphorylation 
at T286 which leads to the translocation of cyclin D1 into the cytosol where it gets 
degraded [229]. Thus, Akt, which inhibits GSK3, has a stabilizing effect on cyclin D1. 
Furthermore, cyclin-dependent kinase inhibitors p21 and p27 are negatively influenced by 
Akt leading to a relieve of cell cycle inhibition [230, 231]. Phosphorylation of p27 by Akt 
induces its sequestration in the cytosol thus preventing its cell cycle inhibitory effect [230, 
232-234]. Also p21 translocation to the nucleus is prevented by Akt-mediated 
phosphorylation [235]. Moreover, expression of p21 is influenced by Akt via MDM2 
(mouse double minute 2 homolog). Phosphorylation of MDM2 by Akt leads to p53 
ubiquitination and subsequent degradation which in turn attenuates p21 transcription [236-
238]. Important features of the complex downstream network of Akt are summarized in 
figure 1.5. 
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Fig. 1.5: Akt kinase is a node in signaling and mediates several cellular functions. Besides regulation of 
transcription, translation, cell growth, migration and angiogenesis, the major functions of Akt signaling are the 
promotion of cell survival by inhibition of apoptosis (green), the facilitation of proliferation (yellow) and the 
control of glucose and lipid metabolism (purple). A detailed description of Akt substrates and their role for 
certain signaling pathways is given in the text. Arrows indicate activation and blunt end arrows represent 
inhibition of the substrates by their phosphorylation. Abbreviations: GSK3: glycogen synthase kinase 3; 
MDM2: mouse double minute 2 homolog; BAD: Bcl-2-associated death promoter; JNK: c-Jun N-terminal 
kinases; SAPK/ MAPK: stress/ mitogen-activated protein kinases; IKK: IκB kinase; IκB: inhibitor of NF-κB, 
NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; CREB: cAMP response element-
binding protein; Bcl2: B-cell lymphoma 2; MCL-1: induced myeloid leukemia cell differentiation protein; 
FOXO: Forkhead box O; BIM: Bcl-2-like protein 11; TRADD: tumor necrosis factor receptor type 1-associated 
death domain; SREBP: sterol regulatory element-binding proteins. (modified from [22, 139, 153]) 
 
Taken together, Akt is a signaling node that influences different pathways and many 
cellular functions. Thereby, Akt plays a great role in tumorigenesis by promoting hallmarks 
of cancer such as cell survival and proliferation. 
1.3.2. Akt signaling in cancer 
The role of Akt in tumorigenesis has been extensively studied. Already when it was 
discovered as the retroviral oncogene v-Akt, a potential role in human cancer was 
supposed [146].  
Oncogenic deregulation of Akt in human cancers is due to either gene amplifications, the 
activation of upstream signaling or a loss of function of negative regulators [239]. Akt gene 
amplification has been described especially for ovarian [240], gastric [241] and pancreatic 
cancer [242-244], whereas over-expression of Akt occurs frequently in prostate cancer 
[245] as well as colorectal cancer [246]. However, in most cases Akt hyperactivity is 
caused by dysregulation of upstream oncogenes or tumor suppressors [247]. Gene 
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amplification of PI3K subunit p110 (PIK3CA) has been observed in ovarian [248] and 
cervix [249] tumors. Furthermore, PI3K can be constitutively activated by active Ras [250, 
251] or by over-expression of receptors such as human HER2 (epidermal growth factor 
receptor 2, also known as erbB2) [252, 253]. Besides, loss-of-function of tumor 
suppressor PTEN is a common alteration in tumors that affects Akt signaling by promoting 
its activation and has been shown to occur in prostate [254], lung [255], breast [256] and 
pancreatic cancer [257], as well as GBM [258-261]. 
Likewise, PI3K-independent mechanisms promote Akt activation and contribute to 
oncogenic transformation. The interaction of Akt with Ack1 (activated Cdc42-associated 
kinase) has been discovered by Mahajan et al. and has been shown to induce PI3K-
independent phosphorylation of Akt at Y176 and subsequent phosphorylation at T308 and 
S473 [262]. Autoactivating Ack1 mutations resulting in activated Akt have been found in 
ovarian cancer [262, 263]. Furthermore, DNA double strand break response via ATM 
(ataxia telangiectasia mutated) has been found to activate Akt via phosphorylation at 
S473 in a PI3K-independent manner to support survival [264]. It is believed, that those 
alternative mechanisms in Akt activation serve as backup pathways that, when aberrantly 
activated, promote Akt-driven transformation [265]. 
 
1.4. Tumorigenic ERK1/2 signaling 
Signaling by the serine and threonine protein kinases of the MAPK family regulates a 
large variety of cellular processes such as proliferation, apoptosis, cell cycle progression, 
differentiation, migration, metabolism and transcription [266-270] in response to a wide 
range of stimuli such as cytokines, growth factors, antigens, toxins as well as chemical 
and physical stresses [271, 272]. In general, MAPK pathways are three tiered cascades 
involving a MAP3K (MAP kinase kinase kinase) that phosphorylates MAP2K (MAP kinase 
kinase) that in turn phosphorylates MAPK. Three main subfamilies of MAPK namely p38, 
JNK (c-Jun N-terminal kinase) which is also referred as to SAPK (stress-activated protein 
kinase) [273], and ERK (extracellular signal-regulated kinase), are known and depicted in 
figure 1.6. [266, 267]. 
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Fig. 1.6: Conventional MAPK signaling pathways proceed in three-tiered modules. Ligand binding to 
cell surface receptors such as GPCR or RTK lead to activation of small GTPases such as Ras, Rac, Src or 
other activating adaptor proteins. Their activation results in initiation of the typical three-tiered MAPK 
signaling and finally to the activation of either p38, JNK or ERK MAPK. Activated MAPK in turn phosphorylate 
and activate distinct transcription factors which induce the production of cytokines, proliferation, 
angiogenesis, apoptosis, development, differentiation and migration. Abbreviations: TRAF: TNF receptor 
associated factor; TAB: TAK1-binding protein; Ras: Rat sarcoma; MAP3K; mitogen-activated protein kinase 
kinase kinase; TAK1: TGF-β-activating kinase; ASK1: apoptosis signal-regulating kinase 1; MEKK = MAP3K; 
Raf: rapidly accelerated fibrosarcoma; MAP2K: mitogen-activated protein kinases kinase; MKK = MAP2K; 
MEK = MAP2K; MAPK: mitogen-activated protein kinases; JNK: c-Jun N-terminal kinases; ERK: extracellular 
signal-regulated kinase. (modified from [223, 274]) 
 
Both, p38 and JNK, are activated in response to pro-inflammatory cytokines or cellular 
stresses [275-277] by distinct three tiered MAPK signaling. While p38 plays a role in the 
production of cytokines, proliferation and angiogenesis [278], JNK is important for 
apoptosis and development [279]. Activation and consequences of ERK1/2 signaling as 
well as its role in cancer will be described in more detail in the following section. 
1.4.1. The Ras-Raf-MEK-ERK signaling pathway 
Among the three main MAP kinases, ERKs are the best studied [280]. The isoforms ERK1 
(p44) and ERK2 (p42) share 84% sequence identity and fulfill more or less the same 
functions [281-283], so they will be referred to as ERK1/2 subsequently. The 
serine/threonine kinases have a size of 44 and 42 kDa, respectively, and are expressed in 
all tissues [266, 274, 282, 283]. 
The ERK1/2 signaling cascade is initiated by a variety of stimuli such as growth factors, 
cytokines, mitogens as well as hormones [284]. Binding of those stimuli to either RTK 
receptors or GPCR triggers the autophosphorylation of the receptors which creates 
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binding sites for the adaptor protein Shc (SHC-transforming protein) [285-287]. Interaction 
of Shc with Grb2 (growth-factor-receptor-bound 2) leads to the binding and activation of 
GEF (guanine nucleotide exchange factors) proteins such as SOS (son of sevenless) 
[288]. SOS gets activated and further activates small GTP binding protein Ras [289], a 
subfamily of small GTPases that is composed of the members H-Ras, K-Ras and N-Ras 
[290, 291]. Activated Ras in turn leads to the activation of Raf kinase [289, 292]. This 
kinase phosphorylates and thereby activates MEK1 and MEK2 which in turn 
phosphorylate ERK1/2 [293-295]. The phosphorylation of ERK1/2 at T202/T204 and 
T185/Y187 leads to dimerization and nuclear translocation where ERK1/2 phosphorylates 
its substrates [296]. Additionally, scaffold proteins such as KSR (Kinase suppressor of 
Ras) [297] enable the cytoplasmic retention of the dimers resulting in the phosphorylation 
of cytosolic substrates [298, 299]. Usually, scaffold proteins are required to form a multi-
enzyme complex with the involved MAPKs to provide signal fidelity [299]. The classical 
Ras-Raf-MEK-ERK pathway and selected substrates are summarized in figure 1.7.  
Besides the described classical MAPK signaling pathway, further kinases have been 
identified to influence the phosphorylation of ERK1/2 or its upstream kinases. PKC 
(Protein kinase C) [300] and MLK3 [301] phosphorylate Raf proteins which results in 
ERK1/2 activation. MAP3K of the p38 or the JNK pathway facilitate the activation of 
ERK1/2 indirectly by the phosphorylation of MEK1/2 [226, 302]. However, also kinases 
such as TPL2 (tumor progression locus 2) [303], MLTK (MLK-like mitogen-activated 
protein triple kinase) [304] or IRAK (interleukin-1 receptor-associated kinase) [305] are 
able to activate ERK1/2 by phosphorylation of upstream MAPKs. 
So far, more than 150 substrates of ERK1/2 have been discovered [306]. In the nucleus, 
ERK1/2 are mainly involved in the activation of transcription factors. The direct binding 
and phosphorylation of Elk1 by ERK1/2 induces its binding to DNA as well as to the co-
activators CBP (CREB-binding protein) and p300, thus resulting in dramatic increase of 
transcriptional activity [306, 307]. Elk1 induces the expression of c-Fos, EGR-1 (Early 
growth response protein 1) [308, 309], as well as p21 and other genes involved in cell 
cycle regulation and proliferation [310]. Furthermore, the c-Fos transcription factor is a 
substrate of nuclear ERK1/2 and the ERK1/2 substrate RSK (ribosomal S6 kinases) [311, 
312]. Phosphorylation of c-Fos by ERK1/2 and RSK results in its stabilization and 
dimerization with c-Jun to form AP-1 transcription factor which is responsible for the 
expression of genes involved in proliferation and survival [313]. Another transcription 
factor family that is phosphorylated by ERK1/2 is FOXO. The phosphorylation of FOXO3a 
increases its binding to MDM2 and thereby promotes its degradation which results in the 
prevention of apoptosis [314]. 
  INTRODUCTION 
19 
 
The binding of ERK1/2 to scaffold proteins allows its retention in the cytosol [299] which 
leads to the phosphorylation of cytoplasmatic substrates such as PDE4 
(phosphodieesterase 4) [315], cytosolic phospholipase A2 [316], as well as cytoskeletal 
proteins such as paxillin [317] and MLCK (myosin light chain kinase) [318]. Moreover, 
RSK is also a cytosolic target for ERK1/2 [319, 320]. As for ERK1/2, a part of cytosolic 
RSK is able to translocate into the nucleus to facilitate the phosphorylation of transcription 
factors. Transcription factors, that are regulated by RSK, are for example CREB, NF-κB 
and NFAT3 (nuclear factor of activated T cells 3) [321-323]. In the cytosol, proteins 
involved in apoptosis such as BAD and DAPK are phosphorylated by RSK [274, 324, 
325]. BAD is suppressed by this phosphorylation [326], and phosphorylated DAPK retains 
ERK1/2 in the cytosol, thus preventing ERK1/2 activity in the nucleus, and promotes 
apoptotic function [327]. How pro- and anti-apoptotic functions of ERK1/2 are linked has 
not been clarified so far, but seems to depend on the specificity of the stimuli as well as on 
the cell type. In general, cell death promoting functions of ERK1/2 are not yet well 
understood [274]. 
Some selected substrates of ERK1/2 are displayed in figure 1.7. Taken together, the Ras-
Raf-MEK-ERK pathway plays a pivotal role in the regulation of apoptosis and proliferation 
and therefore has a major role in tumorigenesis and cancer progression. 
 
 
Fig. 1.7: The Ras-Raf-MEK-ERK pathway. Ligand binding to RTK leads to activation of adaptors such as 
Shc and Grb2 resulting in SOS activation and subsequent activation of Ras. Ras in turn phosphorylates Raf, 
a MAP3K inducing the three-tiered pathway of MAPK resulting in the phosphorylation and activation of 
ERK1/2. Examples for cytosolic substrates of ERK1/2 are PDE4, MLCK and RSK. RSK phosphorylates BAD 
and DAPK which are involved in the regulation of apoptosis. Nuclear substrates of ERK1/2 are the 
transcription factors c-Fos and Elk1 as well as CREB which is phosphorylated by ERK1/2 substrate RSK. 
Arrows indicate activation and blunt end arrows represent inhibition of the substrates. Abbreviations: RTK: 
receptor tyrosine kinase; Shc: SHC-transforming protein; Grb2: growth factor receptor-bound protein 2; SOS; 
Son of Sevenless; Ras: Rat sarcoma; GDP/GTP: guanosine diphosphate/ triphosphate; MEK: MAP2K; ERK: 
Grb2
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extracellular signal-regulated kinase; MLCK: myosin light-chain kinase; RSK: ribosomal s6 kinase; BAD: Bcl-
2-associated death promoter; DAPK: death-associated protein kinase; PDE4: phosphodiesterase 4; 
FOXO3a: Forkhead box O 3a; CREB: cAMP response element-binding protein; Elk1: ETS domain-containing 
protein. CBP: CREB-binding protein. (modified from [328, 329]) 
 
1.4.2. The role of Ras-Raf-MEK-ERK pathway in cancer 
The Ras-Raf-MEK-ERK pathway has been shown to be important for many types of 
cancers. Mutations and dysregulations at several steps of the signaling cascade are 
known to result in increased activity of ERK1/2. 
Receptors that trigger the Ras-Raf-MEK-ERK pathway can be dysregulated which leads 
to tumorigenesis. For instance, over-expression of EGFR has been shown in many 
cancers such as breast [330] lung [331] or colorectal cancer [332]. Furthermore, mutations 
of the receptor, which lead to constitutive activation of the receptor independent of any 
stimuli, have been identified [333]. The so called EGFRvIII mutation, that was first found in 
GBM [334-336], is lacking parts of the extracellular domain responsible for ligand binding 
[337] and has also been reported in breast, ovarian, prostate and lung cancer [338-340]. 
EGFRvIII has been demonstrated to be constitutively associated with the downstream 
adaptor protein Grb2 leading to Ras activation [341-343]. Other RTKs or GPCR that 
influence the initiation and progression of tumors are also affected in cancer by over-
expression or mutation [344, 345]. In about 30% of all cancers members of the Ras family 
are mutated [346, 347]. K-Ras mutations occur in about 85% of tumors, N-Ras in 15% 
and H-Ras in less than 1% [348]. Pancreatic, lung and colon cancer are most affected by 
K-Ras mutations [348]. In general, mutations of Ras lead to constitutive binding of GTP 
which results in stimulus-independent and continuing activation of downstream cascades 
as Raf-MEK-ERK [346, 349]. Raf proteins play an important role in cancer as well. In 
particular, the family member B-Raf is known to be mutated in approximately 8% of 
human cancers, most frequently in thyroid cancer (45%) and melanoma (41%) [348, 350]. 
Most of the 40 known mutations of B-Raf result in constitutive activation and downstream 
signaling [348]. The prevention of Raf inactivation by conformational changes, as seen for 
B-Raf V600E mutation, could be a cause of constitutive activation [351, 352]. 
Furthermore, over-expression of wild-type B-Raf has been reported in melanoma cell lines 
[353]. Another family member of the Raf kinases, Raf-1, has been shown to be mutated in 
cancer cell lines resulting in transformation, but those mutations were not confirmed in 
primary tumor tissue [354-356]. Hyperactivity of Raf-1 is likely caused by over-expression 
and dysregulation of upstream receptors as well as oncogenic Ras [357-360]. In contrast 
to Ras and Raf, mutations of MEKs are rather uncommon [348, 361]. Gain-of-function 
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mutations leading to the activation of MEK1/2 and consequently of ERK1/2 have been 
described in 3% of melanomas and 2% of colon cancers [361]. 
Usually mutations that activate a certain signaling pathway do not occur in parallel within 
the same tumor because they are redundant [348]. However, all of the described 
mutations can lead to increased activation of ERK1/2 and thereby influence cellular 
functions. On the one hand, hyperactive ERK1/2 results in increased proliferation by 
promoting transcription factors such as c-Fos and Elk1 [307, 313]. On the other hand, 
reduced apoptosis and thereby increased survival is mediated by ERK1/2 substrates such 
as FOXO3a and RSK [314, 319]. 
 
1.5. The crosstalk between Akt and ERK1/2 signaling 
The complex crosstalk between the Akt and ERK signaling cascades comprises cross-
inhibition and cross-activation as well as converging of the pathways in the same 
substrates [362]. The initiation of both signaling pathways is facilitated by similar stimuli. 
Besides growth factors that trigger EGFR receptors, also IGF-1 (insulin-like growth factor 
1) [363, 364] and oxidative stress [365, 366] induce Ras as well as PI3K activation [367]. 
Besides the activation of the Ras-Raf-MEK-ERK pathway, Ras has been demonstrated to 
also activate the PI3K-Akt pathway [368, 369]. Moreover, PTEN, a negative regulator of 
Akt, has been identified to also negatively influence Ras activation. Gu et al. as well as 
Thomas and colleagues showed PTEN to dephosphorylate Shc adaptor protein causing 
decreased ERK1/2 activation in glioblastoma [370, 371]. Akt has been shown to 
phosphorylate Raf-1 at S259 resulting in a reduced activity of Raf-1 and inhibition of 
ERK1/2 signaling [372, 373]. Nevertheless, this direct interaction seems not to be 
mandatory as Rommel and colleagues showed the interaction of Raf and Akt for 
differentiated myotubes but could not verify this in undifferentiated myoblasts indicating a 
stage-specific crosstalk [374]. Besides, Raf can be phosphorylated by PKC which is also a 
PI3K substrate [375, 376]. Downstream of Akt and ERK1/2 kinases, both pathways 
converge in some mutual substrates. Especially proteins mediating apoptosis are 
regulated by both signaling pathways. For instance, Akt as well as ERK1/2 phosphorylate 
transcription factors such as FOXO3a and CREB (see 1.3.1.2 and 1.4.1) which leads to 
the expression of Bcl-2 family members [218, 377, 378]. Key components of the apoptosis 
cascade, as for example BAD and BIM, are phosphorylated by Akt and ERK1/2, thereby 
repressing apoptosis [218, 379-382]. Furthermore, proliferation is regulated by both 
cascades. Akt and ERK1/2 downstream kinase RSK phosphorylates YB1 (Y box binding 
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protein 1) [383-385] as well as ERα [386-388] and thereby enhances transcription of 
genes involved in proliferation. Other common substrates of Akt and ERK1/2 are: TSC2 
[389, 390], p70S6K [391], GSK3 [181, 392] and p27 [393-395]. The crosstalk between 
ERK1/2 and Akt signaling cascades as well as their mutual substrates are illustrated in 
figure 1.8. 
 
 
Fig. 1.8: The crosstalk between Ras-Raf-MEK-ERK and PI3K-Akt pathways. The schematic 
representation illustrates both pathways as shown before (Fig 1.4 and Fig. 1.7). Possible cross regulations 
are indicated with arrows whereas arrows stands for activation and blunt end arrows represent inhibition of 
the substrates. Examples of common substrates of both signaling cascades responsible for the regulation of 
either apoptosis or proliferation are listed in the box. Abbreviations: RTK: receptor tyrosine kinase; SOS; Son 
of Sevenless; Shc: SHC-transforming protein; Grb2: growth factor receptor-bound protein 2; Ras: Rat 
sarcoma; MEK: MAP2K; ERK: extracellular signal-regulated kinase; PTEN: phosphatase and tensin 
homolog; PI3K: phosphatidylinositide 3-kinases; PKC: protein kinase C; BAD: Bcl-2-associated death 
promoter; FOXO3a: Forkhead box O 3a; CREB: cAMP response element-binding protein; YB1: Y box binding 
protein 1; ERα: estrogen receptor alpha. (modified from [367, 368, 377, 396]) 
 
Another consequence of ERK1/2 and Akt signaling is the development of 
chemotherapeutic drug resistance. Whereas ERK1/2 mediates a resistance by increased 
expression of efflux pumps such as MDR-1 (multi-drug-resistant 1) [397], Akt facilitates 
the resistance via suppression of p53 induced apoptosis [398-400]. Additionally, the 
cooperation of both signaling cascades complicates cancer therapy. Since Akt and 
ERK1/2 signaling pathways have common substrates, they can easily fill in for the other 
[377]. Furthermore, other pathways such as Jak-STAT and NF-κB are also involved in the 
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complex interplay of signaling pathways [378, 401, 402] and therefore represent possible 
ways to bypass targets of chemotherapeutic drugs. 
 
1.6. Aim of this study 
Glioblastoma multiforme is one of the most common and lethal brain tumors. Many 
signaling pathways such as the Akt and ERK1/2 pathways have already been described 
to play a role in tumorigenesis. The aim of this study was to examine the expression levels 
of members of the non-canonical IKK complex in cancer. It was also planned to identify 
the importance of the non-canonical IKK complex for proliferation of glioma cell lines and 
to study the involved signaling cascades. In addition to knock-down experiments, the 
function of IKKε and TBK1 should also be revealed after their pharmacological inhibition 
with a small molecule inhibitor. Here, also Akt and ERK1/2 signaling cascades should be 
included using specific inhibitors. Furthermore, it was planned to further examine the 
reasons for a potential over-expression of the components of the non-canonical IKK 
complex by measurement of de novo transcription, mRNA stability and protein stability in 
glioma cell lines. It was then interesting to address the consequences of TANK or TBK1 
knock-down on the cell cycle and cell migration. Understanding of the molecular changes 
in GBM can help to improve treatment and survival of patients. 
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2. MATERIALS AND METHODS 
 
2.1. Materials 
2.1.1. Eukaryotic cell lines 
Name Description 
A172 Human glioblastoma cells 
A271 Human glioblastoma cells 
A549 Human lung carcinoma cells 
A764 Human glioblastoma cells 
HeLa Human cervix carcinoma cells 
HCT116 Human colorectal carcinoma cells 
HEK293T 
Human embryonic kidney cells stably expressing the large T 
antigen of the SV40 virus 
Ln229 Human glioblastoma cells 
MCF7 Human breast adenocarcinoma cells 
Phoenix Ampho™ 
Second-generation retrovirus producing, amphotropic packaging 
cells based on HEK293 cells 
SNB19 Human glioblastoma cells 
T98G Human glioblastoma cells 
U118 Human glioblastoma cells 
U251 Human glioblastoma cells 
U343 Human glioblastoma cells 
U373 Human glioblastoma/astrocytoma cells 
U87MG Human glioblastoma/astrocytoma cells 
 
2.1.2. E.coli strains 
Name Description Source 
TOP10 
F– mcrA Δ(mrr-hsdRMS-mcrBC) ϕ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara leu) 7697 galU galK 
rpsL (StrR) endA1 nupG 
Invitrogen 
XL10 Gold 
Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB 
lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
Stratagene 
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2.1.3. Antibodies 
2.1.3.1. Primary antibodies for immunoblotting 
Name Species Source 
anti-Akt  rabbit polyclonal Cell Signaling 
anti-IKKε (12142)  mouse monoclonal Abcam 
anti-p44/42 MAPK (Erk1/2)  rabbit polyclonal Cell Signaling 
anti-Phospho-Akt (Ser473) rabbit polyclonal Cell Signaling 
anti-Phospho-Akt (Thr308) rabbit polyclonal Cell Signaling 
anti-Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204)  
rabbit polyclonal Cell Signaling 
anti-TANK (47632) rabbit polyclonal Abcam 
anti-TANK (D2) mouse monoclonal Santa Cruz 
anti-Phospho-IRF-3  rabbit monoclonal Cell Signaling 
anti-Phospho NF-κB p65 (Ser536) rabbit monoclonal Cell Signaling 
anti-Ubiquitin (P4D1) mouse monoclonal Cell Signaling 
anti-TBK1/NAK (D1B4)  rabbit monoclonal Cell Signaling 
anti-β-Actin (1801)  rabbit polyclonal Abcam 
 
2.1.3.2. Secondary antibodies for immunoblotting 
Name Species Conjugated to Source 
anti-mouse IgG  goat Horseradish peroxidase Dianova 
anti-rabbit IgG  goat Horseradish peroxidase Dianova 
 
2.1.3.3. Antibodies used for co- and chromatin-immunoprecipitation 
Name Species Source 
anti-Akt  rabbit polyclonal Cell Signaling 
anti-IKKε (12142)  mouse monoclonal Abcam 
anti-TANK (D2) mouse monoclonal Santa Cruz 
anti-TBK1/NAK (D1B4)  rabbit monoclonal Cell Signaling 
anti-normal IgG (2025) mouse Santa Cruz 
anti-normal IgG (2027)  rabbit  Santa Cruz 
anti-RNA polymerase II 
CTD phospho S2 
Rabbit polyclonal Abcam 
anti-IgG rabbit Cell Signaling 
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2.1.4. Expression plasmids 
cDNA/ construct/ name Vector Source 
pHCMVG  Addgene 
pMDLg/pRRE  Addgene 
pRSV-Rev  Addgene 
pMD2.G  Addgene 
psPAX2  Addgene 
shScramble pSIREN M.L. Schmitz 
shTANK #1 pSIREN Julia Stellzig 
shTANK #2 pLL3.7 Alain Chariot 
shTBK1 #1 pSIREN Julia Stellzig 
shTBK1 #2 pLKO1 Alain Chariot 
TANK siBlock 
290-pHAGE-hEF1aCAR-PGK Puro-
Linker 
Julia Stellzig 
 
2.1.5. Synthetic oligonucleotides 
2.1.5.1. Oligonucleotides for shRNA cloning 
Primer Sequence (5’3’) 
sh-hTBK1-f GATCCCCGGAGCTACTGCAAATGTCTTTCAAGAGAAGACATTTGCAGTAGCTCCTTTTTGGAAA 
sh-hTBK1-r AGCTTTTCCAAAAAGGAGCTACTGCAAATGTCTTCTCTTGAAAGACATTTGCAGTAGCTCCGGG 
 
2.1.5.2. Oligonucleotides for real-time PCR 
Primer Sequence (5’3’) 
IKKe-2-qRT-fw GCTCAGCTCCTGGACGTGCC 
IKKe-2-qRT-rev TGCCCTGAGCTGGCTGGTCA 
TBK1-qRT2-for GGCGGAGACCCGGCTGGTAT 
TBK1-qRT2-rev ACATTTGCATAGCTCCTTGGCC 
5’UTR-TANK-r TTCCTCTTCGTCCTGTAGCA 
5’UTR-TANK-f AGGATTGTTAGAGCCTGTGGA 
huActin-qPCR-f TCCCTGGAGAAGAGCTACGA 
huActin-qPCR-r AGGAAGGAAGGCTGGAAGAG 
TNF_FW GTGATCGGCCCCCAGAGGGA 
TNF_RV ACTGGAGCTGCCCCTCAGCT 
IL-6_FW CCTGCACGGCATCTCAGCCC 
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IL-6_RV TGCCAGTGCCTCTTTGTCGTC 
Vcam_FW ACGCTGACCCTGAGCCCTGT 
Vcam_RV ACGAGGCCACCACTCATCTCGA 
TBP_FW GAGCTGTGATGTGAAGTTTCC 
TBP_RV TCTGGGTTTGATCATTCTGTAG 
HPRT1_FW TGAGGATTTGGAAAGGGTGT 
HPRT1_RV GAGCACACAGAGGGCTACAA 
 
2.1.5.3. Oligonucleotides for site-directed mutagenesis 
Primer Sequence (5’3’) 
TANK shRNA res-1 AAGACTGAGAATTACGAGCAGAGAATACGTG 
TANK shRNA res-2 TTCTCTGCTCGTAATTCTCAGTCTTTTGCTG 
 
2.1.5.4. Oligonucleotides for chromatin-immunoprecipitation 
Primer Sequence (5’3’) 
GAPDH-UP TACTAGCGGTTTTACGGGCG 
GAPDH-LO TCGAACAGGAGGAGCAGAGAGCGA 
ChIP_hTANK_FW1 TTTGTATGCGTGAGCGAGAG 
ChIP_hTANK_RV1 CGACGATGCTATGCTGACAT 
ChIP_hTANK_FW2 TCTTACCGCGGTTGGAATAC 
ChIP_hTANK_RV2 CAACTGGGGAGAGGACTGAG 
 
2.1.6. Antibiotics 
Name Final concentration Source 
Ampicillin  100 µg/ml Sigma 
Puromycin 1 – 2 µg/ml Invitrogen 
Penicillin / Streptomycin 100 IU / 100 µg/ml Cell Concepts, PAA 
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2.1.7. Inhibitors 
Name Final 
concentration 
Target Source 
1-β-D-Arabinofuranosyl-
cytosine (Cytarabine, AraC) 
1 µM DNA synthesis Calbiochem 
5Z-7-oxozeaenol 1 µM TAK1 Sigma 
Actinomycin D 1 µg/ml 
DNA-dependent RNA 
synthesis 
Sigma 
Akt Inhibitor VIII 
(Isozyme-selective, Akti-1/2) 
5 µM Akt Calbiochem 
Aphidicolin 2 µg/ml DNA polymerase A,D Sigma 
Aprotinin  10 µl/ml 
Serine proteases 
(Trypsin, Chymotrypsin, 
Plasmin) 
Sigma 
BX795  1 µM IKK-related kinases 
Axon 
Medchem 
Complete ULTRA tablets 1 x Proteases Roche 
Cycloheximide 10 µg/ml Ribosomes Roth 
Leupeptine 10 µl/ml Proteases (Lysosomal) Sigma 
PD98059 20 µM MEK1/2 Cell Signaling 
Temozolomide 100 µM DNA replication Sigma 
U0126 5 µM MEK1/2 Cell Signaling 
 
2.1.8. Enzymes 
Name Source 
Calf intestine alkaline phosphatase (CIAP) Fermentas 
Long Range PCR enzyme mix (DNA 
polymerase) 
Qiagen 
Pfu Ultra DNA polymerase Stratagene 
Restriction enzymes Fermentas 
RiboLock R1 RNase Inhibitor Fermentas 
SuperScript™ II reverse transcriptase Invitrogen 
T4 DNA Ligase Fermentas 
T4 polynucleotide kinase (PNK) Fermentas 
RNase A Sigma 
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Taq DNA polymerase Fermentas 
 
2.1.9. Kits 
Name Source 
RNeasy Mini Qiagen 
ABsolute™ qPCR SYBR green ROX mix Thermo (ABgene) 
JETquick gel extraction spin kit Genomed 
JETquick PCR purification kit Genomed 
JETstar 2.0 Plasmid Mini/Midi/Maxi Genomed 
Vybrant® MTT Cell Proliferation Assay Kit Invitrogen 
Long Range PCR kit Qiagen 
QuickChange II site-directed mutagenesis Stratagene 
Pierce® BCA protein assay kit Thermo 
 
2.1.10. Chemical reagents 
Name Source 
1,4-Dithiothreitol (DTT) Invitrogen 
Acetic Acid Roth 
Acrylamide/ Bisacrylamide mix (Roti-
phorese) 
Roth 
Adenosine triphosphate (ATP) Sigma 
Agarose AppliChem 
Ammonium persulfate (APS) Bio-Rad 
Becton™ krypton BD Bioscience 
Bovine serum albumin (BSA) Sigma 
Bromphenol blue Merck 
Calcium Chloride (CaCl2) Roth 
Chloroform Merck 
Cupric sulfate Roth 
Deoxycholat Sigma 
deoxyribonucleotide triphosphates (dNTP) 
mix 
Fermentas 
Dimethyl 3,3-dithiobispropionimidate (DTBP) Therma 
Dimethyl sulfoxide (DMSO) Sigma 
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di-Sodium hydrogen phosphate (Na2HPO4) Roth 
Doxycycline Sigma 
Ethanol Roth 
Ethidium bromide Roth 
Ethylendiamintetraacetic acid (EDTA) Roth 
Ficoll 400 Sigma 
Gelatin Roth 
Glycerine Roth 
Glycerol Roth 
Hexadimethrine bromide (Polybrene) Sigma 
Hydrochloride acid 37% (HCl) Roth 
Isopropanol Roth 
Lithium chloride (LiCl) Merck 
Magnesium chloride (MgCl2) Merck 
Magnesium sulfate (MgSO4) Merck 
Methanol Roth 
N,N,N‘,N‘-Tetramethylethylendiamine 
(TEMED) 
Bio-Rad 
Nonident P40 (NP40) Roche 
Phenylmethanesulfonyl fluoride (PMSF) Fluka 
Polyethylenimine (PEI) Roth 
Potassium chloride (KCl) Roth 
Potassium dihydrogen orthophosphate 
(KH2PO4) 
Roth 
Potassium hydroxide (KOH) Merck 
Propidium iodide (PI) Sigma 
Skim milk powder Merck 
Sodium azide (NaN3) Roth 
Sodium chloride (NaCl) Roth 
Sodium dihydrogen phosphate (NaH2PO4) Merck 
Sodium dodecyl sulfate (SDS) Bio-Rad 
Sodium fluoride (NaF) Roth 
Sodium hydroxide (NaOH) Merck 
Sodium orthovanadate (Na3VO4) Sigma 
TRIS Roth 
Triton X-100 Sigma 
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TRIzol® Ambion 
Tryptone AppliChem 
Tween 20 Gerbu 
Yeast extract Roth 
β-Mercaptoethanol Roth 
 
2.1.11. Other reagents 
Name Source 
Enhanced chemiluminiscence (ECL) solution GE Healthcare 
Fetal calf serum (FCS) Cell concepts 
Generuler™ 1 kb DNA ladder Fermentas 
Generuler™ 100 bp DNA ladder Fermentas 
L-Glutamine (200 mM) Cell Concepts 
Lipofectamine 2000 Invitrogen 
Oligo(dT)12-18 Primer Invitrogen 
PageRuler™ prestained protein ladder Fermentas 
Protein A/G agarose beads Santa Cruz Biotech 
Roti®fect Roth 
TrypLETM Express Gibco 
First Strand Buffer Fermentas 
T4 ligase buffer Fermentas 
FACS Flow™ BD Bioscience 
FACS Clean BD Bioscience 
FACS Rinse BD Bioscience 
Trypsin/EDTA Cell Concepts 
 
2.1.12. Media, buffers and solutions 
2.1.12.1. Media for cultivating prokaryotic cells 
Bacteria were cultured either in Luria Bertani broth (LB) medium or on LB agar plates 
supplemented with an appropriate antibiotic. LB medium was assembled as follows: 
Bacto-trypton 1% (w/v) 
Yeast extract 0.5% (w/v) 
NaCl 1% (w/v) 
LB agar plates additionally contained 1.6% (w/v) agar. 
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2.1.12.2. Media for cultivating eukaryotic cells 
Most eukaryotic cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM), but 
MCF7 cells were kept in RPMI 1640 medium. 
Name Source 
DMEM high glucose Cell concepts 
RPMI 1640 Cell concepts 
DMEM as well as RPMI 1640 medium were supplemented with 10% (v/v) FCS, 1% (v/v) 
penicillin/streptomycin and 2 mM L-glutamine. Decomplementation of FCS was done at 
56 °C for 30 min to inactivate heat-labile complement proteins. 
2.1.12.3. Buffers and other solutions 
All buffers that are described subsequently were prepared using deionized water when 
nothing else is indicated. Water used for buffers in molecular biological methods was 
additionally autoclaved. 
Phosphate Buffered Saline (PBS) (pH 7.4) 137 mM NaCl 
 8.1 mM Na2HPO4 
 2.7mM KCl 
 1.5 mM KH2PO4 
   
TRIS Buffered Saline (TBS-T) (pH 7.4) 250 mM TRIS 
 1.37 M NaCl 
 50 mM KCl 
 7 mM CaCl2 · 2H2O 
 1 mM MgCl2 · H2O 
 0.1% (v/v) Tween 20 
   
TRIS-Acetate-EDTA (TAE) (pH 8.3) 0.05 M EDTA 
 2 M TRIS 
 1 M Acetic acid 
   
5 x SDS sample buffer 250 mM TRIS-HCl (pH 6.8) 
 15% (v/v) β-Mercaptoethanol 
 40% (v/v) Glycerin 
 10% (w/v) SDS 
 0.1% (w/v) Bromphenol blue 
   
SDS stacking gel (5%) 125 mM TRIS-HCl (pH 6.8) 
 5% (v/v) Acrylamide/Bisacrylamide 
 0.1% (w/v) SDS 
 0.04% (v/v) APS 
 0.3% (v/v) TEMED 
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SDS separating gel (8 or 10%) 350 mM TRIS-HCl (pH 8.8) 
 8 or 10% Acrylamide/Bisacrylamide 
 0.1% SDS 
 0.04% APS 
 0.075% TEMED 
   
5 x SDS Running Buffer 125 mM TRIS 
 960 mM Glycerine 
 0.5% (w/v) SDS 
   
Transfer Buffer (Semi-dry Blot) 48.5 mM TRIS 
 39 mM Glycerine 
 20% (v/v) Methanol 
 0.038% (w/v) SDS 
   
NP40 lysis buffer 20 mM TRIS-HCl (pH 7.5) 
 1% (v/v) NP40 
 150 mM NaCl 
 10% (v/v) Glycerol 
 prior to use:  
 25 mM NaF 
 1 mM Na3VO4 
 1 mM PMSF 
 10 µg/ml Aprotinin 
 10 µg/ml Leupeptin 
   
TE buffer 10 mM TRIS-HCl (pH 7.5) 
 1 mM EDTA 
   
6 x DNA sample buffer (pH 8) 15% (w/v) Ficoll 400 
 10 mM EDTA 
 0.1% (w/v) Bromphenol blue 
   
ChIP-SDS buffer 1% SDS 
 10 mM EDTA 
 50 mM TRIS-HCl (pH 8.1) 
 prior to use:  
 10 µg/ml Aprotinin 
 10 µg/ml Leupeptin 
 1 mM PMSF 
   
ChIP Dilution buffer 0.01% SDS 
 1% Trition X-100 
 1.2 mM EDTA 
 16.7 mM TRIS-HCl (pH 8.1) 
 16.7 mM NaCl 
   
ChIP low salt buffer 0.1% SDS 
 1% Triton X-100 
 2 mM EDTA 
 20 mM TRIS-HCl (pH 8.1) 
 150 mM NaCl 
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ChIP high salt buffer 0.1% SDS 
 1% Triton X-100 
 2 mM EDTA 
 20 mM TRIS-HCl (pH 8.1) 
 300 mM NaCl 
   
ChIP LiCl buffer 0.25 M LiCl 
 1% NP40 
 1 mM EDTA 
 20 mM TRIS-HCl (pH 8.1) 
 1% Sodium deoxycholat 
   
Annealing buffer 100 mM Potassium acetate 
 2 mM Magnesium acetate 
 30 mM HEPES-KOH (pH 7.4) 
 
2.2. Methods 
2.2.1. Methods in cell biology 
2.2.1.1. Eukaryotic cell culture 
Human cell lines cultures were grown in appropriate medium in 175 cm² flasks at 37 °C in 
a humidified 5% CO2 incubator. Confluent cells were trypsinized. Therefore, old medium 
was removed, cells were washed with 10 ml prewarmed 1 x PBS and 5 ml Trypsin was 
added. After incubation for 2 – 4 min. at 37 °C, cells were resuspended in complete 
medium to stop trypsinization. A small aliquot of cell suspension was added into a new 
flask with 20 ml of complete medium. 
2.2.1.2. Freezing and thawing 
To store cells for a longer term, they were frozen at -150 °C in 1 ml FCS with 10% (v/v) 
DMSO (freezing medium). Therefore cell suspension was centrifuged for 3 min at 
1300 rpm and the pellet was resuspended in freezing medium. The resulting suspension 
was transferred into labeled freezing vials and gradually cooled down to -150 °C. 
To thaw frozen cell aliquots, vials were placed in a 37 °C water bath until suspension was 
thawed completely. Then cells were immediately resuspended in prewarmed culture 
medium and pelleted to remove DMSO. Culture medium was added to the cell pellet and 
cells were seeded into a new flask. After cells attached to the ground, medium was 
changed to remove dead cells. 
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2.2.1.3. Transfection of eukaryotic cells 
Eukaryotic cells were transfected by liposomes using either PEI, Roti®-Fect or 
Lipofectamine according the manufacturer’s instructions. The plasmid DNA as well as 
transfection reagent were mixed with 100 µl DMEM each without any additives. After 
5 min both solutions were mixed and further incubated for 20 min at room temperature. 
Meanwhile seeded cell were prepared by washing them with 2 ml of 1 x PBS and adding 
of fresh antibiotic-free medium. The DNA-liposome mix was added on the cells drop wise 
and mixed gently. The cells were incubated at 37 °C in a humidified 5% CO2 incubator for 
4 hs. Then medium was exchanged to culture medium and cells were allowed to grow for 
at least 24 hs.  
2.2.1.4. Retro- and lentiviral infection of glioblastoma cell lines 
The introduction of DNA into glioblastoma cell lines was not possible as described above. 
Therefore those cell lines had to be infected with retro- or lentiviruses to express desired 
DNA. Retroviruses were produced in Phoenix Ampho cell line by transfecting pSIREN-
vector containing desired shRNA constructs with Roti®-Fect according to manufacturer’s 
instructions. The produced retroviruses were used to silence proteins in infected 
glioblastoma cell lines by RNA interference. The binding of shRNA to corresponding 
mRNA within the cell leads to degradation of the mRNA by ribonuclease. In order to 
exclude off-target effects, alternative constructs for shTANK and shTBK1 were delivered 
by lentiviral transduction. Thus, HEK293T cells were transfected with either pLL3.7-
shTANK or pLKO1-shTBK1 together with packaging plasmid psPAX2 (encoding HIV-1 
Gag, Pol, Tat and Rev proteins) as well as envelope plasmid pMD2.G (encodes for 
VSVG) using lipofectamine according the manufacturer’s instructions. Furthermore, over-
expression experiments for TANK were also performed using lentiviruses to infect 
glioblastoma cell lines. Lentiviruses were also produced in HEK293T cells by transfecting 
290-pHAGE-hEF1aCAR-PGK Puro-Linker TANK vector together with the packaging 
vectors pMDLg/pRRE, pRSV-Rev and pHCMVG using lipofectamine according the 
manufacturer’s instructions. Two days after transfection of the virus producing cells, the 
virus containing supernatant was collected and filtered through a 0.45 µm filter. After 
adding Polybrene to a final concentration of 5 µg/ml, the supernatant was added to the 
glioblastoma cell lines for 24 hs. Then medium was changed back to culture medium. 
Three days after infecting glioblastoma cell lines were treated with 2 µg/ml Puromycin for 
at least 5 days to select cells containing the desired DNA constructs. 
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2.2.1.5. MTT cell viability and proliferation assays 
To determine cell viability and indirectly the proliferation ability, the Vybrant® MTT cell 
viability assay was performed. Glioblastoma cell lines where either TANK or TBK1 was 
silenced or scrambled control cells were counted and 1 x 10³ cells per well were seeded in 
96-well plates. At the next day, cells were treated with either the cytostatics TMZ and 
AraC or the inhibitor BX795. After 3 days the assay was performed as described in the 
manufacturer’s instructions. Water soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was solubilized in 1 ml PBS by sonification and 10 µl of it 
was added to each well containing 100 µl new complete DMEM medium. Within 4 hs of 
incubation at 37 °C the living cells took up the MTT and converted it into the insoluble 
formazan. To stop the reaction and to lyse the cells, 100 µl SDS-HCl solution was added 
to each well. The plate was then further incubated at 37 °C in a humidified chamber to 
dissolve the formazan. The absorbance of formazan was measured 16 hs later on an 
Ultra Microplate Reader EL-808i at a wavelength of 562 nm. 
2.2.1.6. Proliferation assays 
To measure proliferation of Glioblastoma cell lines, cells were counted in a FACSCalibur. 
Cells were seeded at a density of 5 x 10³ on 6 and 10 cm² plates, respectively, and were 
allowed to grow for either 72 or 120 hs. To harvest the cells, they were first washed with 
1 x PBS and subsequently trypsinized with TrypLETM Express for 5 min. Trypsinization 
was stopped by adding complete medium on the plate. Cell suspension was then 
transferred to round-bottom tubes. The number of cells was counted by FACSCalibur over 
a constant time of 60 sec at medium flow rate (35 ± 5 µl/min) with following settings: 
Param Detector Voltage Amp Gain Mode 
P1 FSC E00 1.00 lin 
P2 SSC 310 1.00 lin 
P3 FL1 394  log 
P4 FL2 340  log 
P5 FL3 200  log 
 
2.2.1.7. Cell migration assays 
The wound-healing assay, also called scratch assay, is a method to determine cell 
migration where an area of a cell layer is scraped off and the migration of cells into this 
gap is monitored microscopically. Knock-down and control glioblastoma cells were seeded 
at a density of 1.5 – 2 x 105 cells per well in 6-well pates and grown to 80% confluence. 
Cells were then kept in serum-reduced complete medium supplemented with 2 µg/ml 
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aphidicolin to prevent proliferation. At text day, a scratch was gently made with a yellow 
pipette tip. The cells were washed twice with prewarmed PBS to remove loose cells and 
serum-reduced medium supplemented with 2 µg/ml aphidicolin was added again. Directly 
after scratching as well as 10 and 24 hs after pictures of the gap were taken with a life cell 
imaging technique using a NIKON Inverted Research Microscope Eclipse TE2000-E to 
retain migration. Taken pictures were analyzed using NIKON NIS-Elements AR 3.22. 
2.2.1.8. Cell cycle analysis by flow cytometry 
A cell cycle profile displays the DNA content of a cell population and thereby provides 
information about the four characteristic phases of the cell cycle. Whereas G1 phase is 
characterized by a diploid set of chromosomes (2N) and S phase by an aneuploid (2N – 
4N), cells in G2 have a fourfold amount of DNA [227]. The DNA amount can be measured 
by flow cytometry after staining with propidium iodide, a fluorescent dye that intercalates 
into DNA. The measured fluorescence then is directly proportional to the DNA content of 
the cells. Either knock-down or control cells were seeded on 10 cm dishes and if required 
treated with 0.3 µM vinblastine for 24 hs to arrest the cell cycle in late G2 phase. After 
collecting the culture medium in a 15 ml tube, cells were detached using TrypLETM 
Express. Detached cells were then transferred to the corresponding tube and pelleted at 
3,000 rpm at 4 °C for 5 min. Cells were washed with PBS and the cell pellets were taken 
up in 300 µl PBS. Cell were fixed by dropwise adding of 1 ml ice-cold ethanol (70%) while 
the suspension was vortexed to avoid the formation of cell clumps. After not less than 1 h 
cells were pelleted again and washed once with PBS. Cell pellets were then resuspended 
in 500 µl PI-TritonX100-RNaseA solution and incubated for 15 min at room temperature in 
the dark. To stop this staining reaction, tubes were put on ice. The emission of propidium 
iodide was then analyzed using a FACSCalibur with different settings for each cell line. 
Percentages of cells in certain cell cycle phases were determined by ModFit LT™ 
software. 
2.2.2. Methods in biochemistry 
2.2.2.1. Preparation of protein extracts 
In order to analyze expression levels of proteins as well as their phosphorylation state 
they first need to be extracted from either eukaryotic cells or patient samples. 
2.2.2.1.1. Protein isolation from patient samples 
Patient tissue of glioblastoma multiforme, astrocytoma grade III and normal brain were 
kindly provided by Prof. Dr. Axel Pagenstecher. Frozen tissue was cutted in a cryo bench, 
weighted and transferred to microcentrifuge tubes. To extract the proteins, 10 x volume of 
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cold NP40 extraction buffer containing a mix of protease inhibitors (1 x Complete ULTRA 
tablet and 5 µg/ml Pepstatin A) was added and the tissue was homogenized by using a 
Turrax. Samples were frozen immediately on dry ice and transferred to -80 °C. 
2.2.2.1.2. Determination of protein concentration 
To determine the protein concentration of homogenized patient tissues, the Pierce® BCA 
protein assay was performed in 96-well plates following the manufacturer’s instructions. 
BSA stocks (2 mg/ml) were used to prepare a set of nine diluted standards ranging from 
0 – 2000 µg/ml. The working reagents were prepared by mixing 50 parts BCA reagent A 
with one part of BCA reagent B. In each well of a 96-well plate 10 µl of either the 
standards or the sample with unknown protein concentration was mixed with 200 µl of the 
working reagent. After incubating the plate at 37 °C for 30 min the plate was cooled down 
to room temperature. The absorbance was measured on an Ultra Microplate Reader EL-
808i with a wavelength of 562 nm within 10 min after cooling. Each measurement was 
carried out in triplicates. The standard curve was used to determine the protein 
concentration of the samples extracted from patient tissue. Before Western blot analysis 
of the samples, they were mixed with 5 x SDS sample buffer to a final concentration of 
1 x SDS. 
2.2.2.1.3. Lysate preparations from eukaryotic cells 
Proteins from glioblastoma cell lines were extracted by SDS lysis to get proteins from all 
the compartments within the cell and even membrane-bound proteins. Cells were first 
washed once with ice-cold PBS, harvested by scraping and then transferred to 
microcentrifuge tubes. After pelleting the cells at 3,000 rpm for 5 min, cells were 
resuspended in 1 x SDS sample buffer. After heating the suspension to 95 °C they were 
sonicated twice for 20 sec to shear the genomic DNA. The samples were then heated 
again to 95 °C for 5 min and frozen at -80 °C. 
2.2.2.2. Co-immunopecipitation 
The interaction of cellular proteins were determined by co-immunoprecipitation. To 
increase the binding stability of the interactions, the proteins were crosslinked before the 
actual precipitation. For the crosslinking, cells were first washed once with cold 1 x PBS 
on the dish. A freshly prepared 0.5 mM DTBP solution in 1 x PBS was added to the cells 
and incubated for 30 min at room temperature. After removing the DTBP solution cells 
were washed two times with PBS containing 200 mM TRIS/HCl (pH 7.5) for 10 min to stop 
the crosslinking reaction. Then cells were harvested by scraping in PBS with TRIS/HCl 
(200 mM, pH 7.5). Harvested and washed cells were lysed under native conditions by 
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resuspending the pellet in NP40 buffer containing protease inhibitors and incubated on ice 
for 20 min. Nuclear DNA was shared by two times sonification for 20 sec. To spin down 
cellular debris, the sonicated lysate was centrifuged 10 min at 13,000 rpm and the 
supernatant was transferred to new tube. After taking out 10% of the lysate as input 
control, the samples were incubated with A/G sephasose for 60 min at 4 °C to prevent 
nonspecific binding. After spinning down the beads by centrifugation, the supernatants 
were transferred to a new tube and 1 - 2 µg of primary antibody or control IgG were 
added. The antibodies were allowed to bind the proteins in the samples overnight at 4 °C 
on a spinning wheel. At the next day, 25 µl of A/G sepharose was added and samples 
were again incubated at 4 °C gently rocking for 2 hs. The supernatant was discarded and 
the beads were washed 5 times with NP40 buffer containing protease inhibitors. To elute 
bound proteins from the beads they were boiled at 95 °C in 2 x SDS sample buffer for 
4 min. The eluates were then further analyzed by SDS-PAGE and Western Blot. 
2.2.2.3. Polyacrylamide gel electrophoresis  
In order to separate equally charged proteins by their molecular weight a discontinuous 
polyacrylamide gel electrophoresis (SDS-PAGE) was performed. Samples were mixed 
with 5 x SDS sample buffer to a final concentration of 1 x SDS. Cells were already lysed in 
1 x SDS sample buffer as described in 2.2.2.1.3. This sample buffer contains SDS to 
denature and negatively charge the proteins as well as β-mercaptoethanol to reduce 
disulfide bonds. SDS polyacrylamide gel contained a separating gel with an acrylamide 
concentration between 8 and 15%, depending on the expected size of the proteins, and a 
stacking gel containing 5% acrylamide which is necessary to focus the proteins in a single 
sharp band. This stacking of proteins was performed at 80 V. Once the separation of 
proteins started, the current was increased up to 120 V. To estimate the approximate size 
of various proteins, a pre-stained protein marker was loaded on the polyacrylamide gel 
next to the samples. Proteins were visualized by Western blotting. 
2.2.2.4. Western blot and immune detection 
Western Blot is a method to detect proteins by transferring them on a membrane and 
identify the proteins by binding of specific antibodies. Separated proteins from the SDS-
PAGE were transferred to and immobilized on polyvinylidene difluoride (PVDF) 
membranes using a semi-dry transfer method. Therefore, the PVDF membrane was 
activated by methanol for a few seconds and whatman papers were incubated in transfer 
buffer. Two of those whatman papers were placed into the electroblotting device. The 
activated PVDF membrane, the SDS polyacrylamide gel and another whatman paper 
were added on top. After removing carefully air bubbles between the layers, the device 
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was closed and a constant voltage of 24 V was applied. Depending on percentage of the 
SDS polyacrylamide gel, the size of the protein of interest and the number of gels per 
device, the transfer was performed for 40 to 195 min. The membranes with the transferred 
proteins were blocked by incubating for at least 30 min in blocking solution containing 
either 5% skim milk powder or BSA dissolved in TBS-T. After washing the membrane 
twice in TBS-T, the incubation with primary antibodies was carried out overnight at 4 °C. 
After washing three times with TBS-T for 10 min., the membranes were incubated with 
secondary peroxidase-coupled antibody for 1 h at room temperature. The non bound 
antibody was removed from the membranes by washing again three times for 10 min with 
TBS-T. Proteins with bound antibodies were then detected by autoradiography using an 
enhanced chemiluminiscence (ECL) system. 
2.2.3. Methods in molecular biology 
2.2.3.1. Preparation of competent E.coli 
E.coli stains were used to amplify plasmid DNA in high copy numbers. To ensure the 
uptake of the DNA bacteria were made chemically competent using the CaCl2 method. An 
Erlenmeyer flask with 10 ml LB medium was inoculated with E.coli and incubated 
overnight shaking at 37 °C. Next day, additional 90 ml of prewarmed LB medium were 
added and cells were allowed to grow further for approximately 70 min. Bacteria were 
cooled down and harvested by centrifugation at 4,000 g for 15 min at 4 °C. Cell pellets 
were resuspended in 50 ml ice-cold 0.1 M CaCl2 solution and incubated at 4 °C for 
30 min. Bacteria were again pelleted by centrifugation and resuspended in 3 ml of a 10% 
glycerol/0.1 M CaCl2 solution. Competent E.coli were aliquoted at 100 µl and stored at  
-80 °C. 
2.2.3.2. Competent E.coli transformation 
Various chemically competent E.coli stains were transformed to amplify plasmids. An 
aliquot of 50 µl of E.coli, which was thawed on ice, was mixed with 1 µg of the DNA and 
incubated for 20 min on ice. To induce the uptake of DNA into the bacteria via heat-shock, 
they were placed at 42 °C for 90 sec. After incubating the suspension for additional 5 min 
on ice, LB medium was added and the bacteria were allowed to grow shaking for 1 h at 
37 °C. Finally the transformed bacteria were plated out on LB agar plates supplemented 
with appropriate antibiotic to select for transformed cells. Plates were incubated overnight 
at 37 °C. 
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2.2.3.3. Plasmid DNA Purification 
Isolation of DNA from transformed E.coli was either performed by miniprep to identify the 
right clones or by maxiprep for large-scale preparations of highly pure DNA for 
transfection of eukaryotic cells. Both protocols follow the principles of alkaline lysis by 
Birnboim and Doly [403]. Minipreps were done by inoculation of bacteria in 3 ml of LB 
medium and further growth overnight at 37 °C. Next day, they were transferred to a tube 
and pelleted by centrifugation for 5 min at 5,000 rpm. LB medium was aspirated and 
bacteria were resuspended on ice in 200 µl buffer P1. To lyse the cells, 200 µl of buffer P2 
was added and mixture was incubated for 5 min at room temperature. After neutralization 
with 200 µl precooled buffer P3, tubes were incubated for 20 min. on ice. Thereafter the 
solution was centrifuged 10 min at 13,000 rpm and the supernatant was transferred to a 
new tube. To precipitate the DNA 350 µl isopropanol was added and the well mixed 
solution was centrifuged 15 min at 13,000 rpm. The supernatant was discarded and DNA 
washed with 500 µl 70% ethanol. DNA was pelleted, air-dried and redissolved in 30 µl TE 
buffer. 
For Maxiprep the Jetstar 2.0 Plasmid Mini/Midi/Maxi kit was used according the 
manufacturer’s instructions. Pelleted bacteria cells, that were grown overnight at 37 °C in 
250 ml LB medium supplemented with antibiotics, were resuspended in 10 ml buffer E1 
containing 100 µg/ml RNase. Suspension was then mixed with 10 ml buffer E2 in order to 
lyse cells. After incubation for 5 min at room temperature, lysates were neutralized by 
adding 10 ml buffer E3. Cell debris was spinned down and supernatant was applied to a 
Jetstar 2.0 column pre-equilibrated with 30 ml buffer E4. Once lysate ran through the 
column by gravity flow, it was washed once with 60 ml of buffer E5. After elution of DNA 
from the column by adding 15 ml of buffer E6, DNA was precipitated with 0.7 volumes of 
isopropanol and centrifuged for at least 30 min at 12,000 x g. The formed pellet was 
washed once with 5 ml of 70% ethanol and recentrifuged. Air dried DNA was dissolved in 
a suitable volume of TE buffer and quantified spectrophotometrically. 
2.2.3.4. Introduction of DNA fragments in vector molecules – cloning 
Plasmids are commonly used to introduce a desired DNA into eukaryotic cells. This 
certain DNA first has to be cloned into a suitable vector. 
2.2.3.4.1. Polymerase chain reaction 
The DNA fragment that will be cloned into a vector can be produced either by 
amplification by PCR (polymerase chain reaction) method or by annealing of two 
oligonucleotides. Polymerase chain reaction is a common method to amplify defined DNA 
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sequences. To minimize the risk of unwanted point mutations the Long Range PCR Kit of 
Qiagen was used that contains a DNA polymerase with an 3’-5’ exonuclease activity for 
proof-reading. The PCR reaction was set up on ice as followed: 
 Template DNA 20 ng 
 10x LongRange PCR buffer 5 µl 
 dNTP mix 0.5 mM 
 forward primer 0.4 µM 
 reverse primer 0.4 µM 
 Long Range PCR enzyme mix 2 units 
 RNase-free water to a total volume of 50 µl 
The amplification of the DNA in a Bio-Rad thermocycler was carried out under following 
conditions: 
 Initial activation: 3 min 95 °C 
 Denaturation: 15 sec 95 °C 
 Annealing 30 sec 55 - 62 °C (~5 °C below Tm of primers) 
 Extension: 1 min/kb 68 °C 
After 35 cycles an additional elongation step at 68 °C for 5 - 7 min was added. The 
annealing temperature depends on the melting point of the designed primers that usually 
contain a further non-complementary sequence coding for specific endonuclease 
restriction sites that are used to ligate the DNA into a vector that was opened with the 
same restriction enzymes. 
For smaller DNA fragments it is also possible to anneal oligonucleotides to get fragments 
that can be ligated into an opened vector. Therefore 5 µg of each oligonucleotide were 
mixed in annealing buffer to a total volume of 50 µl. The mixture was incubated 5 min at 
95 °C and then slowly cooled down by shutting off the heating block. After cooling down of 
the annealed oligonucleotides to room temperature, they were stored at -20 °C. 
2.2.3.4.2. Restriction enzyme digestion, agarose gel electrophoresis and gel 
extraction 
Vectors are used as vehicles to bring desired DNA into eukaryotic cells. Both DNA 
fragments and vectors first need to be cut with certain restriction endonucleases to 
generate compatible ends before they can be ligated. Restriction enzymes commonly 
used for digestions recognize and cut short palindromic sequences of 4 to 7 base pairs. In 
order to digest DNA the following mixture was prepared on ice and incubated for 2 hs at 
the enzyme specific optimal temperature: 
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DNA 3 µg 
10 x restriction buffer 1 µl 
restriction enzyme 1 (10 U/µl) 0.5 µl 
restriction enzyme 2 (10 U/µl) 0.5 µl 
MilliQ water to a total volume of 10 µl 
The digested products were analyzed by agarose gel electrophoresis. To separate DNA 
fragments according to their size, 0.8 – 2% (w/v) agarose was melted in TAE buffer. To 
visualize the DNA under UV light 0.5 µg/ml ethidium bromide was added to the liquid gel. 
Ethidium bromide intercalates in DNA double strands and emits fluorescent light when 
exposed to UV light. Before loading DNA samples on the gel they were mixed with 
6 x Loading Dye. Then the gels was run at a constant voltage of 80 V in TAE buffer.  
For further cloning desired fragments were excised from the agarose gel under reduced 
UV exposure using a clean scalpel. The JETquick gel extraction kit was used according to 
the manufacturer’s instructions to isolate the DNA from the gel slice. Therefore the 
excised gel was melted at 50 °C in buffer L1 for 15 minutes. The mixture was loaded on a 
spin column where the DNA binds to the resin. After washing the DNA with solution L2, it 
was eluted in 30 µl sterile water and stored at -20 °C. 
2.2.3.4.3. Dephosphorylation and 5’-phosphorylation of DNA 
To obviate the religation of plasmid DNA that was digested with just one restriction 
enzyme, the 5’-phosphates were removed using calf intestine alkaline phosphatase 
(CIAP). Following mixture was therefore prepared: 
Linearized plasmid DNA (1 µg/µl) 1 - 3 µl 
10 x CIAP reaction buffer 1 µl 
CIAP (1 U/µl) 1 µl 
MilliQ water to a total volume of 10 µl 
This mixture was then incubated at 37 °C for 30 min. After stopping the reaction by 
heating at 85 °C for 10 min the plasmid DNA could be used for ligation reaction or stored 
at -20 °C. 
The dephosphorylation of plasmid DNA necessitate the 5’-phosphorylation of the DNA 
fragment that shall be ligated into the vector. The transfer of γ-phosphate of ATP to the 5’-
OH group the DNA was accomplished by T4 polynucleotide kinase (PNK) according the 
subsequent procedure. First, the following mixture was prepared: 
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Purified PCR products 1 – 5 µl 
10 x reaction buffer A 2 µl 
ATP (10 mM) 2 µl 
PNK (10 U/µl) 1 µl 
MilliQ water to a total volume of 20 µl 
The reaction mixture was incubated at 37 °C for 20 min. Heating the solution at 75 °C for 
10 min inactivates the kinase. Products can be directly used for ligation reaction or stored 
at -20 °C. Sometimes it can be useful to repeat the agarose gel electrophoresis and gel 
extraction at this step to remove the enzyme when it is not completely inactivated. 
2.2.3.4.4. Ligation of DNA fragments 
Finally the opened and dephosphorylated plasmid DNA and the 5’-phosphorylated DNA 
fragment can be ligated to create a new plasmid used for transferring DNA into eukaryotic 
cells. 
The ligation reaction was set up with different molar ratios of plasmid to insert to assure 
the best outcome. Vector:Insert mixtures with ratios ranging between 1 : 1 and 1 : 10 were 
mixed with 1 µl 10 x T4 DNA ligase buffer and 1 µl T4 DNA ligase (1 U/µl) and were filled 
up with sterile water to a final volume of 10 µl. Samples were then either incubated for 
2 hs at room temperature or slowly cooled down to 4 °C overnight. Ligation reaction mix 
was directly used for the transformation of appropriate E.coli stains and remaining mixture 
was stored at -20 °C. 
2.2.3.4.5. Site-directed point mutagenesis 
In order to alter the function of proteins, single amino acids can be changed by mutating 
one or several base pairs in the sequence of the protein of interest. Besides it is possible 
to create proteins that are resistant to silencing by certain siRNA or shRNA by introducing 
a silent mutation that has no influence on the amino acid sequence and thereby does not 
alter the function of the protein. 
To introduce silent mutations the site-directed mutagenesis was performed using the 
QuickChange II site-directed mutagenesis kit from Stratagene according the 
manufacturer’s suggestions. The design of two synthetic complementary primers 
containing the single point mutations was carried out according to the manufacturer’s 
instructions. The following mixture was prepared for a typical PCR reaction: 
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Template DNA (100 ng/µl) 1 µl 
10 x reaction buffer 5 µl 
Quick solution 3 µl 
dNTP mix (10 mM) 1 µl 
Forward primer (10 µM) 1.2 µl 
Reverse primer (10 µM) 1.2 µl 
Pfu ultra DNA polymerase 1 µl 
MilliQ water to a total volume of 50 µl 
The linear amplification of PCR products containing the desired mutation was performed 
with the following PCR parameters for 18 cycles: 
 Initial activation 2 min 95 °C 
 Denaturation 50 sec 95 °C 
 Annealing 30 sec 60 °C  
 Extension 1 min/kb 68 °C 
After the 18th cycle an additional elongation step at 68 °C for 5 min was carried out to 
ensure the generation of full-length products. To digest the methylated template DNA, 1 µl 
of DnpI restriction enzyme (10 U/µl) was added and the samples were incubated for 2 hs 
at 37 °C. Unmethylated DNA resulting from polymerase chain reaction is not affected by 
this digestion. Finally the PCR product was directly transformed into highly competent 
XL10 Gold E.coli that were provided with the kit. 
2.2.3.5. RNA extraction 
2.2.3.5.1. TRIzol® RNA extraction from patient tissue 
In order to isolate total RNA from patient samples, frozen tissue was prepared as 
described for protein extraction in 2.2.2.1.1 and then homogenized in 500 µl TRIzol®. 
After adding of 100 µl chloroform and vigorously agitation, samples were incubated at 
room temperature for phase separation. Samples were then centrifuged for 10 min at 
13,000 rpm at 4 °C. The mixtures should be separated in three phases where the RNA 
resides in the upper aqueous phase which was transferred to a new tube. RNA was then 
precipitated by adding of 250 µl isopropanol (100%) and incubated at room temperature 
for 10 min. Precipitated RNA was pelleted by centrifugation for 10 min at 13,000 rpm and 
washed with 150 µl 70% ethanol. The pellet was air dried and resuspended in 20 µl 
RNase-free water. Samples were stored at -80 °C. 
2.2.3.5.2. RNA isolation from eukaryotic cells 
Total RNA was isolated from eukaryotic cells using the RNeasy kit from Qiagen following 
the manufacturer’s instructions. Cells were washed with PBS and harvested by scraping. 
Cells were lysed by adding 600 µl of RLT buffer containing β-Mercaptoethanol (10µl/ml) 
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and passing them trough a blunt 20-gauge needle for at least five times. Lysates were 
then mixed with 600 µl ethanol (70%) and loaded on a provided spin column. The column 
was first washed once with 700 µl RW1 buffer and afterwards twice with 500 µl RPE 
buffer. To remove remaining ethanol of buffer RPE, the column was centrifuged without 
adding further buffers. RNA was then eluted by adding 30 µl RNase-free water on the 
column and centrifugation. RNA concentration and purity was measured in a 
spectrophotometer, afterwards 1.5 µl RiboLock R1 was added to prevent RNA 
degradation. RNA was stored at -80 °C. 
2.2.3.6. Synthesis of complementary DNA 
Before the expression of mRNA of interest can be analyzed by semi-quantitative real-time 
PCR, mRNA was transcribed into cDNA. The CDNA synthesis was performed using the 
SuperScript™ II reverse transcriptase kit by Invitrogen. The following reaction mix was set 
up: 
Template RNA  1 µg 
dNTP mix (10 mM) 1 µl 
Oligo(dT)12-18 primer 1 µl 
MilliQ water to a total volume of 12 µl 
By using Oligo(dT)12-18 primer, that bind to the poly(A)-tail of mRNAs, it is ensured that 
whole mRNA is transcribed into cDNA. For certain questions it can be necessary to use 
specific primers for any mRNA. The reaction mixture described above was incubated at 
70 °C for 5 min and immediately put on ice. Then following reagents were added to each 
reaction: 
5 x First-strand buffer  4 µl 
DTT (100 mM) 2 µl 
RiboLock R1 1 µl 
SuperScript II reverse transcriptase 1 µl 
MilliQ water to a total volume of 20 µl 
Samples were the further incubated in a thermocycler at 42 °C for 55 min. The reaction 
was stopped by heat inactivation at 70 °C for 15 min. The resulting cDNA was diluted to a 
final volume of 100 µl with sterile water and stored at -20 °C. 
2.2.3.7. Semi-quantitative real-time polymerase chain reaction 
The semi-quantitative real-time PCR is a common method to quantify changes of gene 
expression of target genes between different samples. By adding the fluorescent reagent 
SYBR green to the reaction that intercalates with double stranded DNA the amplification 
of synthesized DNA can be measured. 
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Real-time PCRs were performed by preparing the following reaction mixtures per well in 
triplicates on a 96-well plate: 
Template cDNA (10 ng/µl) 2 µl 
Absolute SYBR green ROX mix 12,5 µl 
Forward primer (5 μM) 0.5 – 1.5 µl 
Reverse primer (5 μM) 0.5 – 1.5 µl 
MilliQ water to a total volume of 25 µl 
Following, amplification and analyzes were executed using an Applied Biosystems 7300 
real-time PCR system with the following parameters for PCR reaction: 
Initial activation: 15 min 95 °C  
Denaturation: 15 sec 95 °C  
Annealing 30 sec 60 °C 40 cycles 
Extension: 30 sec 72 °C  
    
Data were normalized to the mRNA levels of the house-keeping genes β-Actin or Tbp and 
Hprt1 and relative changes in expression levels compared to any calibrator (e.g. with 
shScramble silenced cells, untreated cells or healthy brain samples) were calculated by 
the ΔΔCt method.  
2.2.3.8. Chromatin-immunoprecipitation 
In order to analyze the de novo transcription of the Tank gene in different glioblastoma cell 
lines, a chromatin-immunoprecipitation (ChIP) was performed. Thereby, active 
polymerase II, which was bound to the DNA, was precipitated. Co-precipitated DNA was 
then determined by real-time PCR. To crosslink the proteins that are bound to the DNA, 
10 ml of a 1% formaldehyde solution was added to confluent grown cells and incubated 
for 10 min at room temperature. Formaldehyde was then neutralized by adding 1 ml of 
1.25 M glycine, followed by an incubation at room temperature for 2 minutes. After 
washing cells were washed twice with ice-cold PBS, they were harvested by scraping and 
pelleted by centrifugation at 1,500 rpm for 5 min. Pelleted cells were lysed in 1,600 µl 
ChIP-SDS buffer supplemented with Aprotinin (10 µg/ml), Leupeptin (10 µg/ml) and PMSF 
(1 mM), and incubated for 10 min on ice. To shear genomic DNA, lysates were sonicated 
intervallic (4 times for 1 minute with 1 min breaks). Cell debris was removed by 
centrifugation of the lysate for 20 min at 13,200 rpm. The supernatant was transferred to a 
new tube. Aliquots of the lysates were frozen at -80 °C and 100 µl was taken as input 
control. To examine the quality of DNA shearing as well as the amount of DNA, the input 
control was first reverse crosslinked. Therefore, input was mixed with 100 µl ChIP TE 
buffer and 2 µl RNase A and incubated at 37 °C for 30 minutes. Following, 5 µl of a 
10% SDS solution and 5 µl Proteinase K was added and further incubation at 37 °C for at 
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least 4 hs and subsequently at 65 °C for 6 hs. DNA was then isolated using the Jet PCR 
Purification Kit according to the manufacturer’s instructions. DNA concentration was 
determined by spectrophotometry. The shearing of DNA was controlled by agarose gel 
electrophoresis. Fragments should appear between 300 - 800 bp. To precipitate active 
polymerase II, cell lysates were thawed on ice and mixed with ChIP dilution buffer to a 
final volume of 1 ml. To reduce non-specific binding at the A/G sepharose beads, lysates 
were pre-cleaned by adding the beads and subsequent incubation for 1 h at 4 °C in a 
rotating wheel. Beads were pelleted and supernatant was agitated with 35 µl A/G 
sepharose as well as 2 µg of either active polymerase II or IgG antibody. The mixture was 
incubated rotating overnight at 4 °C. At the next day, beads were washed consecutively 
with 1 ml ChIP low salt buffer, 1 ml ChIP high salt buffer, 1 ml ChIP LiCl buffer and two 
times with 1 ml ChIP TE buffer. Then beads were resuspended in 100 µl ChIP TE buffer. 
Finally, samples were reverse crosslinked as described before and DNA was extracted. 
Purified DNA was then used as template for real-time PCR analysis using specific primers 
for either GAPDH or TANK whereas two distinct regions of the Tank gene were chosen for 
the analysis. All data were fist normalized to IgG as negative control for each ChIP pull-
down and eventually to GAPDH to exclude differences between the cell lines. 
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3. RESULTS 
 
3.1. The expression of the non-canonical IKK complex in 
glioblastoma multiforme 
3.1.1. Protein and mRNA levels of the non-canonical IKK complex in primary 
patient tissue samples 
The kinases of the non-canonical IKK complex are already known to be involved in the 
oncogenesis of different types of cancer such as breast, lung and colon cancer [404]. A 
database research using the integrated cancer database Oncomine 
(http://www.oncomine.org) turned out an over-expression of the adaptor protein TANK 
(Fig. 3.1.A-B). Here, an in silico expression analysis was performed by comparing 
different microarray studies of various normal and glioma tissue samples. In order to 
confirm the expression of the adaptor protein TANK as well as the two IKK-related kinases 
TBK1 and IKKε in primary glioma tumors, proteins were extracted from patient tissue 
samples, that were kindly provided by Prof. Dr. Axel Pagenstecher, and analyzed by 
Western blot (Fig. 3.1.C). Elevated protein levels of TANK but also of TBK1 and IKKε 
indicate that some cancers show over-expression of components of the non-canonical IKK 
complex in GBM and astrocytoma grade III. Considerable fluctuation of the measured 
protein levels further indicate a great variance between different patients. In addition, the 
expression of Akt and ERK1/2 kinases was examined, since both play a crucial role in the 
development and progression of GBM (see 1.1.2). Akt kinase as well as ERK1/2 also 
show increased protein levels in some gliomas compared to normal brain as well as a 
great variance among the patients. Akt is constitutively phosphorylated at T308 and S473. 
Additionally, ERK1/2 was phosphorylated in the investigated primary brain tissues. The 
phosphorylation of both kinases is higher in normal brain tissue compared to 
glioblastomas/astrocytomas whereas the expression is elevated in 
glioblastomas/astrocytomas tissue. The complete set of analyzed patient samples are 
shown in supplementary figure S1, further illustrating variable expression and 
phosphorylation levels.  
In parallel, RNA was isolated from the patient tissue samples and mRNA levels of TANK, 
TBK1 and IKKε were determined by real-time PCR (Fig. 3.1.D). Consistent with the 
findings for protein levels, also the mRNA levels were elevated in 
glioblastoma/astrocytoma patient samples in comparison with normal brain tissue. The 
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variance of mRNA levels was even more striking compared to protein levels. Besides 
TANK, also mRNA levels of IKKε varied a lot whereas mRNA levels of TBK1 show less 
variability among the analyzed patient samples. To visualize and compare this variance, 
mRNA levels were displayed as boxplots (Fig. 3.1.E) indicating increased mRNA levels of 
IKKε and TANK and to a lesser extent of TBK1 compared to normal brain. The variance 
between the values was most remarkable for TANK. 
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Fig. 3.1.: Expression analysis of members of the non-canonical IKK complex in primary patient 
tissues. (A) The expression of TANK was analyzed by an in silico expression analysis of normal brain (light 
blue, n=10) and GBM patient samples (dark blue, n=515) using the database Oncomine. Each bar 
represents an individual tissue sample (Reporter ID: 209451_at; Nucleotide Acc. No.: U59863). (B) The data 
of (A) were summarized in boxplots. The box illustrates the interquartile range (75
th
 to 25
th
 percentile). The 
upper part of the bar shows the 90
th
 percentile and lower bar the 10
th
 percentile. The dots stands for 
outliners. The graph was created using the Oncomine 3.0 software. (C) Patient tissue samples of normal 
brain (NB), glioblastoma multiforme (GBM) and astrocytoma grade III (A III) were (if possible) divided in two 
parts and either protein or RNA was extracted. Proteins were extracted from patient tissues by homogenizing 
of the material in NP40 lysis buffer and using a Turrax. Endogenous protein expression was then analyzed 
by Western blot using the indicated antibodies for endogenous proteins. More GBM and A III patient samples 
are shown in supplementary figure S 1. (D) Total RNA was extracted by TRIzol® and translated into cDNA 
using Oligo(dT) primers. The amount of mRNA was quantified by real-time PCR using specific primers for 
either TANK, TBK1 or IKKε. Expression levels of NB were set as 1. Housekeeping genes Tbp and Hprt1 
were used to normalize values. Error bars express the standard deviation of two experiments performed in 
triplicates. The variation of mRNA levels of TANK, TBK1 and IKKε were further visualized in boxplots (E), in 
which the box represents the interquartile range with median, error bars show the overall range of values and 
dots symbolize outliners. 
 
Taken together, the analysis of patient tissues from GBM and astrocytoma grade III 
validate an over-expression of the non-canonical IKK complex in some cases, but apart 
from that, highly variable levels of the proteins were found. As during resection of cancer 
tissue usually transformed and non-tumorigenic cells are gathered together, expression 
levels might be biased. Therefore, also glioblastoma cell lines were analyzed for the 
expression of the non-canonical IKK complex. 
3.1.2. Protein and mRNA levels of the non-canonical IKK complex in glioma cell 
lines 
Next, glioblastoma cell lines were analyzed and protein as well as mRNA levels of TANK, 
TBK1 and IKKε were determined. Therefore, 11 glioma cell lines were lysed and analyzed 
by Western blot (Fig. 3.2.A). The levels of TANK protein were elevated in most of the 
glioma cell lines. The expression was especially high in the cell lines Ln229, U118, U343, 
U373 and U87MG. Both IKK-related kinases were as well expressed, but the observed 
high variability in TANK protein levels was not seen for the kinases. Moreover, protein 
levels of Akt and its phosphorylation status were analyzed. The kinase was expressed in 
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all examined cell lines, but Ln229 and T98G showed remarkable high protein levels of Akt. 
The residue S473 is highly phosphorylated among all cell lines whereas the 
phosphorylation at the main activation site T308 was found in 9 of 11 cell lines. In 
contrast, the phosphorylation of ERK1/2 was inversely correlated with Akt T308. 
Furthermore, the expression of the non-canonical IKK complex was examined on mRNA 
levels (Fig. 3.2.B). Thus, total RNA was isolated from all analyzed glioma cell lines and 
real-time PCR was performed to detect mRNA levels of TANK, TBK1 and IKKε. Reflecting 
the results observed for protein levels (Fig. 3.2.A), mRNA levels of TANK were 
exaggerated and highly variable. The mRNA levels of TBK1 and IKKε showed less 
variability (see also supplementary Fig. S2). The variance of mRNA levels is further 
visualized as boxplots in figure 3.2.B. Since TANK forms a complex with IKKε and TBK1 
[67, 81, 405], it was interesting to investigate whether this complex also occurs in GBMs. 
To address this question, co-immunoprecipitation experiments were performed 
(Fig. 3.2.D). Two cell lines were chosen and endogenous proteins were precipitated with 
anti-TANK antibody. The following analysis of the eluates by Western blot revealed the 
co-precipitation of TBK1 and IKKε in both cell lines, confirming the formation of the non-
canonical IKK complex with the adaptor protein TANK. As the IKK-related kinases can 
phosphorylate Akt [125, 137], it was also interesting to test whether Akt co-
immunoprecipitates with IKKε and TBK1. However, co-immunoprecipitation experiments 
failed to detect such an interaction. 
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Fig. 3.2.: Expression analysis of members of the non-canonical IKK complex in glioma cell lines. (A) 
Proteins were extracted from 11 glioma cell lines in 1 x SDS sample buffer and analyzed by Western blot 
using the indicated antibodies to detect either endogenous proteins or their phosphorylation. (B) Total RNA 
was extracted and translated into cDNA using Oligo(dT) primers. The amount of mRNA was further semi-
quantitatively analyzed by real-time PCR using specific primers for either TANK, TBK1 or IKKε. Expression 
levels of T98G were set as 1 after normalization to the housekeeping gene β-Actin. Error bars express the 
standard deviation of three independent experiments performed in triplicates. The variation of mRNA levels 
of TANK, TBK1 and IKKε were further visualized in boxplots (C), in which the box represents the interquartile 
range with median, error bars show the overall range of values and dots symbolize outliners. (D) T98G and 
U251 cells were lysed and endogenous proteins were precipitated using anti-Akt and anti-TANK antibodies 
as well as anti-IgG as negative control. Eluates were analyzed by Western blot using the indicated 
antibodies, input samples of the cell lysates are shown to confirm expression of the proteins. 
 
In summary, the results for mRNA and protein levels are consistent with the findings for 
patient tissue samples, indicating TANK to be dysregulated in GBM. 
3.1.3. The interplay of gene transcription and mRNA stability in the regulation of 
TANK expression 
The measured mRNA levels of TANK do not exactly correlate with protein levels in each 
cell line. For instance, the cell line U87MG shows high protein levels and low mRNA levels 
for TANK. The A764 cell line contains high mRNA levels and moderate protein levels of 
TANK (Fig. 3.2. A and C). In order to explain this discrepancy of mRNA and protein levels 
of TANK in the glioma cell lines, mechanisms of mRNA and protein regulation were 
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examined. In general, the steady-state level of a certain mRNA is defined by mRNA 
synthesis and simultaneously occurring mRNA decay [406, 407]. Similarly, the steady-
state levels of proteins is regulated by the relative rates of protein synthesis and decay 
[408]. 
To determine ongoing transcription of the Tank gene as possible explanation for 
considerable differences in mRNA levels of TANK between distinct glioma cell lines, a 
chromatin-immunoprecipitation was performed (Fig. 3.3.A). Since elongation of the 
transcript is associated with the occupancy of the gene by active RNA polymerase II, that 
is phosphorylated at S2, this occupation can be seen as indicator for active transcription 
[409]. Thus, a chromatin-immunoprecipitation using a specific antibody for RNA 
polymerase II phosphorylated at S2 (Pol II S2p) was performed using cell lines with high 
(A764) and low (U251, U87MG) mRNA levels of TANK. The amount of precipitated 
genomic DNA was measured by real-time PCR using specific primers that cover two 
distinct regions in intron 1 (TANK#1 and TANK#2). In line with the findings for mRNA 
levels, the de novo transcription of TANK was higher in A764 cells when compared to 
U251 and U87MG cells that showed reduced de novo transcription and steady-state 
mRNA levels. To measure the stability of TANK mRNA, the analyzed cell lines were 
treated with Actinomycin D to inhibit the de novo transcription. The amount of mRNAs was 
measured at various time points, as displayed in figure 3.3.B. The relative mRNA stability 
of TANK was different for every cell line. In U87MG cells associated with high protein but 
low mRNA levels of TANK (Fig. 3.2. A and C), a high mRNA stability was observed. In 
contrast, A764 cells with high mRNA levels (Fig. 3.2.C) revealed a high rate of mRNA 
decay resulting in lower protein levels (Fig. 3.2.A). Although the mRNA stability of TANK 
was higher in the U251 cell line than observed in A764 (Fig. 3.3.B), the protein level in 
U251 was lower in the end (Fig. 3.2.A). Interestingly, the mRNA stability of TBK1 was 
similar in all analyzed cell lines (Fig. 3.3.B, right panel). Additionally, a possible regulation 
of protein levels by protein turnover was analyzed. Through the inhibition of the protein 
synthesis with cycloheximide (CHX) the protein decay can be followed. Three glioma cell 
lines were treated for various periods with CHX and the protein abundance was examined 
by Western blot (Fig. 3.3.C). U251 and U87MG cells displayed a stable protein level of 
TANK and TBK1 within the observed time, indicating that TANK and TBK1 are not 
regulated at protein levels to an appreciable extent. Only TBK1 protein levels decrease 
after 12 hs treatment with CHX in U87MG cells. The T98G cell line with low TANK protein 
levels was chosen as a positive control for the CHX treatment. Here TANK and TBK1 
were already degraded after 2 hs treatment with CHX. 
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Fig. 3.3.: The interplay of gene transcription and mRNA stability in the regulation of TANK protein 
levels. (A) A764, U251 and U87MG cell were analyzed for de novo transcription of the Tank gene by ChIP. 
After crosslinking of proteins to the DNA, ChIP assays were performed using either a Pol II S2p antibody or 
an unspecific IgG control antibody. Binding of actively elongating polymerase to two distinct regions of the 
Tank gene as well as Gapdh as housekeeping gene was determined by real-time PCR using specific 
antibodies. The amount of Pol II S2p associated with the indicated genomic region is calculated as fold 
enrichment over IgG control and enrichment in Gapdh gene was set as 1 to compare different cell lines 
among each other. (B) A764, U251 and U87MG cells were treated with 1 µg/ml Actinomycin D for the 
indicated times. Total RNA was extracted and translated into cDNA using Oligo(dT) primers. The mRNA 
stability of either TANK (left panel) or TBK1 (right panel) mRNA was examined by real-time PCR using 
specific primers. Values were calculated by the ΔΔCt method and normalized to β-Actin. Untreated cells were 
set as 100%. Mean values ± SD of three independent experiments performed in triplicates are shown. (C) 
The protein stability of TANK and TBK1 was assessed in U251, U87MG and T98G cells by treating the cells 
with 50 µg/ml Cycloheximide (CHX) for the indicated times. Cells were lysed in 1 x SDS sample buffer and 
lysates were analyzed by Western blot using the indicated antibodies. Anti-β-Actin was used to confirm equal 
protein loading. 
 
In summary, these findings show that the variable levels of the TANK protein in glioma 
result from differences at all analyzed gene expression levels (de novo transcription, 
mRNA stability and protein stability). 
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3.2. The influence of TANK and TBK1 on cellular functions of 
glioma cell lines 
3.2.1. The role of the non-canonical IKK complex in proliferation 
Cancer cells are usually characterized by high proliferation rates. Several factors 
dysregulating the healthy balance between proliferation and apoptosis are already known 
[410]. Proliferation assays were performed, in order to validate the role of the non-
canonical IKK complex in this context, and revealed a great diversity among the glioma 
cell lines (Fig. 3.4). 
 
 
Fig. 3.4.: The proliferation of different glioma cell 
lines. Diverse glioma cells were seeded at a density 
of 5x10
4
 cells. Number of cells was determined with 
a FACSCalibur 72 and 120 hs after seeding. Mean 
values ± SD are shown of three independent 
experiments.  
 
Subsequently, components of the complex were silenced and the effects on the cell 
proliferation were determined. Retroviral knock-down was performed for the adaptor 
TANK as well as the kinase TBK1. Clark and colleagues demonstrated that the absence 
of the adaptor destroys the complex and impairs the function of TBK1 whereas the 
function of IKKε is completely abrogated [411]. TANK or TBK1 were silenced in 11 glioma 
cell lines using retroviral gene transfer of shRNA to induce RNA interference. Proliferation 
assays were performed as described above. Additionally, MTT assays were carried out for 
all cell lines. By measuring the metabolic activity of cells, the MTT assay provides 
information about the cell viability and proliferation. The effects of either TANK or TBK1 
silencing on glioma cell lines are summarized in figure 3.5.D. The results shown in 
figure 3.5.A-C exemplify the proliferation and MTT assays for three cell lines. The full data 
set is depicted in supplementary figure S3. The proliferation ability of A172 cells was 
affected remarkably by silencing either TANK or TBK1. The same was true for the 
metabolic activity measured by MTT assay (Fig. 3.5.A). The cell lines U343 and U87MG 
showed the same effects (Fig S3). TBK1 had a much lesser impact on proliferation and 
metabolism in the SNB19 cell line when compared to TANK (Fig. 3.5.B). This was also 
seen in the cell lines A764 and U251. Interestingly, just the A271 cell line showed the 
opposite - a major decrease in proliferation when TBK1 was silenced compared to the 
TANK knock-down. However, the U373 cell line represents a group of 3 cell lines where 
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the effect of silencing TANK or TBK1 on proliferation were low (Fig. 3.5.C). Only in the 
T98G cell line the influence of TANK or TBK1 on proliferation was not detectable probably 
due to an insufficient knock-down. 
 
 
Fig. 3.5.: The role of TANK and TBK1 in the proliferation ability of glioma cell lines. (A) A172 cells were 
retrovirally transduced to express shRNAs leading to a knock-down of TANK, TBK1 or a scrambled shRNA 
as a control. Transduced cells were selected with puromycin and used to determine cell proliferation (upper 
graphs) or alternatively cell viability (lower left graph). Proliferation was measured by seeding cells at a 
density of 5x10
4
 cells, followed by determination of cell numbers after 72 and 120 hs using a FACSCalibur. 
Error bars show standard deviations from three independent experiments. Aliquots of the cells were lysed 
and tested by Western blotting for efficient knock-down (lower right). MTT assays were performed by seeding 
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knock-down cells at a density of 1x10
3
 cells/well, followed by further growth for 4 days and performance of 
the MTT assay according to the manufacturer’s instructions. Relative metabolic activity of control cells was 
arbitrarily set as 1, error bars show standard deviations of three independent experiments. (B) Experiments 
of A were performed for SNB19 cells. (C) Experiments of A were performed for U373 cells. (D) Results from 
proliferation assays from all cell lines are summarized. Symbols indicate strength of influence on 
proliferation: - no, + low, ++ great influence and nd not detectable. 
 
Taken together, 10 out of 11 examined cell lines display an impact of TANK or TBK1 
knock-down on proliferation. Thus, these experiments revealed an important role of the 
non-canonical IKK complex in proliferation of glioma cell lines. 
Unspecific side effects of shRNA constructs, also called off-target effects, are a well 
described problem of RNA interference [412] that is usually excluded by confirming the 
effects with a second shRNA construct containing a distinct binding sequence. Within the 
scope of this work, off-target effects were excluded using alternative shRNAs for either 
TANK or TBK1 (Fig. 3.6). For that purpose, U251 cells were infected with the viruses 
carrying the distinct shRNAs to silence either TANK (Fig. 3.6.A) or TBK1 (Fig. 3.6.B) and 
proliferation assays were performed to determine the functional outcome. Decreased 
proliferation rates were observed for TANK or TBK1 knock-down to a comparable extent 
for each construct, indicating that the observed effect is not due to artificial side effects. 
 
 
Fig. 3.6.: shRNAs for TANK and TBK1 do not induce unspecific side effects. U251 cells were infected 
with either retro- (#1) or lentiviruses (#2) to express shRNA targeting either TANK (A) or TBK1 (B) as well as 
scrambled shRNA as control. After selection with puromycin, cells were seeded at a density of 1x10
4
. The 
amount of cells was determined with FACSCalibur 72 and 120 hs after seeding to further follow the 
proliferation. Mean values ± SD are shown of three independent experiments. An aliquot of cells was lysed in 
1 x SDS sample buffer and analyzed by Western blot for efficient knock-down. 
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3.2.2. The role of the non-canonical IKK complex in cell cycle progression 
A role of the non-canonical IKK complex in the regulation of cell cycle progression has 
been described before [69]. The decreased proliferation ability after silencing TANK or 
TBK1 raises the question whether those effects are caused by an impact of either TANK 
or TBK1 on the cell cycle. 
For that purpose, cell cycle profiles were recorded for three selected glioma cell lines by 
propidium iodide staining and subsequent analysis by flow cytometry (Fig. 3.7). The 
distribution of cells within the cell cycle phases was illustrated in stacked-bar graphs 
(middle panels). The cell cycle profiles for A764 cell line (Fig. 3.7.A) did not reveal any 
differences between TANK-depleted cells and the control cells. Also U251 cells 
(Fig. 3.7.C) showed just slight changes. Here, the silencing of TANK led to an increasing 
number of cells in G1 and S phase. In contrast, U373 cells (Fig. 3.7.B) revealed an 
accumulation of cells in S phase after the knock-down of TANK. For most of the 
investigated cell lines no changes in cell cycle profile after TBK1 knock-down were 
observed, apart from A764 where the knock-down of TBK1 led to slightly increased cell 
number in G1 phase. 
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Fig. 3.7.: Cell cycle analysis of glioma cell lines after TANK or TBK1 knock-down. (A) TANK or TBK1 
were knocked down as described previously in A764 cell line. After selection with puromycin, DNA content of 
the cells was measured by staining with propidium iodide and subsequent analysis by flow cytometry (left 
panel) using FACSCalibur. Amount of cells in certain phases of the cell cycle were quantified by ModFit 
software and depicted as stacked-bar graph (middle panel). Aliquots of cells were lysed and analyzed by 
Western blots for efficient knock-down (right panel). Those experiments were also done for U373 (B) as well 
as U251 (C) cell lines. 
 
In summary, TANK is able to influence the cell cycle by inhibiting the progression from S 
to G2 phase, but not all glioma cell lines show this altered cell cycle profile. In order to 
investigate the impact of the TANK or TBK1 knock-down on cell cycle progression, the 
kinetic parameters of cell cycle were examined. Therefore, knock-down cells were treated 
with vinblastine to block progression of the cell cycle in late G2 phase and cell cycle 
profiles were analyzed by propidium iodide staining as described above after 10 or 24 hs 
(Fig. 3.8). Confirming the previous results, the knock-down of TANK caused an arrest in S 
phase in the U373 cell line, but did not alter the cell cycle profile in the A764 cell line. The 
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cell cycle profiles of both cell lines were also not altered upon silencing of TBK1. As the 
arrest in late G2 phase was more pronounced in the U373 cell line compared with the 
A764 cell line, it is conclusive that the U373 cell lines progresses faster in the cell cycle 
(Fig. 3.4). This indirectly indicates that the U373 cell lines proliferates faster. The 
treatment of TANK-depleted cells with vinblastine did not result in further changes of the 
cell cycle profile in both investigated cell lines which indicates a stop of cell cycle 
progression. This also suggests a repressive effect on the cell proliferation by the knock-
down of TANK. Additionally, TBK1 silencing also resulted in inhibited cell cycle 
progression after vinblastine treatment in the A764 cell line, but failed to lead to an arrest 
in late G2 phase in the U373 cell line. So, the cell cycle progression and eventually the 
proliferation of the U373 cell line does not depend on TBK1. Finally, vinblastine has been 
described to induce apoptosis [413, 414], explaining sub G1 peaks in both cell lines after 
treatment. 
 
 
Fig. 3.8.: The influence of TANK and TBK1 on the cell cycle progression of glioma cell lines. (A) TANK 
or TBK1 were knocked down as described previously for the A764 cell line. After selection with puromycin, 
cells were treated with 0.3 µM vinblastine to arrest cells in M/ late G2 phase of the cell cycle. Shifts in cell cycle 
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profiles to the G2 phase were followed by measuring the DNA content of the cells by staining with propidium 
iodide and subsequent analysis by flow cytometry (upper panel) using FACSCalibur after 10 or 24 hs 
treatment with vinblastine. Aliquots of cells were lysed and analyzed by Western blot for efficient knock-down 
(lower panel). Those experiments were also done for U373 cell line (B). 
 
Taken together, the ability of glioma cell lines to progress in cell cycle is affected by the 
depletion of TANK or TBK1. Interestingly, TANK knock-down can also lead to an S phase 
arrest is some glioma cell lines. 
3.2.3. The role of the non-canonical IKK complex in migration 
Formation of metastases and invasion into tissues are further important hallmarks of 
cancer [410]. Invasion is well described for GBM in particular. In order to evaluate the role 
of the non-canonical IKK complex in the migration of glioma cell lines, either TANK or 
TBK1 were silenced by shRNA as described before and wound-healing assays were 
performed (Fig. 3.9). For all investigated cell lines, control knock-down cells were found to 
close the scratch almost completely within 24 hs. However, the knock-down of TANK had 
a great impact on the migration ability of the analyzed cell lines. Except for U251, also 
TBK1 knock-down prevented the closure of the scratch. In summary, TANK but also TBK1 
influence the migration ability of glioma cells. 
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Fig. 3.9.: The influence of TANK and TBK1 on the migration ability of glioma cell lines. (A) Knock-down 
and control A764 cells were seeded at densities between 1,5-2x10
5
 in a 6 well plate and allowed to grow to 
80% confluency. To prevent proliferation cells were cultured in serum-free medium supplemented with 1 µg/ml 
aphidicolin over night before the assay was carried out (left panel). A scratch was gently made with a pipette 
tip. The cells were then washed two times with PBS and serum-free medium was added. Immediately, after 10 
and after 24 hs a picture of the scratched area was taken with a NIKON Inverted Research Microscope 
Eclipse TE2000-Ea. The size of the scratch was quantified (upper right panel). Mean values ± SD of three 
independent experiments are shown. Aliquots of cells were lysed and analyzed by Western blot to ensure 
efficient knock-down (lower right panel). Experiment was also performed with U373 (B) and U251 (C) cell 
lines. 
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3.3. The influence of the non-canonical IKK complex on cell 
death induced by chemotherapeutic drugs 
In the treatment of GBM a lot of chemotherapeutic drugs have been developed [415]. In 
this work, two commonly applied drugs were taken into consideration. Activated AraC is 
able to inhibit DNA replication by its incorporation into nascent DNA instead of CTP 
(cytidine triphosphate) [416]. This results in cell cycle arrest, reduced growth as well as 
apoptosis [417]. More often, TMZ is used in the treatment of GBM. TMZ is an alkylating 
agent which is able to damage the DNA, thereby leading to cell death [418]. 
Since TANK and TBK1 were influencing several hallmarks in cancer, it was interesting to 
investigate the role of the non-canonical IKK complex on drug sensitivity. For that 
purpose, the consequences of TANK or TBK1 knock-down on the sensitivity of tumor cells 
towards either AraC or TMZ was studied. First of all, the cytostatic function of both 
chemotherapeutic agents was validated by MTT assays (Fig. 3.10). Therefore, 11 glioma 
cell lines were plated out in 96-well plates and treated with either AraC or TMZ for three 
days, before the metabolic activity was measured. Compared to untreated control cells, all 
glioma cell lines were affected in their cell viability by both drugs to a similar extent. In line 
with the mechanisms behind the drugs, slowly growing cell lines such as A764 still reveal 
a higher cell viability compared to fast growing cell lines as for instance U251 (see also 
Fig. 3.4). This result illustrates the cytostatic function of both drugs for all examined cell 
lines. 
 
 
Fig. 3.10.: Analysis of the cell death induced by the chemotherapeutic drugs AraC and TMZ. All 
investigated cell lines were seeded at a density of 1x10
3 
cells, treated next day with 1 µM AraC or 100 µM 
TMZ. 72 h later, MTT assays were carried out according to the manufacturer’s instructions. Mean values ± SD 
are shown of three independent experiments 
 
Next, a potential contribution of TANK or TBK1 to the death-inducing effects of AraC and 
TMZ was investigated. Accordingly, either TANK or TBK1 were silenced by shRNA in 
A764, U251 or U373 cell lines and cells were treated with AraC or TMZ as described 
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above. Cell viability was again measured by MTT assays (Fig. 3.11). As shown afore, the 
treatment with either AraC or TMZ decreased cell viability for all investigated cell lines. In 
the same way, each knock-down was sufficient to diminish cell viability. While TANK 
knock-down further decreased the cell viability moderately in combination with AraC or 
TMZ in all cell lines, the effects of TBK1 silencing were not as pronounced. These 
experiments show that only the knock-down of TANK slightly increased drug induced cell 
death in the examined cell lines. 
 
 
Fig. 3.11.: The influence of TANK and TBK1 on drug-induced cell death in glioma cell lines. (A) A764 
were retrovirally infected with shRNA to knock-down either TANK or TBK1. Cells were seeded at a density of 
1x10
3
 cells and treated the next day with 1 µM AraC or 100 µM TMZ. 72 hs later MTT assays were 
performed, mean values ± SD from three independent experiments are shown. Western blot of lysed cell 
aliquots proved sufficient knock-down of TANK or TBK1 (lower panels). Experiments were also performed for 
U251 (B) and U373 (C) cell lines. 
 
3.4. The non-canonical IKK complex in Akt and ERK1/2 
signaling pathways 
Cell proliferation is a process influenced by many factors. On the one hand, intrinsic 
signaling leads to regulation of cell cycle and thereby controls the proliferation. On the 
other hand, transcription factors can induce expression and release of soluble factors 
such as growth factors and cytokines that influence the proliferation of surrounding cells. 
[419, 420] 
This raises the question whether the effects of TANK or TBK1 depletion are caused by 
intrinsic signaling or by soluble factors secreted in the culture medium. To address this 
question, the effect of medium from knock-down cells on cell proliferation was measured 
in proliferation assays (Fig. 3.12). The previously described repressive effect of either the 
TANK or TBK1 knock-down on cell proliferation of different glioma cell lines was 
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confirmed. In contrast, medium taken from TANK- or TBK1-silenced A764 cells did not 
result in decreased proliferation of control A764 cells, but even led to slightly increased 
proliferation. The same was true for U373 cell line, suggesting that the medium from 
knock-down cells does not contain soluble factors negatively affecting cell proliferation. 
Moreover, the slightly increased proliferation in response to the medium from knock-down 
cells suggests the presence of pro-proliferative factors. 
 
 
Fig. 3.12.: The influence of knock-down-induced spilled factors in the medium on the proliferation of 
control cells. (A) A764 cells were retrovirally infected with shRNA against TANK. After puromycin selection, 
proliferation assays were performed. Thereby, knock-down control cells were seeded in either fresh culture 
medium or in medium taken from cells with a TANK knock-down. Proliferation was measured as described 
previously. Mean values ± standard deviation of three independent experiments are shown. (B) Experiment 
was repeated as in (A) for A764 where TBK1 was silenced. Assay was also performed for U373 cell line with 
either TANK (C) or TBK1 (D) knock-down. (E) A part of the cells was lysed and further analyzed by Western 
blotting for efficient knock-down. 
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3.4.1. The effects of TANK on constitutive AKT and ERK1/2 signaling 
Akt as well as ERK1/2 are known kinases involved in the regulation of proliferation [419, 
420]. Since both of them are constitutively phosphorylated in glioma cell lines (Fig. 3.2.A), 
the influence of the non-canonical IKK complex on their activity was further analyzed. 
Therefore, the adaptor protein TANK was silenced in the glioma cell lines by retroviral 
infection with shTANK. Protein expression and phosphorylation of Akt and ERK1/2 were 
subsequently analyzed by Western blot (Fig. 3.13). The phosphorylation of Akt was 
altered at the two main activation sites S473 and T308 in a few cell lines. While the 
phosphorylation of S473 was reduced in 5 cell lines, T308 phosphorylation was alleviated 
in only 2 of 11 (Ln229 and U373) examined cell lines. The phosphorylation of ERK1/2 was 
reduced in 6 glioma cell lines. In three cell lines (SNB19, U251 and U373) the 
phosphorylation of Akt at S473 was correlated with the phosphorylation of ERK1/2. T308 
phosphorylation of Akt correlated with ERK1/2 phosphorylation in those 2 cell lines (Ln229 
and U373) that were shown to have reduced levels of T308 phosphorylation after 
silencing TANK.  
 
 
Fig. 3.13.: Analysis of the role of TANK on Akt and ERK1/2 phosphorylation in glioma cell lines. (A) 
TANK was silenced by shRNA as described before in 11 glioma cell lines. Cells were lysed in 1 x SDS 
sample buffer and protein expression as well as phosphorylation of Akt and ERK1/2 was analyzed by 
Western blot. (B) Results were summarized in tables showing the indicated correlations between Akt and 
ERK1/2 phosphorylation. 
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In summary, the repressive effect of TANK silencing on the phosphorylation of Akt and 
ERK1/2 kinases was found for about half of the examined cell lines. 
3.4.2. The effects of TBK1 on constitutive AKT and ERK1/2 signaling 
To measure the effect of the IKK-related kinase TBK1 on constitutive Akt and ERK1/2 
phosphorylation, TBK1 was knocked down in the glioma cell lines by shRNAs. The 
analysis of protein extracts for expression and phosphorylation of proteins showed that 
silencing of TBK1 resulted not just in reduced protein levels of TBK1 but also decreased 
IKKε protein levels. (Fig. 3.14). Silencing of TBK1 led to reduced phosphorylation of Akt 
and ERK1/2 in about half of the investigated cell lines but did not increase the 
phosphorylation in any case. In A171, A271 and Ln299 cell lines S473 phosphorylation of 
Akt was correlated with ERK1/2 phosphorylation. The same three cell lines and the U251 
cells additionally revealed a correlation between T308 phosphorylation of Akt and ERK1/2 
phosphorylation.  
 
 
Fig. 3.14.: Analysis of the role of TBK1 on Akt and ERK1/2 phosphorylation in glioma cell lines. (A) 
TBK1 was silenced by shRNA as described before in 11 glioma cell lines. Cells were lysed in 1 x SDS 
sample buffer and protein expression as well as phosphorylation of Akt and ERK1/2 was analyzed by 
Western blot. (B) Results were summarized in tables by correlation Akt and ERK1/2 phosphorylation. 
 
Taken together, TBK1 positively regulates the kinases Akt and ERK1/2 in most of the 
glioma cell lines by inducing their phosphorylation and consequently their activation. 
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In order to verify the results obtained upon TBK1 silencing, a pharmacological approach 
was used to inhibit the IKK-related kinases IKKε and TBK1 by treating the cells with the 
small molecule inhibitor BX795. Subsequent analysis by Western blot is shown in 
figure 3.15.A and summarized in tables in 3.15.B. The analysis of the phosphorylation 
status in BX795 treated glioma cell lines revealed similar effects as for TBK1 depletion. 
Reduced phosphorylation of Akt at S473 was observed in 7 of 11 cell lines and T308 
phosphorylation was alleviated in 8 of 11 cell lines. Also decreased phosphorylation of 
ERK1/2 was found in the majority of investigated cell lines. For five cell lines, the reduced 
phosphorylation of Akt at T308 and S473, respectively, was correlated with decreased 
ERK1/2 phosphorylation. In contrast, for two cell lines an increase in ERK1/2 
phosphorylation was detected (A271 and U343) in response to TBK1 silencing. 
While earlier results showed that the knock-down of TBK1 does not significantly change 
the sensitivity of cells towards chemotherapeutic drugs (Fig. 3.11), it was then interesting 
to investigate whether the activity of the IKK-related kinases has an impact on the 
response to chemotherapeutic drugs. Therefore, TBK1 as well as IKKε were inhibited 
using BX795. These cells were additionally treated with AraC or TMZ and cell viability was 
measured by MTT assays (Fig. 3.15.C-D). The treatment with BX795 alone resulted in 
decreased cell viability, also indirectly indicating a negative effect on the cell proliferation. 
The combination of BX795 and AraC treatments did not result in a further decrease of the 
cell viability compared to cells only treated with AraC. Similar findings were shown for the 
TMZ treatment. However, combined treatment of TMZ and BX795 in the cell lines T98G, 
U118 and U251 led to slightly further decreases of the cell viability compared to each 
compound alone. Interestingly, the knock-down of TBK1 in U251 cells had no additional 
effects on the drug-induced cell death, whereas the inhibition of both IKK-related kinases 
by BX795 resulted in a further decrease of the cell viability at least in the combination with 
TMZ. 
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Fig. 3.15.: Analysis of the role of the IKK-related kinases on Akt and ERK1/2 phosphorylation and 
drug-induced cell death in glioma cell lines. (A) Glioma cell lines were treated 24 hs with 1 µM BX795, 
lysed in 1 x SDS sample buffer and analyzed by Western blot using indicated antibodies to detect 
phosphorylation of Akt and ERK1/2. (B) Results from (A) were summarized in tables showing the indicated 
correlations between Akt and ERK1/2 phosphorylation. (C) MTT Assays were performed to determine cell 
viability. Cells were seeded at a density of 1x10
3
 cells/well and treated the next day with either 1 µM BX795 
and/or 1 µM AraC. 72 hs later cell viability was determined by MTT assays, mean values ± SD are shown 
from three independent experiments (D) The experiment was done as in (C) with the only difference that the 
glioma cells were treated with either 1 µM BX795 and/ or 100 µM TMZ. 
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In summary, TANK and TBK1 influence the phosphorylation of downstream kinases such 
as Akt and ERK1/2. The inhibition of the IKK-related kinases showed no or only weak 
effects on chemotherapeutic-induced cell death in glioma cell lines. 
3.4.3. The interplay of signaling pathways in glioma cell lines 
How can TANK and TBK1/IKKε regulate signaling to Akt and ERK1/2? To address this 
question, the signaling network was examined by combinatorial treatments with different 
kinase inhibitors. On the one hand, Akt inhibitor VIII was used to inhibit the 
phosphorylation of Akt at the two main phosphorylation sites that are crucial for proper 
activation of the kinase [421]. ERK1/2 phosphorylation was inhibited by U0126 which 
interferes with the activity of the direct upstream regulator MEK1/2 [422]. The TAK1 kinase 
which is involved in signaling pathways such as NF-kB and MAPK was specifically 
blocked with 5Z-7-oxozeaenol [423]. All inhibitors were applied either alone or together 
with BX795 to additionally block the non-canonical IKK complex. 
Eight glioma cell lines were treated with either BX795 and Akt inhibitor VIII alone or in 
combination. Phosphorylation of Akt and ERK1/2 were determined by subsequent 
analysis by Western blot and are shown in figure 3.16.A. The consequences of the 
treatments are summarized in tables (Fig. 3.16.B). As expected, the treatment with Akt 
inhibitor VIII led to blocked phosphorylation of Akt at both crucial phosphorylation sites. In 
5 of 8 cell lines also ERK1/2 phosphorylation was decreased (A271, A764, U251, U343 
and U373). An additional treatment with BX795 had contradictory effects on the ERK1/2 
phosphorylation. In some cell lines ERK1/2 phosphorylation was restored (U373), in 
others the reduced phosphorylation did not change further (A172, A764). 
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Fig. 3.16.: The effect of the Akt inhibitor VIII on the constitutive active signaling network in glioma cell 
lines. (A) Cells were treated for 24 hs with Akt inhibitor VIII (5 µM), BX795 (1 µM) or with a combination of 
both, lysed in 1 x SDS sample buffer and analyzed by Western blot using indicated antibodies to detect 
phosphorylation of Akt and ERK1/2. (B) Results from (A) were summarized in tables showing the correlations 
between Akt and ERK1/2 phosphorylation. 
 
Next, the consequences of the MEK inhibitor U0126 on the phosphorylation of Akt and 
ERK1/2 were examined. The experiment settings were as described previously and 
results are shown in figure 3.17.A. Furthermore, the phosphorylation of Akt was correlated 
with the ERK1/2 phosphorylation (Fig. 3.17.B). Most of the analyzed glioma cell lines did 
not respond to the inhibitor U0126 with reduced phosphorylation of ERK1/2. Only the cell 
lines A271 and U343 exhibited alleviated levels of ERK1/2 phosphorylation upon the 
treatment with U0126. Interestingly, most of the glioma cell lines (5 of 8) showed 
increased phosphorylation of Akt at S473 and 6 of 8 cell lines revealed higher 
phosphorylation levels at residue T308 when MEK1/2 were inhibited. The combined 
treatment with U0126 and BX795 did not induce further changes in the phosphorylation of 
ERK1/2, except for two cell lines. In A764 and Ln229 each treatment alone was not 
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efficient to decrease ERK1/2 phosphorylation considerably, whereas the combination of 
both resulted in extensive reduction thereof, indicating two independent signaling axis that 
are able to compensate each other. 
 
 
Fig. 3.17.: The effect of the MEK1/2 inhibitor on the constitutive active signaling network in glioma 
cell lines. (A) Glioma cell lines were treated 24 hs with 5 µM U0126, 1 µM BX795 or in combination of both, 
lysed in 1 x SDS sample buffer and analyze by Western blot using indicated antibodies to detect 
phosphorylation of Akt and ERK1/2. (B) Results from (A) were summarized in tables showing the correlations 
between Akt and ERK1/2 phosphorylation. 
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BX795, or with the combination of both. Cell lysates were analyzed by Western blot for 
phosphorylation of Akt and ERK1/2 (Fig. 3.18.A) and summarized in figure 3.18.B. The 
TAK1 inhibitor was sufficient to increase Akt phosphorylation at T308 and S473 in about 
half of the investigated cell lines. In contrast, the phosphorylation of ERK1/2 was not 
altered in most of the cell lines. Only A764 and Ln229 exhibited reduced ERK1/2 
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phosphorylation. A correlation between Akt and ERK1/2 phosphorylation after the 
treatment with 5Z-7-oxozeaenol was not detected. The combined treatment of the glioma 
cells with 5Z-7-oxozeaenol and BX795 also had no further impact in most of the cell lines. 
However, in A271 cells an increased ERK1/2 phosphorylation after combined treatment 
with BX795 and 5Z-7-oxozeaenol was detected, whereas treatment with both inhibitors 
decreased ERK1/2 phosphorylation in U373 cell line. 
 
 
Fig. 3.18.: The effect of the TAK1 on the constitutive active signaling network in glioma cell lines.. (A) 
Cell lines were treated 24 hs with 1 µM 5Z-7-oxozeaenol, 1 µM BX795 or a combination of both, lysed in 
1 x SDS sample buffer and analyzed by Western blot using indicated antibodies to detect phosphorylation of 
Akt and ERK1/2. (B) Results from (A) were summarized in tables showing correlations between Akt and 
ERK1/2 phosphorylation. 
 
Taken together, the treatment experiments revealed new insights in the complex signaling 
network in GBM. On the one hand, the repression of the IKK-related kinases showed a 
negative effect on the phosphorylation of the kinases Akt and ERK1/2 in most of the cell 
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activate proliferation and survival signals in glioblastomas. On the other hand, the 
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MEK1/2-induced repression of the Akt phosphorylation indicates a possible negative 
feedback loop on the Akt-induced phosphorylation of ERK1/2. Finally, the loss of ERK1/2 
phosphorylation after inhibiting the TBK1/IKKε together with MEK1/2 lead to the idea of a 
MEK-independent ERK1/2 activation at least in some glioma cell lines. 
 
3.5. The effect of TANK and TBK1 on the pro-inflammatory 
microenvironment in glioma cell lines 
The link between inflammation and cancer is well documented [424]. GBM has been 
described to be associated with a pro-inflammatory microenvironment [425, 426]. Since 
the non-canonical IKK complex is involved in inflammatory signaling by modulating NF-κB 
and IRF transcription factors, the impact of TANK and TBK1 on these processes was 
studied. Therefore, in two cell lines (U373 and U251) either TANK or TBK1 were silenced 
as described before. Western blot analyses were performed to reveal the phosphorylation 
of NF-κB and IRF transcription factors, and mRNA levels of certain pro-inflammatory 
cytokines were measured by semi-quantitative real-time PCR (Fig. 3.19). The depletion of 
TANK resulted in reduced phosphorylation of IRF3 in U373 cells. In contrast, the 
phosphorylation of IRF3 was in general much lesser in this cell line compared to U87MG, 
where IRF3 phosphorylation was slightly increased upon TANK silencing. The constitutive 
phosphorylation of p65 at S536 was higher in the U87MG cell line compared to U373. 
Silencing of TBK1 markedly impaired p65 phosphorylation in U87MG cells. Additionally, 
real time PCR analysis of mRNA levels of pro-inflammatory cytokines was carried out 
(Fig. 3.19.B) in both cell lines. On the one hand, the U373 cell line was found to express 
increasing amounts of TNFα and Vcam1 mRNA after silencing TANK. On the other hand, 
the knock-down of TBK1 led to a slightly increased expression of IL-6 mRNA in U373 
cells. In contrast, the knock-down of either TANK or TBK1 in U87MG cells generally had a 
more repressive effect on the mRNA levels of TNFα, Vcam1 and IL-6. Just the knock-
down of TANK did not lead to changes in the TNFα mRNA levels in U87MG cells. In this 
cell line, the strongest effect was found for the IL-6 expression in response to a TBK1 
knock-down. 
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Fig. 3.19.: Analysis of the effect of TANK and TBK1 on the pro-inflammatory microenvironment in 
glioma cell lines. (A) U373 and U87MG cells were used to silence TANK or TBK1 as described above. One 
fraction of the knock-down cells was lysed in 1 x SDS sample buffer and subsequently analyzed by Western 
blot using indicated antibodies. (B) In parallel, another fraction of cells was used to measure mRNA levels of 
pro-inflammatory cytokines. Total RNA was isolated and transcribed into cDNA using Oligo(dT) primers. Real 
time PCR was carried out using specific primers for TNF, IL-6 and Vcam. Mean values ± SD of three 
independent experiments are shown. 
 
3.6. The influence of TANK protein levels on signal output 
Adaptor proteins such as TANK usually do not facilitate intrinsic enzyme activity but serve 
as bridges for proteins to ensure proper signaling. Nevertheless, a well balanced 
expression of such adaptors is necessary to form functional protein complexes. [427] In 
order to address the importance of stoichiometric amounts of TANK, U373 cells were 
infected with viruses either leading to the shRNA-mediated downregulation of TANK or 
allowing the over-expression of the adapter protein. Both silencing and over-expression of 
TANK resulted in reduced phosphorylation of IRF3, a downstream target of the non-
canonical IKK complex (Fig. 3.20.A), whereas the phosphorylation of p65 was not altered 
as shown previously (Fig. 3.19.A). Additionally, the functional consequences of TANK 
expression were examined in U251 cells. TANK was either silenced or over-expressed 
and cell proliferation was analyzed (Fig. 3.20.B). Both over-expression and silencing 
revealed the same effects and led to decreased proliferation in the U251 cell line. Taken 
together, glioma cell lines depend on a stoichiometric expression of the adaptor protein 
TANK to mediate signal output from the non-canonical IKK complex. Too low as well as 
too high TANK levels presumably interfere with the correct formation of the complex and 
interrupt appropriate signaling. 
A B
anti-TANK
anti- ℗ IRF3
anti-TBK1
anti-p65 ℗ S536
anti-β-Actin
shTBK1
shScramble
shTANK
+
+
+
+
+
+
U373 U87MG
0
1
2
3
4
5
6
7
8
TNFα IL-6 Vcam1
re
la
ti
v
e
 m
R
N
A
le
v
e
ls
U373
shScramble
shTANK
shTBK1
0
0.2
0.4
0.6
0.8
1.0
1.2
TNFα IL-6 Vcam1
re
la
ti
v
e
 m
R
N
A
le
v
e
ls
U87MG
shScramble
shTANK
shTBK1
  RESULTS 
77 
 
 
 
Fig. 3.20.: Analysis of the functional consequences of the dysregulation of TANK in glioma cell 
lines(A) U373 cell lines were infected in order to over-express or silence TANK. Cells were lysed in 1 x SDS 
sample buffer and protein expression as well as phosphorylation of IRF3 and p65 were determined by 
Western blot. (B) U251 cells were also infected to induce TANK over-expression or silencing and were 
seeded at a density of 5x10
4
. Number of cells was determined with FACSCalibur 72 and 120 hs after 
seeding. Mean values ± SD of three independent experiments are shown. The right part shows a control 
Western blot ensuring reduced or increased protein expression.  
 
3.7. The role of the non-canonical IKK complex in different 
cancer types 
The non-canonical IKK complex is expressed in several tissues [72, 74]. As the data thus 
far indicate a role of TANK and TBK1 for the proliferation of GBM cells, it was interesting 
whether they may also regulate proliferation of other cancer types. 
In order to address this question, several cell lines derived from different types of cancer 
were taken into consideration. The HeLa cell line is a prominent cancer cell line used in 
research and derived from cervix carcinoma. MCF7 is a breast cancer cell line, HCT116 a 
colon cancer cell line and A549 cells are derived from a lung adenocarcinoma. 
Either TANK or TBK1 were silenced in those four cell lines as described previously to 
investigate their impact on signaling and cell function (Fig. 3.21). Western blot analysis 
revealed great differences in TANK expression among different cancer types, as it also 
occurred within several glioma cell lines (Fig. 3.2.A). Whereas HCT116 expressed high 
levels of TANK, A549 cells contained only little amounts of this adapter protein. Akt and 
ERK1/2 were expressed and constitutively phosphorylated in all of these cancer cell lines, 
although to a different extent. In contrast to glioma cell lines, their phosphorylation was not 
changed after silencing of TANK or TBK1, raising the possibility that TANK and TBK1 do 
not affect ERK1/2 and Akt signaling in all cancer types. Proliferation assays were 
performed with MCF7, HCT116 and A549 cell lines to analyze possible functional 
consequences of silencing TANK or TBK1 (Fig. 3.21.B-D). MCF7 breast cancer cells 
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showed a decreased proliferation upon reduced TANK or TBK1 levels, further supporting 
the idea, that the non-canonical IKK complex is involved in the regulation of proliferation in 
breast cancer cells [128]. In contrast, proliferation of colon colorectal cancer and lung 
adenocarcinoma cell lines was only weakly decreased upon silencing of either TANK or 
TBK1. 
 
 
 
Fig. 3.21.: Analysis of the role of the non-canonical IKK complex in other cancer types. (A) Either 
TANK or TBK1 were silenced in HeLa, MCF7, HCT116 and A549 cells by infecting with shRNA as described 
before. After puromycin selection cells were lysed in 1 x SDS sample buffer and subsequently analyzed for 
protein expression and phosphorylation by Western blot using the indicated antibodies. (B) Proliferation 
assays with control cells and cells silenced for TANK or TBK1 were performed with MCF7 cells by seeding 
selected cells at a density of 5 x 10
4 
cells. The number of cells was determined with FACSCalibur 72 and 
120 hs after seeding. Mean values ± SD are shown. Experiments were also carried out for HCT116 (C) and 
A549 (D) cell line. 
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4. DISCUSSION 
 
4.1. The expression of TANK is dysregulated in glioblastoma 
multiforme 
Glioblastoma multiforme is one of the most lethal brain tumors [13]. Here, many signaling 
pathways such as Akt and the Ras-Raf-MEK-ERK cascade have been discovered to be 
dysregulated leading to tumorigenesis [28]. To identify other molecular factors involved in 
gliomagenesis this study focused on the adaptor protein TANK, usually involved in TBK1 
and IKKε mediated IRF transcription factor activation after bacterial or viral infection [67], 
and its role in glioblastomas. 
The analysis of patient tissue samples as well as several glioma cell lines revealed a 
highly varying expression of the adaptor protein TANK (figures 3.1-2). This great variation 
is a feature that can also be observed for other proteins expressed in GBM. Mineo and 
colleagues investigated the expression of HER2 (epidermal growth factor receptor) in 57 
glioma tissues and found a fluctuation of HER2 expression in different GBM population 
samples which is caused by inter-individual variations and depends on the tumor types 
[428]. The clinical picture of GBM is chameleonic and exhibits a variable appearance in 
morphology and histology as Bailey and Cushing reported when they characterized GBM 
for the first time [1]. Of note, protein as well as mRNA levels were different between 
primary patient tissue and glioma cell lines (figure 3.1-2). GBM tissue is characterized by 
necrotic areas [27] and hyperplastic blood vessels [429]. In fact, glioblastoma is one of the 
most vascularized tumors [430]. Thus, the presence of distinct cell subpopulations could 
contort the expression levels of TANK, TBK1 and IKKε measured in patient tissue 
samples. Furthermore, post-surgical treatment and freezing of patient tissues could 
technically influence the amount of detectable protein and especially RNA levels and lead 
to contortion of the findings between patient tissue samples and glioma cell lines. Isolated 
cells from cancer tissues are immortalized and able to proliferate in culture but still reflect 
their genetic and molecular characteristics [431].  
Additionally, the findings of this study indicate an over-expression of TANK in many GBM 
cases (figure 3.1). A constitutive expression of TANK has been documented by Conti et 
al. in glioma patient tissues [432]. In general, there are several mechanisms which could 
lead to this over-expression. Gene amplification, epigenetic changes, increased 
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transcription, higher mRNA stability as well as greater stability of the proteins are possible 
alterations which could cause exaggerated TANK protein levels. 
Several numerical and structural changes of chromosomes appear in GBM. Besides gains 
and losses of chromosomes, also breakpoints in chromosomes have been discovered 
[433-435]. Rogatto and Casartelli identified a region in chromosome 2 where 6 out of 12 
human primary gliomas exhibit a specific recurrent chromosome break – 2q24-2q32 [436]. 
Interestingly, the Tank gene is located in this region. The break in chromosomes can lead 
to translocation of the genetic information behind a more active promoter or can even 
result in a duplication of the genetic information, both possible explanations for increased 
levels of TANK. However, Crespo et al. characterized the genome of 46 patients suffering 
from GBM and did not find gene rearrangements in the TANK-encoding region [437]. 
The transcriptional rate of the Tank gene has been assessed using ChIP technique 
revealing distinct intensities for transcription of TANK in different glioma cell lines 
(figure 3.3). The transcription of the Tank gene has shown to be induced by the 
transcription factor SOX11 (SRY-related HMG-box) [438]. However, the role of this 
transcription factor in tumorigenesis remains unclear, since on the one hand, it has been 
found to be over-expressed in glioma tissue [439], but on the other hand, it was shown to 
induce differentiation [440, 441] thereby preventing tumorigenesis [442]. In order to 
investigate ongoing transcription at the Tank gene by an alternative approach, a nuclear-
run-on-assay could be performed including a control cell line such as non-transformed 
human fibroblasts to conclude on changes of Tank gene transcription. Furthermore, it 
would be of interest to focus on the transcription factor SOX11, and if it is dysregulated in 
glioma cell lines. 
The mRNA stability of TANK was considerably higher in glioma cell lines with lower 
transcriptional activity (figure 3.3), indicating that TANK protein levels are also controlled 
by post-transcriptional processes. Hao and Baltimore found the expression of pro-
inflammatory molecules to be regulated by transcriptional control as well as mRNA 
stability [443]. Generally, the mRNA half-life is determined by cis and trans elements 
regulating either the decay of the mRNA or its stabilization. Important cis-acting elements 
that influence mRNA stability can be found in the 5’UTR and 3’UTR as well as in the 
coding sequence of mRNAs. Examples for cis elements are the poly(A)-tail, miRNA 
binding sites or AU-rich elements (ARE). AREs are found in the 3’UTR of many mRNAs 
with short half-lives such as transcription factors and cytokines, and were shown to target 
those mRNAs for rapid deadenylation and decay [444-446]. Additionally, decapping of the 
mRNA induces its subsequent degradation by exoribonucleases [447]. The influence of 
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cis-regulatory elements on the stability of mRNA in GBM has been addressed by 
Tsukamoto et al. who investigated the stability of GLUT1 mRNA. Here, the destabilization 
of the mRNA by instability determinants in the 3’UTR lead to under-expression of the 
glucose transporter [448]. The mRNA of human TANK contains 7 AUUUA pentamers in 
the 3’UTR (http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi) which are a classical ARE 
feature. AREs are able to recruit several trans-acting factors such as the RNA binding 
protein HuR (human antigen R) [449]. The recruitment of this trans regulatory factor is 
known to stabilize mRNAs by protecting the mRNA body from degradative enzymes [450]. 
Bolognani et al. reported HuR to be over-expressed in glioma cancer tissues in correlation 
with the tumor grade. Higher levels of HuR have been found in higher grade gliomas 
[451]. Furthermore, Filippova and colleagues found HuR to be important for growth and 
survival of glioma cell lines [452]. In this context, over-expressed HuR could lead to an 
increased mRNA stability of TANK and in turn contribute to elevated protein levels of 
TANK in GBM. The investigation of other possible mechanisms regulating mRNA stability 
in GBM such as impaired binding of destabilizing factors will be an interesting challenge 
for the future.  
The protein stabilities of TANK and TBK1 were also taken into consideration. Here, all 
investigated glioma cell lines exhibit high stabilities for both proteins, but the protein 
stability of the adaptor protein TANK was higher compared to the kinase TBK1 
(figure 3.3). This is in accordance with the findings of Wu et al. who identified protein 
kinases to be less stable than other protein classes upon the release of their stabilizing 
binding partner [453]. Considering that a high expression of functional proteins does not 
consequently lead to their activation, it would be interesting to investigate the constitutive 
activation of the non-canonical IKK complex in GBM by a kinase activity assay. Finally, it 
would be of interest to determine post-translational modifications that are known to be 
involved in the activation of the non-canonical IKK complex such as phosphorylation or 
ubiquitination. 
The measured mRNA levels for TANK in different glioma cell lines were not always in 
accordance with the observed protein levels. This discrepancy is in line with the findings 
of Vogt et al. who observed a similar phenomenon when investigating the TERT gene 
(telomerase reverse transcriptase) amplification. This amplification was suggested to lead 
to enhanced mRNA and consequently protein levels, but Vogt et al. just found a little 
correlation between mRNA and protein levels [454]. 
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4.2. The non-canonical IKK complex influences cellular 
functions in glioma cell lines 
TANK has been found to be dysregulated in GBM. In order to address the consequences 
of this dysregulation, cellular processes such as proliferation and migration were 
investigated. TANK and TBK1 were identified to play an important role in mediating 
proliferation (figure 3.5). Among the three components of the non-canonical IKK complex, 
only the two kinases have been linked to proliferation so far. Qin and Cheng reported an 
anti-proliferative effect of IKKε knock-down in breast cancer cell lines [128]. Similarily, 
IKKε knock-down also led to decreased proliferation in glioma cell lines [455]. Since IKKε 
and TBK1 are structurally and functionally similar, it is likely that also TBK1 fulfills a role in 
promoting proliferation in cancer. For instance, Kim et al. described a decrease in 
proliferation after TBK1 knock-down in hepatocellular carcinoma cells [456]. The activity of 
both IKK-related kinases has further been shown to depend on an adaptor molecule such 
as TANK [80, 457], thus, its absence results in a decrease of IKKε and TBK1 activity and 
in turn in reduced proliferation. In order to investigate the reason for this anti-proliferative 
effect of the non-canonical IKK complex in gliomas, cell cycle analyses were performed. A 
vinblastine induced cell cycle arrest led to delayed or even rarely detectable accumulation 
of cells in G2 phase after silencing TANK and in some cell lines also for TBK1 silencing 
(figure 3.8). This confirms the inhibitory effects of the knock-down on proliferation. 
Furthermore, the knock-down of TANK or TBK1 in glioma cell lines led to a slightly 
increased proportion of cells in G1 phase in some cell lines (figure 3.7). This is in line with 
the findings of Kittler et al. who reported the TANK knock-down to induce G0/G1 arrest in a 
genome-scale RNAi profiling of HeLa cells [458]. Additionally, IKKε knock-down 
experiments in breast cancer lines and glioma cell lines have been found to induce a cell 
cyle arrest in G0/G1 phase which resulted in decreased proliferation [128, 455]. This arrest 
in G0/G1 has been associated with a decrease in NF-κB activation, thus leading to a 
reduced expression of cyclin D1 [455]. Furthermore, the phosphorylation of ERα by IKKε 
has been shown to induce the transcriptional expression of cyclin D1 [131] which has 
been demonstrated to be over-expressed in various cancers and to promote G1/S 
transition [459, 460]. In contrast to IKKε, the role of TBK1 in cancer cell proliferation is not 
that clear. The proliferation ability of some breast cancer cell lines seems to depend on 
TBK1 [127]. However, the suppression of TBK1 in cancer cell lines, which depend on 
oncogenic KRas expression, rather induces apoptosis than a decrease in proliferation. 
Here, TBK1 activates anti-apoptotic NF-κB signals [461].  
Interestingly, one of the investigated glioma cell lines accumulated in S phase after 
silencing TANK (figures 3.7-8). A defect in the transition from S to G2 phase has been 
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reported for cells over-expressing p21. The binding of p21 to PCNA (proliferating cell 
nuclear antigen) results in the inhibition of DNA synthesis [462-464]. The expression and 
activity of p21 can be modulated by Akt and ERK1/2 kinases [235, 310], both known to 
crosstalk and to be dysregulated in GBM. The role of the non-canonical IKK complex in 
this crosstalk of Ras-Raf-MEK-ERK and PI3K-Akt signaling pathways will be discussed 
later. 
Invasion is a multifactorial process involving interaction of cells with neighboring cells and 
the ECM (extra-cellular matrix) as well as biochemical processes leading to active cell 
movement [465]. In contrast to invasion which is defined as three dimensional movement 
of cells within a matrix, migration describes a two dimensional and directed motion which 
is necessary for invasion [466]. In the present study, the influence of TANK or TBK1 
knock-down regarding migration was investigated and revealed a great role of the non-
canonical IKK complex for the migration ability of glioma cells (figure 3.9.). Because 
effects of TANK silencing exceeded those of TBK1 silencing, it is likely that IKKε 
additionally plays a great role for cell migration of glioma cell lines. This is in accordance 
with the literature where inhibited migration upon IKKε silencing in glioma and breast 
cancer cell lines, respectively, has been described [128, 455]. Other components of the 
NF-κB signaling network are also associated with migration in cancer cells. Very recently, 
IKKα and IKKβ-induced NF-κB activation was identified to modulate migration in HNSCC 
(head and neck cancer) probably by affecting c-Jun [467]. Furthermore, both canonical 
IKKs are involved in NF-κB-mediated MMP9 expression (matrix metalloproteinase 9) 
which is necessary for migration [468]. MMP9 is a member of the MMP family which is 
responsible for the breakdown of the ECM [469]. Serving as type IV collagenase, MMP9 
secretion results in degradation of collagen of the ECM thereby providing space for 
invading cells [465]. Moreover, Akt kinase, that also can be directly phosphorylated by 
IKKε and TBK1, was identified to modulate MMP9 expression in cancer cells by inducing 
NF-κB activation [470]. The role of hyperactive Akt in migration has further been 
investigated by Zhang and colleagues. They reported that Notch1 is dysregulated in 
glioma which leads to an activation of Akt. Akt in turn increases the β-catenin activity 
which leads to the expression of genes that are necessary for the epithelial-to-
mesenchymal transition [471, 472]. Furthermore, increased β-catenin leads to a disruption 
of the cadherin-catenin complex and decreases the intercellular contact which promotes 
migration. One of the cadherins, that can be bound by β-catenin, is the transmembrane 
cell adhesion protein E-cadherin [473]. The role of E-cadherin in migration still seems to 
be controversial. On the one hand, Lewis-Tuffin et al. found E-cadherin to be over-
expressed in one third of glioma cases which leads to exaggerated growth, migration and 
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invasiveness [474]. On the other hand, reduced levels of the tumor supressor E-cadherin 
were reported to be associated with increased migration by disrupting intercellular 
contacts [475, 476]. The supression of E-cadherin in gliomas can be caused by the 
transcription factors ZEB1 [477] or ZEB2 (Zinc finger E-box-binding homeobox 1 and 2) 
[478] which results in increased migration. Edwards and colleagues investigated the 
relation between E-cadherin, ZEB transcription factors and NF-κB in glioblastoma and 
demonstrated that the activation of NF-κB can lead to the binding of ZEB1 to the E-
cadherin promotor which results in the supression of E-cadherin and subsequently in 
enhanced migration [477]. Qi and colleagues showed an increased expression of ZEB2 in 
glioma which they found to be responsible for migration by the repression of E-cadherin 
[478]. In future, it would be of interest to further address the role of the non-canonical IKK 
complex in invasion by either performing a transwell invasion assay to measure invasion 
in vitro or a spheroid confrontation assay in order to determine cell invasion into tissue.  
 
4.3. The importance of stoichiometric TANK expression 
Even though adaptor proteins such as TANK do not hold any catalytic function, their 
expression is necessary for signaling [427]. Thereby, the amount of the expressed 
adaptor protein can influence the fidelity of signaling as depicted in figure 4.1. 
 
Fig. 4.1: Model of the consequences of over- 
or under-expression of adaptor proteins 
such as TANK. The optimal amount of adaptor 
proteins is necessary for a high fidelity of the 
signal outcome. For instance, too high as well 
as too low levels of TANK lead to a disruption of 
the complex resulting in decreased downstream 
signaling. 
In accordance with this model, stoichiometric shifts within the complex by either silencing 
or substantial over-expression of TANK consequently resulted in reduced IRF activation 
as well as reduced proliferation in glioma cell lines (figure 3.20). In general, the observed 
phenomenon of decreased signal fidelity of a functional complex by over- and under-
expression of its scaffold proteins has been described by Burack and Shaw using the 
example of scaffold proteins in the MAPK signaling pathway [479]. Silencing of the 
scaffold protein MP1 (MEK partner 1) has been shown to reduce ERK activation in breast 
cancer cells [480]. Schaeffer et al. found, that the over-expression of the scaffold protein 
MP1 resulted in enhanced signaling output only when ERK1 kinase was additionally over-
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expressed [481]. Based on those findings, Burack and Shaw pointed out the importance 
of near-stoichiometric levels of the scaffold and the ligand for a functional complex and 
proper signaling [479]. 
The idea that TANK over-expression leads to a decrease in the signal fidelity of the non-
canonical IKK complex seems to be in contrast to the observation that TANK over-
expression results in promotion of proliferation and migration in GBM. As Goncalves and 
colleagues argued, the TANK adaptor protein competes with SINTBAD and NAP1 for the 
binding of the IKK-related kinases [80]. Those other possible adaptors are as well 
expressed in brain tissues [482, 483] and form alternative complexes with TBK1 and IKKε 
which have similar functions in the kinase activation [67, 80]. TANK has been shown to 
have the lowest affinity for TBK1- and IKKε-binding compared to SINTBAD and NAP1 
[80]. So, the more TANK is expressed in glioma cells, the more likely is the binding of 
TANK to both IKK-related kinases, until a certain maximum is reached and the complex 
cannot form properly. Furthermore, IKKε has been identified to be over-expressed in 
gliomas and to be responsible for increased proliferation and migration [455]. This 
suggests that TANK might assemble an alternative complex with an IKKε homodimer 
which is involved in gliomagenesis. This would also be in accordance with results in this 
study which demonstrate greater effects of TANK knock-down than of TBK1 silencing on 
cellular functions such as proliferation and migration. TBK1 has not been described to be 
over-expressed in GBM but in other cancer types such as lung, colon and breast cancer 
[69, 79]. 
Further experiments investigating the role of NAP1 and SINTBAD in glioma cell lines by 
measuring their expression and influence on cellular functions will help to estimate the 
role of the non-canonical IKK complex in GBM. In this context, it would be interesting to 
address the affinity of the three adaptor proteins for TBK1- and IKKε-binding in glioma cell 
lines. 
 
4.4. The non-canonical IKK complex is integrated in a complex 
network of signaling pathways 
4.4.1. The influence of TANK and TBK1 on the proliferation of glioma cell lines is 
regulated by intrinsic signaling 
In order to identify mechanisms by which the non-canonical IKK complex facilitates its 
function on proliferation, this study first determined whether the observed effects on 
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proliferation resulted from their influence on other signaling pathways or were an indirect 
consequence of secreted soluble factors. The treatment of control cells with supernatant 
of knock-down cells did not result in reduced proliferation, indicating that the influence of 
the non-canonical IKK complex on the proliferation of glioma cells is not a consequence of 
secreted factors but of altered intrinsic signaling (figure 3.12). In contrast, the cells treated 
with the supernatant showed a slightly increased proliferation. This could be caused by 
pro-proliferative factors in the extracellular environment such as growth factors and 
cytokines as IL-11, IL-6 and TNFα [426, 484, 485]. For instance, IL-6 has been shown by 
Qiu et al. to be over-expressed in glioma stem cells [486]. Furthermore, Kudo and 
colleagues reported high IL-6 expression in glioma cell lines to positively regulate 
proliferation by the activation of the JAK-STAT signaling pathway [487]. 
Predominantly, the decreased proliferation of glioma cell lines after silencing components 
of the non-canonical IKK complex seems to derive from changes in the intracellular 
signaling network. Since proliferation and migration in cancer cells often have been found 
to depend on Akt or ERK1/2 signaling [377, 398], it was interesting to assess, if and how 
the non-canonical IKK complex could be integrated into the signaling network described in 
1.5. 
4.4.2. TANK and TBK1 influence the phosphorylation of Akt and ERK1/2 in 
glioma cell lines 
Within the present study, endogenous levels of Akt and ERK1/2 proteins as well as their 
phosphorylation status were determined and their constitutive activation was revealed. 
Interestingly, the analyses of the glioma cell lines disclosed an inverse phosphorylation 
pattern of Akt T308 and ERK1/2, meaning that if Akt is highly phosphorylated, ERK1/2 
phosphorylation is decreased and in turn, if ERK1/2 is highly phosphorylated, Akt 
phosphorylation is decreased. The repressive effect of activated Akt on ERK1/2 activation 
has been shown by Mabuchi et al. in ovarian cancer cells as well as by Lee and 
colleagues in prostate cancer cell lines [372, 488]. Akt phosphorylates and inactivates 
Raf-1, thereby impairing ERK1/2 activation [372]. Taken together, Akt seems to have a 
suppressive effect on the phosphorylation of ERK1/2 in glioma cell lines. 
But what is the role of the non-canonical IKK complex in the phosphorylation of Akt and 
ERK1/2? Within the scope of this study, silencing of either TANK or TBK1 has been 
shown to reduce Akt as well as ERK1/2 phosphorylation (figures 3.13-14). Furthermore, 
the inhibition of the non-canonical IKK complex by BX795 confirmed this effects as 
summarized in figure 4.2.A. This is the first time the non-canonical IKK complex is linked 
to ERK1/2 signaling. Recently, Akt has been demonstrated to act downstream of TBK1 
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and IKKε [125, 136, 137]. Moreover, Akt is known to act upstream of ERK1/2 through the 
activation or inhibition of the upstream kinase Raf [372, 374]. Some substances have 
been shown to decrease the phosphorylation of Akt and ERK1/2 simultaneously in 
different cell lines [489-491]. Chai et al. reported Sorafenib, a multikinase inhibitor known 
to target Raf [492], to induce apoptosis in neuroblastoma cell lines by the down-regulation 
of Akt and ERK1/2 phosphorylation [490]. Also Fei et al. showed decreased ERK1/2 
phosphorylation in response to Perifosine [489] which is a Akt kinase inhibitor [493]. 
Furthermore, Ellert-Miklaszewska and colleagues described a repressive effect on Akt 
and ERK1/2 phosphorylation in a rat glioma cell line after the treatment with Cannabinoids 
which resulted in cell death and decreased proliferation [491]. Those effects can be 
explained by the crosstalk among the MAPKs and the influence of Akt kinase on this 
crosstalk. Activated Akt has been shown to block the activity of JNK [224, 494]. In turn, 
JNK has been found to have a repressive effect on ERK1/2 within the MAPK crosstalk 
[495, 496]. So, if Akt is inhibited, JNK activity is exaggerated and the repressive effect of 
JNK on ERK1/2 is increased which results in reduced phosphorylation of ERK1/2. Another 
possible connection between the non-canonical IKK complex, Akt and ERK1/2 might lead 
through GSK3α. Gulen and colleagues found IKKε to inactivate GSK3α by 
phosphorylation at S21 in response to IL-1. Furthermore, GSK3α inhibits Akt by the 
phosphorylation within the substrate binding site at T312 [497]. Wang et al. identified 
GSK3 as a negative regulator of ERK1/2 phosphorylation in colon cancer cells in a PKC-
dependent manner [498]. Thus, the knock-down of IKKε would lead to increased GSK3 
activity and consequently reduced Akt as well as ERK1/2 phosphorylation. Finally, it is 
also possible, that TBK1/IKKε directly (independent of Akt) phosphorylate ERK1/2 or 
possibly the upstream kinase MEK1/2. But so far, there is no evidence for such an 
interaction in literature. Also database researches did not reveal phosphorylation motifs in 
ERK1/2 or MEK1/2 that could be target sites for TBK1 or IKKε. 
The negative correlation between Akt T308 and ERK1/2 phosphorylation in glioma cells 
shifted to a positive correlation upon silencing/inhibiting of the non-canonical IKK complex. 
In general, T308 is the major residue that needs to be phosphorylated to activate Akt, but 
full activation is known to additionally require S473 phosphorylation [153]. Both residues 
have been demonstrated to be phosphorylated by many kinases in response to different 
stimuli [247]. Moreover, the phosphorylation of tyrosine residues of Akt have been 
identified to be essential for its biological function [499]. This suggests the possibility that 
certain phosphorylation patterns determine whether Akt has a supportive or repressive 
effect on ERK1/2 phosphorylation. This distinct regulation of protein function by post-
transcriptional modification patterns, termed barcode hypothesis, has been described for 
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p53 [500]. p53 can be induced by a wide range of stress stimuli and finally lead to either 
apoptosis or DNA repair [238, 501]. The phosphorylation of p53 at certain sites thereby 
influences the cellular outcome. For instance, the phosphorylation of one residue can lead 
to changes in the subcellular localization and thereby results in altered function. The 
phosphorylation of p53 at S315 has been associated with the inhibition of p53 by its 
export to the cytosol and its degradation [500, 502]. p53 phosphorylation at S315 is 
additionally known to induce the binding of p53 to E2F1, which leads to its retention in the 
nucleus and to p53-dependent gene expression [503]. The term barcode hypothesis has 
already been adopted for other proteins such as p65. Moreno et al. found that the 
combination of post-translational modifications of p65 is important to direct its 
transcriptional activity in a target specific fashion [95]. 
Finally, combined inhibition of Akt and the non-canonical IKK complex did not have any 
further effect on the ERK1/2 phosphorylation, suggesting the IKK-related kinases and Akt 
to act upstream of ERK1/2 in one signaling path. 
4.4.3. The role of MEK1/2 and TAK1 in TANK/TBK1/IKKε-mediated ERK1/2 
phosphorylation 
The dependence of Akt-induced ERK1/2 phosphorylation on MEK1/2 has been 
investigated by MEK1/2 inhibition (summarized in figure 4.2.B). However, the treatment 
with U0126 failed to reduce ERK1/2 phosphorylation in most glioma cell lines 
(figure 3.17). On the one hand, Yip-Schneider and colleagues reported the development 
of a reversible resistance to U0126 within 24 hs in liver cancer cells as a consequence of 
feedback mechanisms to the Ras-Raf-MEK pathway [504]. Thus, it is possible that the 
investigated glioma cell lines also developed a resistance against the inhibitor U0126 
since they were also treated for 24 hs. On the other hand, the observed ERK1/2 
phosphorylation upon MEK1/2 inhibition could indicate the presence of an MEK1/2-
independent pathway to activate ERK1/2. The treatment with MEK inhibitor U0126 was 
also insufficient to block Akt phosphorylation, indicating that Akt acts upstream of ERK1/2 
in another signaling path (figure 3.17). Nevertheless, Akt phosphorylation was increased 
upon U0126 treatment suggesting the existence of a feedback loop from MEK1/2 or 
ERK1/2 to Akt. The paradox phenomenon of increased Akt phosphorylation after the 
treatment with MEK inhibitors has also been observed by Normanno et al. in breast 
cancer cell lines, and was found to result in proliferation and survival [505]. However, the 
underlying mechanisms still remain unclear and need to be investigated. A combined 
inhibition of MEK1/2 and the IKK-related kinases resulted in the abolishment of ERK1/2 
phosphorylation in some glioma cell lines (figure 3.17.). This result further supports the 
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idea of an alternative ERK1/2 activating pathway, which is independent of MEK1/2, to 
ensure proliferation in GBM. In future it would be of interest to identify the players of this 
pathway. In this context, Grammer and Blenis found the PI3K-Akt pathway as well as PKC 
to be linked to an MEK1/2-independent ERK1/2 activation [506]. However, so far there is 
no evidence for a direct phosphorylation of ERK1/2 by either PKC or Akt. Taken together, 
these findings support the idea of escape signaling mechanisms in GBM to maintain rapid 
proliferation. The simultaneous inhibition of participating pathways thereby could improve 
the treatment of cancer. 
Similar to the MEK inhibition, the treatment of glioma cell lines with a TAK1 inhibitor 
revealed an increased Akt phosphorylation in most cell lines as summarized in 
figure 4.2.D. This increased Akt phosphorylation did not correlate with ERK1/2 
phosphorylation which was found not to be altered. Whereas TAK1 has been shown to 
activate p38 and JNK MAP kinases, there is no evidence for ERK1/2 activation by TAK1 
[507]. The repressive effect of TAK1 on the phosphorylation of Akt is in contrast with the 
findings of Lee et al. who reported TAK1 to activate Akt in response to LPS in a PI3K-
dependent manner in pre-B cells [507]. Furthermore, the existence of a TAK1-MEK-Akt 
pathway involved in survival has been claimed by Gingery and colleagues in osteoclasts 
in response to TGF-β [508]. Since the combination of TAK1 inhibitor with BX795 did not 
show any further effects on the phosphorylation of Akt and ERK1/2 compared to the 
treatments only with BX795 or 5Z-7-oxozeaenol, it is likely that there is no crosstalk 
between the non-canonical IKK complex and TAK1 in glioma cell lines (figure 3.18). In 
order to confirm the role of TAK1 in Akt and ERK1/2 signaling in glioma cell lines, further 
investigations need to be done. Silencing of TAK1 followed by the measurement of Akt 
and ERK1/2 phosphorylation as well as the measurement of TBK1/IKKε activity could 
reveal better insights into the signaling crosstalk. Furthermore, it would also be interesting 
to assess the role of TAK1 in cellular functions in glioma cell lines by investigating 
proliferation, migration and apoptosis after silencing TAK1. 
The following figure summarizes the findings of this work (A-D) as well as the discussed 
crosstalk between the non-canonical IKK complex, Akt and ERK1/2 (E) and thereby 
shows a presumable model of signaling that occurs in GBM. 
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Fig. 4.2: Presumable signaling network regulating Akt and ERK1/2 in glioma cell lines. The effects of 
the indicated inhibitors on Akt and ERK1/2 phosphorylation in glioma cell lines are depicted in subfigures A 
to D. Here, the amount of arrows is representing the amount of glioma cell lines where the effect was 
detected. (E) The model of the signaling network in GBM how it could be explained by the literature. The 
non-canonical IKK complex has been identified to activate Akt. Akt in turn has distinct functions on ERK1/2 
activation. Whereas ERK1/2 phosphorylation is repressed by Akt phosphorylated at T308 in steady-state 
conditions, the inhibition of Akt phosphorylation at both activation sites likewise resulted in reduced ERK1/2 
phosphorylation. Underlying mechanisms are not clear so far but could depend on the crosstalk of MAP 
kinases with each other and Akt or on upstream GSK3, which in turn represses the activation of Raf-MEK-
ERK by inhibiting PKC as well as Akt. Furthermore, MEK1/2 and TAK1 have been discovered in the present 
study to repress Akt activation independently of the non-canonical IKK complex. Abbreviations: SOS; Son of 
Sevenless; Shc: SHC-transforming protein; Grb2: growth factor receptor-bound protein 2; Ras: Rat 
sarcoma; MEK: MAP2K; ERK: extracellular signal-regulated kinase; JNK: c-Jun N-terminal kinases; PKC: 
protein kinase C;.GSK3: glycogen synthase kinase 3; TANK: TRAF family member-associated NF-κB 
activator; IKKε: IκB kinase epsilon; TBK1: TANK binding kinase 1; PI3K: phosphatidylinositide 3-kinases; 
TAK1: TGF-β-activating kinase. 
 
Of note, the proposed model is solely based on an approach using specific inhibitors, so it 
has to be validated by other techniques such as silencing experiments and kinase assays 
as well as by the determination of the cellular outcome such as proliferation and survival. 
Nevertheless, first hints disclose a network of signaling pathways in glioma involving 
ERK1/2, Akt and the non-canonical IKK complex to promote proliferation. 
4.4.4. The role of the non-canonical IKK complex in other cancer cell lines 
The influence of the non-canonical IKK complex on proliferation of cancer cell lines other 
than glioblastoma revealed a minor effect on HCT116 and A549 proliferation. In contrast, 
a profound decrease in proliferation has been observed in MCF-7 cell line after silencing 
either TANK or TBK1 (figure 3.21). Several groups found IKKε to induce transformation 
and further increase proliferation in some cancer types. Especially breast cancer is known 
to be dependent on IKKε-mediated transformation [127, 509]. Guo et al. showed this 
effect for breast cancer cell lines including MCF-7 [137]. Also Akt has been shown to 
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promote tumorigenic transformation in about 50% of breast cancer cases [510]. Boehm et 
al. showed in an integrative genomic approach, that IKKε is able to substitute Akt in 
cellular transformation [127] which would explain the influence of the non-canonical IKK 
complex on MCF-7 proliferation without changes in the Akt phosphorylation. Furthermore, 
Akt2 has been reported to act upstream of IKKε in breast cancer cell lines by influencing 
its expression [511]. Additionally, Kim et al. demonstrated that basal Akt phosphorylation 
was not altered after silencing of TBK1 in lung cancer cells [512]. In summary, this work 
did not show any influence of TANK or TBK1 silencing on the phosphorylation of Akt and 
ERK1/2 (figure 3.21), indicating that the described crosstalk of the non-canonical IKK 
complex, Akt and ERK1/2 is exclusively present in GBM. 
 
4.5. TANK and TBK1 regulate inflammatory signaling cascades 
in glioblastoma multiforme 
The importance of inflammation in cancer and especially GBM has been well described 
[425, 426]. The role of the non-canonical IKK complex in pro-inflammatory signaling in 
glioma cell lines was investigated. Thereby, a heterogeneous picture concerning the 
phosphorylation of IRF3 and p65 and the expression of pro-inflammatory cytokines was 
revealed (figure 3.19). A constitutive activation of NF-κB in GBM has been described by 
Raychaudhuri et al. as well as Tsunoda and colleagues [513, 514]. In many different types 
of cancers an aberrant NF-κB activation also leads to an increase in the expression of 
pro-inflammatory cytokines [119]. The mechanisms underlying the constitutive activation 
of NF-κB are still not clearly understood. In general, the constitutive phosphorylation and 
degradation of IκBα, which has been reported for instance in melanomas, results in 
nuclear translocation of the NF-κB dimer [515]. Furthermore, deletions or loss-of-function 
mutations of IκBα could induce this constitutive activation of NF-κB [516]. Such a deletion 
of NFKBIA has been found in glioblastomas [50]. Besides NF-κB, also other signaling 
cascades are involved in the expression of pro-inflammatory cytokines as for instance IL-
6. Here, dysregulated MAPK signaling has been found to be important. Yeung and 
colleagues identified p38 to be responsible for the over-expression of IL-6 in GBM cell 
lines. However, the underlying mechanism remain unclear [517]. Although, Zauberman et 
al. found the transcription factor STAT3 to be activated by p38 which results in increased 
IL-6 expression [518]. 
The pro-inflammatory transcription factor IRF3 is known as a tumor suppressor and 
consequently lowly expressed in GBM [519]. Furthermore, IRF3 expression suppresses 
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migration and proliferation of glioma cells [519]. In general, the non-canonical IKK 
complex is able to influence NF-κB and IRF3 transcription factors by modulating their 
phosphorylation. It still needs to be investigated in detail how the complex cytokine 
network is affected by the over-expression of the complex in glioma cell lines. Within the 
scope of this study, a controversial picture of the influence of TANK and TBK1 on the 
inflammatory signaling in GBM became apparent.  
 
4.6. The role of the non-canonical IKK complex in the treatment 
with chemotherapeutic drugs 
As GBM is one of the most aggressive brain tumors with a bad prognosis, great effort has 
been done during the last decades to develop new treatment possibilities. At present, 
eight open studies for glioblastoma are in phase III of clinical studies 
(http://clinicaltrial.gov). So far, only TMZ arose as standard-of-care in the 
chemotherapeutic treatment. The cell death-inducing feature of TMZ has been confirmed 
in this study. Furthermore, also physiological concentrations of AraC have been found to 
induce cell death in glioma cell lines (figure 3.10). AraC has been reported to induce 
phosphorylation of the checkpoint kinase Chk1, but has no activating effect on the 
ATM/Chk2 pathway [520, 521]. This results in cell cycle arrest, reduced growth as well as 
apoptosis [417]. 
The influence of the non-canonical IKK complex on AraC and TMZ-induced cell death has 
been investigated. Thereby, an additional effect of TBK1 has been found which was even 
more pronounced for TANK (figure 3.11 and 3.15). This suggests, that IKKε seems to be 
the kinase mainly responsible for the additional effect of the non-canonical IKK complex 
on the TMZ or AraC treatment, respectively. Indeed, IKKε has been shown to be involved 
in anti-apoptotic functions in response to DNA damage. Renner et al. identified IKKε to be 
activated in response to DNA damage induced by Etoposide which results in the 
prevention of cell death. Here, the phosphorylation of p65 at S468 by IKKε induced the 
expression of p21 and MDM2 [96]. Moreover, Guan and colleagues demonstrated an anti-
apoptotic state in glioma cells treated with UV light or Adriamycin (Doxorubicin) which was 
caused by IKKε-induced NF-κB signaling and subsequent Bcl-2 expression. In this 
context, the knock-down of IKKε further increased the cell death induced by the stimuli 
[522]. This is in line with the results of the present study and further underlines the anti-
apoptotic function of the non-canonical IKK complex. Additionally, NF-κB might be 
involved in the pro-apoptotic function of TMZ and AraC. Caparoli et al. reported TMZ to 
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induce ATR activation and subsequent Akt phosphorylation which results in pro-apoptotic 
NF-κB signaling [523]. Akt kinase has also been shown to induce apoptosis in response to 
DNA damage mediated by ATM [524]. Furthermore, ATM has been identified to be 
activated in response to TMZ and to interact with NEMO which leads to pro-apoptotic NF-
κB signaling [525, 526]. Taken together, cell death induced by TMZ could be mediated by 
NF-κB as well as suppressed by IKKε also depending on NF-κB signaling. In general, NF-
κB is known to support both pro- and anti-apoptotic signaling in response to DNA damage. 
The balance of pro-and anti-apoptotic signals depends on cell type and stimulus [527, 
528]. In order to receive a better impression of the role of the non-canonical IKK complex 
in the induction of apoptosis, the measurement of apoptosis by Annexin V/FITC staining 
after silencing components of the complex would be an interesting approach. The 
additional treatment of glioma cells with chemotherapeutic drugs such as TMZ or AraC will 
thereby verify the shown effect of the non-canonical IKK complex on the drug-induced cell 
death. Additionally, the identification of involved DNA damage sensors and signaling 
pathways would provide a better insight into the role of the non-canonical IKK complex in 
drug-induced apoptosis. 
In future, the development of new chemotherapeutic drugs for the treatment of GBM will 
be of great importance. This study revealed new insights in the complex signaling network 
in GBM. The non-canonical IKK complex as well as Akt signaling were identified to play a 
role in ERK1/2 phosphorylation. The activation of alternative pathways provides the cell 
with mechanisms to escape chemotherapeutic drugs. Thus, targeting several players in 
the network simultaneously could be an interesting approach for drug discovery studies. 
Treatments with special respect to genetic and molecular changes will play a crucial role 
to keep up with the diversity and multiform appearance of GBM and to avoid the 
development of drug resistances by escape mechanisms. 
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5. SUMMARY 
Glioblastoma multiforme is one of the most common and lethal brain tumors. Many 
genetic and molecular changes have been described to occur in this type of brain cancer. 
Within this work, the role of the non-canonical IKK complex in glioblastoma multiforme 
was investigated. The non-canonical IKK complex is composed of the IKK-related kinases 
TBK1 and IKKε as well as adaptor proteins such as TANK, and is usually involved in the 
defense against viral and bacterial pathogens by the induction of type I interferon 
expression. This work shows, that TANK is dysregulated and over-expressed in a wide 
range of GBM patient tissue samples as well as glioma cell lines. Several mechanisms 
have been found to be responsible for the greatly varying protein levels of TANK. Various 
experimental approaches showed, that differences in the de novo transcription of the Tank 
gene and differential stabilities of TANK mRNAs account for the variances in TANK 
protein levels in glioma cell lines. The influence of members of the non-canonical IKK 
complex on cellular functions of glioma cell lines was then investigated after the knock-
down of TANK or TBK1. Proliferation assays as well as MTT assays revealed a markedly 
reduced proliferation rate of some glioma cell lines after silencing of TANK or TBK1. The 
proliferation of other glioma cells was dependent on either TANK or TBK1. The 
proliferation of the minority of glioma cell lines was not affected by the knock-down of 
TANK or TBK1. Additionally, the ability of glioma cells to progress in cell cycle was found 
to be reduced upon TANK or TBK1 knock-down in those glioma cell lines where the 
knock-down caused a reduced proliferation ability. The migration ability was examined by 
wound-healing assays. These experiments showed that cells, which depend on TANK or 
TBK1 for proliferation, also need these proteins for cell migration. Usually those cellular 
functions are regulated by signaling pathways such as the Ras-Raf-MEK-ERK or PI3K-Akt 
signaling pathways. Therefore, the involvement of the non-canonical IKK complex in those 
signaling cascades was determined in this work. Akt as well as ERK1/2 have been shown 
to be constitutively phosphorylated and activated in some primary tissue samples of GBM 
or astrocytoma grade III patients as well as most of the glioma cell lines. The knock-down 
of either TANK or TBK1 as well as the inhibition of both IKK-related kinases (TBK1 and 
IKKε) by BX795 had a repressive effect on those phosphorylations in some of the glioma 
cell lines. Thus, an alternative signaling path for the activation of proliferation and survival 
signals in glioblastoma multiforme was identified which is dependent on the cell line. A 
pharmacological approach was applied to study the complex signaling network in detail 
and revealed a negative feedback loop from MEK1/2 to Akt as well as a MEK-independent 
signaling pathway to activate ERK. Whether the MEK-independent TBK1/IKKε-Akt 
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signaling axis leads to the phosphorylation and activation of ERK directly or indirectly still 
needs to be clarified in the future. However, this TBK1/IKKε-Akt-ERK pathway represents 
an alternative pathway to activate proliferation and survival signals in cancer, thus 
providing new opportunities in the discovery of treatments of glioblastoma multiforme. 
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6. ZUSAMMENFASSUNG 
Das Glioblastom zählt nachwievor zu einem der häufigsten und tödlichsten Hirntumoren. 
Bisher konnten einige genetischen und molekularen Veränderungen in diesem Tumor 
identifiziert werden, die für diese Tumorart charakteristisch sind. Ziel der vorliegenden 
Arbeit war es, die Rolle des nicht kanonischen IKK Komplex im Glioblastom zu 
charakterisieren. Der nicht kanonische IKK Komplex besteht aus den beiden Kinasen 
TBK1 und IKKε, die durch ein Adaptorprotein wie beispielsweise TANK 
zusammengehalten werden. In erster Linie ist der Signalweg über diesen Komplex für die 
Reaktion auf virale oder bakterielle Pathogene verantwortlich, und führt in dieser Folge 
zur Ausschüttung von Typ I Interferonen. Im Rahmen dieser Arbeit konnte gezeigt 
werden, dass die Expression des Adaptorproteins TANK in einer Vielzahl von Patienten 
und Gliomzelllinien dereguliert und erhöht ist. Dabei wurden eine unterschiedliche de 
novo Transkription und mRNA Stabilität als mögliche Ursachen für die schwankenden 
Proteinlevel von TANK in den Gliomzelllinien gefunden. Weiterhin wurde die Rolle des 
nicht kanonischen IKK Komplexes auf zelluläre Funktionen der Gliomzelllinien untersucht, 
indem das Adaptorprotein TANK sowie die Kinase TBK1 retroviral herunter reguliert 
wurden. Dabei verdeutlichten Proliferationsstudien und MTT-Tests eine deutlich 
reduzierte Proliferationsfähigkeit in einigen Gliomzelllinien. In anderen Gliomzelllinien war 
die Proliferation abhängig von TANK oder TBK1, und in einigen wenigen Zelllinien hatten 
beide Proteine keinen Einfluss auf die Proliferation. Auch der Zellzyklusverlauf war in den 
Gliomzelllinien vermindert, in denen der Knock-down von TANK oder TBK1 zu einer 
reduzierten Proliferation führte. Des Weiteren wurde die Abhängigkeit der Zellmigration 
von TANK und TBK1 mittels Wound-healing Experimente in Gliomzelllinien untersucht 
und zeigte, dass in einigen Zelllinien auch diese TANK und TBK1 benötigt. Grundsätzlich 
werden Zellfunktionen durch verschiedene Signalwege wie beispielsweise den Ras-Raf-
MEK-ERK- oder den PI3K-Akt-Signalweg reguliert. Deshalb wurde der Einfluss des nicht 
kanonischen IKK Komplexes auf diese Signalwege untersucht. Zunächst wurde 
festgestellt, dass sowohl Akt als auch ERK1/2 in einigen Gliomen und den meisten 
Gliomzelllinien konstitutiv phosphoryliert und damit aktiviert sind. Der Knock-down von 
TANK bzw. TBK1 wie auch die Inhibierung beider Kinasen (IKKε und TBK1) durch BX795 
führte in einigen Gliomzelllinien zu einer Reduzierung dieser Phosphorylierungen. Damit 
konnte ein alternativer Signalweg aufgezeigt werden, der zu einer Aktivierung von 
Proliferations- und Überlebenssignalen in einigen Gliomzelllinien führt. Um einen 
genaueren Einblick in die komplexe Vernetzung der beteiligten Signalwege zu 
bekommen, wurde ein pharmakologischer Ansatz gewählt. Hierbei wurden eine negative 
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Rückkopplung von MEK1/2 zu Akt gefunden sowie ein ERK1/2-aktivierender Signalweg, 
der unabhängig von MEK1/2 ist. Inwiefern dieser TBK1/IKKε-Akt-Signalweg direkt oder 
indirekt zur Phosphorylierung und Aktivierung von ERK1/2 führt, muss noch in 
weiterführenden Experimenten untersucht werden. Dennoch stellt der Signalweg eine 
Alternative zur Aktivierung von Proliferations- und Überlebenssignalen in Krebszellen dar, 
und liefert damit neue Möglichkeiten für die Entwicklung von Therapien zur Behandlung 
des Glioblastoms. 
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7. SUPPLEMENTARY FIGURES 
 
 
 
Fig. S1.: Analysis of the protein levels of members of the non-canonical IKK complex primary patient 
tissue samples. Patient tissue samples of normal brain (NB), glioblastoma multiforme (GBM) and 
astrocytoma grade III (A III) were kindly provided by Prof. Dr. Pagenstecher. Proteins were extracted from 
patient tissue by homogenizing of the material in NP40 lysis buffer and using a Turrax. Endogenous protein 
expression was then analyzed by Western blot using the indicated antibodies for endogenous proteins. A 
comparison of GBM/ A III with normal brain tissue is shown in figure 3.1.A. 
 
 
 
 
 
Fig. S2.: Analysis of the mRNA levels of the IKK-related kinases in glioma cell lines. Total RNA was 
extracted and translated into cDNA using Oligo(dT) primers. The amount of mRNA was further semi-
quantitatively analyzed by real-time PCR using specific primers for either TBK1 or IKKε. Expression levels of 
T98G were set as 1 after normalization to the housekeeping gene β-Actin. Error bars express the standard 
deviation of three independent experiments performed in triplicates. 
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Fig. S3: The role of TANK and TBK1 in the proliferation ability of glioma cell lines. (A) A172 cells were 
retrovirally transduced to express shRNAs leading to a knock-down of TANK, TBK1 or a scrambled shRNA 
as a control. Transduced cells were selected with puromycin and used to determine cell proliferation. 
Proliferation was measured by seeding cells at a defined density, followed by determination of cell numbers 
after 72 and 120 hs using a FACSCalibur. Error bars show standard deviations from three independent 
experiments. (B-K) Experiments of (A) were performed for indicated cell lines cells. (L) Results from 
proliferation assays from all cell lines are summarized. Symbols indicate strength of influence on proliferation: 
- no, + low, ++ great influence and nd not detectable. (M) MTT assay was performed by seeding knock-down 
cells at a density of 1x10
3
 cells/well, followed by further growth for 4 days and performance of the MTT assay 
according to the manufacturer’s instructions. Relative metabolic activity of control cells was arbitrarily set as 
1, error bars show standard deviations of three independent experiments. 
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